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Understanding of cell death mechanisms is important to identifying therapeutic 
approaches to treat excess cell growth, as seen in tumors, or to inhibit excess cell death, as seen 
in neurodegenerative disease and ischemia. In the first part of this work, we aim to extend the 
understanding of a non-apoptotic cell death phenotype, ferroptosis, through use of a genome-
wide siRNA screen. We identified knockdown of CARS, or cysteinyl-tRNA synthetase, as an 
inhibitor of erastin-induced ferroptosis. Loss of CARS led to upregulation of the transsulfuration 
pathway, where methionine is used as the source of sulfur for cysteine synthesis, as a suppressive 
mechanism. Upregulation of the transsulfuration pathway may serve as a biomarker to identify 
tumor types that may be insensitive to ferroptosis-inducing therapeutics. On the other hand, 
induction of the transsulfuration pathway may be beneficial in disease contexts that involve 
excess cell death. In the second part of this work, we elucidate the mechanism of action of a 
small molecule Mdm2 inhibitor, or MEL. Mdm2 is a negative inhibitor of p53; therefor, an 
inhibitor of Mdm2 may be useful in treating tumors driven by Mdm2 overexpression. We found 
MEL to inhibit the E3-ligase activity of Mdm2/MdmX heterocomplex, proving to be a useful 
tool to probe the importance of the heterocomplex in normal physiology and disease 
development. We also explored the structural scaffold of MEL compounds, an indole, and 
 
identified a novel ferroptosis inducer, increasing the chemical toolbox available to study 
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CHAPTER ONE:  
Introduction 
 
Cell death  
Homeostasis in living organisms involves the precise regulation of cell survival and cell 
death. Although all cells endure the same fate, there are many paths that lead to the end. Ever 
since the first documentation of cell death by Karl Vogt in 1842 (Vogt, 1842), scientists have 
continued to define cell death in physiology and disease pathology. The idea of “programmed 
cell death”, that cell death can be genetically encoded, was coined by Richard Lockshin and 
Carroll Williams in 1964 when describing insect metamorphosis (Lockshin and Williams, 1964). 
Apoptosis was coined by John Kerr, Andrew Wyllie and Alastair Currie in 1972 and used to 
describe a programmed phenomenon that could be observed in normal physiology and in 
response to external stimuli (Kerr et al., 1972). Soon afterwards, in 1973, Schweichel and 
Merker observed rat embryo cell death in response to toxins and categorized cell death into three 
types; Type I associated with condensation and phagocytosis (eating of another) now known as 
apoptosis, Type II as associated with lysosome formation, now sometimes referred to as 
autophagy (eating of self), and Type III associated with disintegration of cells into fragments, or 
non-regulated cell death (Schweichel and Merker, 1973). For the last few decades, apoptosis has 
been viewed as the predominant form of programmed cell death involved in physiology. 
However, recent interest in alternative forms of programmed cell death have led to the definition 
of a handful of other types of cell death, even leading to the formation of a Nomenclature 
Committee on Cell Death that recommends almost on an annual basis on how to use cell death 





Classical view of cell death 
 As mentioned above, there are three general types of cell death; Type I apoptosis, Type II 
autophagy, and Type III non-regulated cell death. In this chapter, I describe these cell death 
mechanisms and their contribution to normal physiology and disease, along with new forms of 
cell death that have been recently described.  
  
Apoptosis  
 Apoptosis, coined in 1972 to describe the morphology of a dying cell, has been the most 
well-studied type of cell death. Kerr et. al. observed single cells with cytoplasmic shrinkage, 
chromatin condensation and a blebbing phenotype, morphological characteristics that are still 
used to identify cells undergoing apoptosis (Kerr et al., 1972). The genetic regulators of 
apoptosis were elucidated in the laboratory of Robert Horvitz, who over a decade time-span had 
observed cells in Caenorhabditis elegans undergoing the same sequence of morphological 
changes before disappearing, and identified specific mutations that affected this death process 
(Sulston and Horvitz, 1977; Sulston et al., 1983). Screening for mutations that perturbed cell 
death in C. elegans, Horvitz identified ced-3 and ced-4 as essential to programmed cell death in 
nematode development (Ellis and Horvitz, 1986; Hengartner et al., 1992). ced-3 was later 
identified to encode a cysteine protease and scientists began identifying human homologs of ced 
genes, which was identified to be  interleukin-1β converting enzyme (ICE) (Thornberry et al., 
1992; Yuan et al., 1993).  
 The central player in the execution of apoptosis is cysteine-aspartic proteases, or 
caspases (Fernandes-Alnemri et al., 1994; Kuida et al., 1996; Orth et al., 1996; Tewari et al., 





activation (Khan and James, 1998). Many types of stimuli activate caspases, including growth 
factor withdrawal, ionizing radiation, and exposure to death-inducing cytokines. There are two 
pathways in which caspases are activated; through the intrinsic and the extrinsic pathways 
(Figure 1.1). In the extrinsic pathway, ligands such as tumor necrosis factor (TNF)-α or Fas 
ligand bind to their cell surface receptors, TNF receptor or Fas (Ashkenazi, 2008). The ligand 
activates the formation of the death-inducing signaling complex (DISC), which activates 
caspase-8. Activated caspase-8 then goes on to activate effector caspases-3 and -7, which cleaves 
substrates involved in the death process. Caspase-8 can be inhibited by a caspase-like molecule, 
cFLIP. Activated caspase-8 can also cleave Bid and initiate mitochondrial outer-membrane 
permeabilization (MOMP) through Bax and Bak (Lindsten et al., 2000; Wei et al., 2001). 
MOMP is a common characteristic of apoptosis activated through both the intrinsic and extrinsic 
pathways. 
 In the intrinsic pathway, sensors detect cellular stress such as unfolded protein, DNA 
damage and oxygen radicals and induce proteins that activate BH3-only proteins, such as Bim 
and Bid (Fulda and Debatin, 2006). BH3-only proteins are named so because they contain only 
the BH3 domain and are part of the Bcl-2 family of proteins (Youle and Strasser, 2008). BH3-
only proteins antagonize anti-apoptotic Bcl-2 family members, such as Bcl-2, Bcl-XL or Mcl-1. 
Other BH3-only proteins, Bax and Bak, form the pores necessary for MOMP upon activation. 
After MOMP, cytochrome C is released into the cytosol and acts as a base for the formation of 
the apoptosome, the scaffold for caspase-9 activation (Li et al., 1997). Apoptotic protease-
activating factor-1 (Apaf-1) is also part of the apoptotsome (Li et al., 1997). Cleaved caspase-9 







Figure 1.1. Apoptosis induced through intrinsic and extrinsic pathway.  
In the extrinsic pathway, death ligands such as FasL and TNFα stimulate formation of death 
receptor oligomers. Death receptor oligomerization activates cleavage of Caspase 8, sometimes 
Caspase 10, which cleaves effector caspases 3/6/7 to induce apoptosis. The intrinsic pathway 
involves the mitochondria and BAX/BAK mediated mitochondrial pore formation, which allows 
for cytochrome c release. Cytochrome c and Apaf-1 form the apoptosome, which serves as the 





Many transgenic mouse models have been generated that probe the significance of 
apoptosis in physiological development and disease progression. For example, Bax-/- or Bak-/- 
knockout mice have limited developmental aberrations (Knudson et al., 1995), while Bax-/-Bak-/- 
double knockout mice displayed developmental defects, including interdigital webs and 
accumulation of excess cells within the central nervous system and the hematopoietic system 
(Lindsten et al., 2000). This suggests that Bax and Bak have some overlapping functions in cells 
in the execution of apoptosis. Bax-/-Bak-/- double knockout mice are resistant to truncated Bid 
(tBid)-induced apoptosis (Wei et al., 2001) and Bim or Bad-induced apoptosis (Zong et al., 
2001), indicating that Bax and Bak act downstream of Bid, Bim or Bad-induced apoptosis and is 
essential for mitochondrial dysfunction seen in apoptosis. Apaf-1 knockout mice have also been 
generated, and while there are gross developmental defects in utero and only 5% survive to birth, 
some mice are able to survive without supposedly having a functional apoptotic machinery 
(Honarpour et al., 2000). Furthermore, well characterized developmental cell death processes can 
occur independently of caspases, for example in digit formation (Chautan et al., 1999) and motor 
neuron cell death (Oppenheim et al., 2001). Using these transgenic mice targeting apoptosis 
genes has led to interest in identifying alternative forms of cell death.  
 
 
Autophagic cell death 
 Schweichel and Merker observed vacuole formation associated with cell death 
(Schweichel and Merker, 1973). For the last few decades, the existence of this Type II 
autophagic cell death (ACD) mechanism has been debated (Kroemer and Levine, 2008). In the 





have recommended using ACD to describe cell death processes where pharmacologic or genetic 
inhibition of the autophagic machinery delays or inhibits the death process (Galluzzi et al., 
2014). ACD has been observed under many circumstances, including in development, tissue 
homeostasis and pathological conditions in prokaryotes and eukaryotes (Beaulaton and 
Lockshin, 1977). 
 There are three general types of autophagy; microautophagy, macroautophagy, and 
chaperone-mediated autophagy. Macroautophagy (herein, autophagy) is most widely studied, 
and is also the type of autophagy associated with cell death (Mizushima, 2007). Autophagy is 
induced in response to nutrient starvation, when ATP is limiting, or when AMP kinase is 
activated (Green and Levine, 2014). Another means of autophagy induction is through growth 
factor or amino acid starvation, which leads to inhibition of TORC1 and activation of autophagy 
(Mizushima and Klionsky, 2007). The main purpose of autophagy is to deliver cytosolic 
materials in vacuoles called autophagosomes to the lysosome, leading to the degradation of 
cytosolic materials, such as proteins that are broken down to amino acids, which then can be 
recycled and used for cellular processes essential for the cell to survive the nutrient deprivation 
stress. A form of autophagy specifically removes damaged organelles from the cell, and is called 
selective autophagy, as compared to general autophagy which is induced in cells under stress 
conditions. 
 The autophagosome is a double-membrane structure that involves LC3-II, a proteolipid 
molecule, and phosphatidylethanolamine (Kabeya et al., 2000) (Figure 1.2). Autophagosome 
formation is conserved through evolution, so identification of many of the proteins and genes 
involved in autophagy have been elucidated in yeast (Klionsky et al., 2003; Tsukada and 





al., 2009). Class III phosphatidylinositol 3 kinase complex (VPS3 complex) then generates PI3P, 
an essential component of autophagosomes (Noda et al., 2010). Through a cascade of 
modifications to LC3-I, which can involve ATG7, ATG3, ATG16L and ATG12-5, ATG10 and 
ATG5, also known as the elongation reaction, LC3-II is produced and forms the autophagosome 
(Nakatogawa et al., 2009). The autophagosome then fuses with lysosomes, which assist in 
degradation of the encapsulated material.      
	  
 
Figure 1.2. Scheme of autophagy.  
In mammalian cells, Ulk complex activation commences the autophagy cascade. Autophagy 
related genes, the ATG’s, partake in conversion of LC3-I to LC3-II to form the autophagosome, 
which fuses with lysosomes to degrade autophagic cargo.  
  The controversy surrounding whether or not ACD exists, or if autophagosome formation 
is a consequence of a death process and not the final death committing mechanism, is still 
debated (Edinger and Thompson, 2004; Galluzzi et al., 2007; Yuan and Kroemer, 2010). There 
are some observations of autophagic vacuoles in degenerative muscle and neuronal diseases, 





experiments revealed that the increased vacuole formation was due to defects in autophagosomal 
maturation (Levine and Kroemer, 2008). In Bax-/-Bak-/- knockout mouse embryonic fibroblasts, 
treatment with etoposide or staurosporine resulted in non-apoptotic cell death accompanied by 
autophagic vacuolization, and this death process was rescued with concomitant knockdown of 
Atg5 (Shimizu et al., 2004). Other work has shown knockdown of ATG leading to reduction in 
cell death, both in vitro (Maiuri et al., 2007) and in vivo (Berry and Baehrecke, 2007; Koike et 
al., 2008; Samara et al., 2008). However, research showing that autophagy leads to cell survival 
has also been increasing. For example, in mammalian cells, ATG knockout enhances cell death 
induced by nutrient starvation (Maiuri et al., 2007). Autophagy is important in cell homeostasis, 
but its true importance in cell death is still debated.  
 
Non-regulated cell death/Necrosis 
 The third type of cell death is necrosis, or non-regulated cell death, which involves cell 
organelle swelling, an increase in cell volume and vacuolization, and rupturing of the plasma 
membrane, leading to an inflammatory response (Zong and Thompson, 2006). Necrosis has been 
thought of as the cell death type that results from bioenergetic catastrophe, where ATP levels are 
depleted to a point where survival or recovery is unattainable (Edinger and Thompson, 2004). 
Necrosis has been observed in many circumstances, including pathological and developmental 
neuronal cell death (Clarke, 1990), large and small intestine epithelium renewal (Chautan et al., 
1999; Mayhew et al., 1999), diabetes (Saldeen, 2000) and ischemia (Fujikawa, 2000). Oncosis, 
or the swelling of organelles, can lead to necrosis, and is observed in ischemic cell death (Majno 
and Joris, 1995). Necrosis was thought to be an “accidental” cell death, where the death 





characterized a programmed form of necrosis termed necroptosis, described below (Degterev et 
al., 2005).  
 
Non-apoptotic forms of cell death 
 Alternative forms of cell death to the three types mentioned above exist in development 
and in a diverse range of pathologies, such as in neonatal brain hypoxia (West et al., 2006), acute 
pancreatitis (Mareninova et al., 2006) and multiple organ failure (Cauwels et al., 2003). 
Described below are some other forms of cell death, some of which are observed primarily in 
vitro, or poorly characterized in vivo.  
 Necroptosis, as the name suggests, describes a regulated necrotic cell death mechanism. 
Tumor necrosis factor (TNF)-induced cell death was observed early on to be both apoptotic and 
necrotic (Grooten et al., 1993; Laster et al., 1988). Receptor-interacting protein (RIP) kinase 1 
and 3 were identified later as important kinases for mediating TNF-induced necrosis, which then 
became known as necroptosis (Cho et al., 2009; Degterev et al., 2008; Degterev et al., 2005; 
Feng et al., 2007; He et al., 2009; Holler et al., 2000; Zhang et al., 2009). Small molecule 
inhibitors of necroptosis, or necrostatins, have been used to inhibit this cell death mechanism in 
disease models of ischemic brain injury (Degterev et al., 2005).  
 Beth Levine’s lab described a form of autophagic cell death that involves Na+/K+ -
ATPase that has been dubbed “autosis” (Liu et al., 2013). Autosis has been observed in vivo in 
the brain of rats subjected to ischemic insults, and unlike many other types of programmed cell 
death that does not have a small molecule inducer, autosis can be induced by a cell-permeant 
autophagy-inducing peptide, Tat-Beclin 1, in cell culture. This death can be suppressed with a 





 Oxytosis is a form of glutamate induced cell death (Tan et al., 2001). In this case, 
glutamate inhibits system xc-, a glutamate/cystine antiporter. In exchange for glutamate, system 
xc- imports cystine into cells, where it is reduced into cysteine (Albrecht et al., 2010). When 
system xc- is inhibited, intracellular cysteine levels decrease, leading to a decrease in glutathione 
levels. Glutathione is a tripeptide consisting of cysteine, glutamate and glycine, with cysteine 
abundance being the rate limiting substrate in glutathione synthesis (Sies, 1999). Glutathione is 
one of the most important regulators of cellular redox levels, and when depleted, inhibits the 
cells ability to detoxify toxic reactive oxygen species (ROS). In oxytosis, activation of 
lipoxygenases and production ROS leads to cGMP-gated channels to open, allowing for influx of 
extracellular calcium, leading to the cell death. Cell death induced by abnormally high 
concentration of calcium can also termed excitotoxicity (Szydlowska and Tymianski, 2010).  
    Many other forms of cell death, such as pyroptosis (Bergsbaken et al., 2009), a caspase 1-
dependent death seen in inflammatory response, necrapoptosis (Lemasters, 1999), seen in 
response to mitochondrial permeability transition onset and displays features of both necrosis 
and apoptosis, and paraptosis (Sperandio et al., 2000), involving caspase-9 but in an Apaf-1-
independent manner, among others, have been described. However, many of these death 
modalities are rarely described in disease and normal physiology, and may only be observed 
under specific artificial contexts.  
 
Ferroptosis  
Ferroptosis is an oxidative, iron-dependent form of cell death defined in our lab in 2012 
(Dixon et al., 2012). It is biochemically and morphologically distinct from other forms of cell 





molecules, a unique feature to ferroptosis within other forms of programmed cell death (apart 
from apoptosis), implying that ferroptosis can be induced in contexts with aberrant cell survival, 
such as in oncology.  
Ferroptosis was elucidated using a chemical probe, erastin (Figure 1.3). Erastin was 
discovered in a synthetic lethal screen using isogenic fibroblast cell lines, where one cell line 
overexpressed oncogenic Ras and the other did not (Dolma et al., 2003a). Synthetic lethality 
describes a situation where a small molecule is lethal only in the context of a mutation in a 
specific gene. Erastin was synthetically lethal to oncogenic Ras expressing BJ fibroblasts over 
non-oncogenic Ras overexpressing fibroblasts. Yagoda et al. elucidated that the cell death 
induced by erastin was distinct from other forms of cell death in that caspases and PARP were 
not cleaved, signifying no activation of the apoptotic machinery (Yagoda et al., 2007). Similarly, 
Bax-/-Bak-/- double knockout MEF’s were equally sensitive to erastin as compared to wild-type 
MEF’s (Dixon et al., 2012). Small molecule RSL3 was discovered to induce ferroptosis in a 
similar synthetic lethal screen against oncogenic Ras (Yang and Stockwell, 2008a).  
Both erastin and RSL3 induce ferroptosis, as defined by their lethality being rescued by 
iron chelators and antioxidants, but by targeting different molecules in the cell. Erastin is 
proposed to bind to system xc-, the cystine/glutamate antiporter. System xc- inhibition by 
glutamate has been described to lead to oxytosis in certain contexts, as described above, but 
oxytosis differs from ferroptosis in that oxytosis can be modulated by altering calcium levels, 
whereas ferroptosis is insensitive to intracellular calcium perturbation (Dixon et al., 2012; 










Figure 1.3. Scheme of ferroptosis.  
In normal conditions (left side), system xc- is responsible for transporting the oxidized form of 
cysteine, cystine, into cells in exchange for glutamate. Once inside the cell, cystine is reduced to 
cysteine, which is the rate-limiting component of glutathione. Glutathione acts as the major 
antioxidant in cells, partially through acting as a cofactor for ROS detoxifying enzymes such as 
GPX4. GPX4 is a selenoprotein that detoxifies lipid ROS. Ferroptosis (right side) can be induced 
with erastin or RSL3. Erastin inhibits system xc-, which inhibits cell uptake of cystine, depleting 
cellular cysteine and glutathione, thereby inhibiting GPX4 activity. RSL3 directly inhibits GPX4, 
inhibiting its ability to detoxify lipid ROS. As a consequence, the build-up of lipid ROS leads to 
disruption of cellular membranes and eventual cell death.  





RSL3’s lethal mechanism is induced by binding to and inhibiting the activity of 
glutathione peroxidase 4 (GPX4), an enzyme that detoxifies cells of ROS by using glutathione as 
a cofactor to produce non-harmful products. GPX4 activity is dependent upon the availability of 
glutathione, so when glutathione is depleted with erastin treatment, GPX4 activity is also 
inhibited. Ferroptosis is thought to occur by an accumulation of the same species of lipid 
peroxides that can be degraded by GPX4 (Yang et al., 2014).   
Other small molecules can induce ferroptosis; FIN56 (Shimada et al., under review), 
sorafenib and sulfasalazine. FIN56 was discovered through modulatory profiling of caspase-
independent lethal compounds with unknown mechanisms of action (Wolpaw et al., 2011). 
FIN56 inhibits GPX4 activity by decreasing levels of GPX4 protein through a mechanism that is 
still being elucidated. Sorafenib and sulfasalazine can also inhibit system xc- and induce 
ferroptosis at high concentrations, although apoptosis can also be induced under certain 
circumstances (Dixon et al., 2014; Shukla et al., 2011).  
Ferroptosis has been implicated in the pathophysiology of some diseases. Ferrostatin-1, a 
specific inhibitor of ferroptosis, has been used in many in vitro and in vivo models of disease to 
probe the significance of ferroptosis in disease. Using rat brain slice models of glutamate 
excitotoxicity, ferrostatin-1 was able to rescue cells from death induced by glutamate (Dixon et 
al., 2012). Ferrostatin-1 has also been used to rescue from lethality induced by mutant 
Huntington expression in rat brain slices, in models of periventricular leukomalacia using 
oligodendrocytes undergoing cell death in response to cystine-deprivation, and in models of 
kidney proximal tubule damage, where mouse kidney proximal tubules were treated with 





Recently, ferroptosis was implicated in renal tubular cell death (Linkermann et al., 2014) and 
acute renal failure (Friedmann Angeli et al., 2014) using mouse models.  
The regulatory network of ferroptosis has been elucidated through small molecule and 
genetic analysis. Antioxidants, iron chelators and ferrostatin-1, have been shown to inhibit 
ferroptosis (Dixon et al., 2012; Yang and Stockwell, 2008a). A small set of shRNA’s targeting 
mitochondrial genes compiled by Vamsi Mootha and kinases were tested to identify genetic 
inhibitors of erastin induced cell death; however, these analyses were focused on a small subset 
of genes. Intact mitochondrial fatty acid metabolism, or presence of genes acyl-CoA synthetase 
family member 2 (ACSF2) and citrate synthase (CS), was found to be essential for ferroptosis, 
suggesting that ferroptosis may require a lipid precursor derived from the mitochondria for its 
lethal mechanism. To cast a wider net and to identify genes involved in ferroptosis outside of 
genes associated with the mitochondria and kinases, we sought to conduct a genome-wide RNAi 
screen to identify gene modulators of ferroptosis, as described in this thesis.  
 
Importance of identifying ways to modulate cell death 
 Despite the identification of many modes of cell death processes, there may be many 
more ways in which a cell may undergo death, increasing the possibility of targeting such death 
pathways for therapeutics.  
Resistance to apoptosis is one of the hallmarks of cancer (Hanahan and Weinberg, 2011). 
Tumor cells acquire mutations in genes that regulate cell death, such as tumor suppressor p53, 
which is mutated in over 50% of tumors (Harris and Levine, 2005). p53 is described in detail in 
Chapter 4, but therapeutics that reactivate p53 and sensitize to apoptosis are being used in 





proteins, such as the Bcl-2 family of proteins. Use of inhibitors of anti-apoptotic proteins is 
another method to resensitize tumor cells to apoptosis. Another method to treat uncontrolled 
growth is to force cells to die through non-classical cell death modalities, such as through 
ferroptosis in response to erastin. Knowledge of what genetic or metabolomic signature makes 
cells sensitive to such cell death mechanisms may help target therapeutics to tumors that will 
benefit the most from this type of therapy. 
In disease contexts where excess cell death is observed, such as in ischemia and 
neurodegenerative disease, the scope of cell death modalities involved is still not fully 
understood (Gorman, 2008). Understanding of how neurons and ischemic cells die will lead to 
development of therapeutics that inhibit the cell death, rescuing patients from the detrimental 
symptoms of the disease.     
 
Ways to modulate cell death 
 There are a few ways to study cell death, including classical genetic and biochemical techniques. 
Traditionally, classical genetic methods to study cellular processes involved complete aberration of the 
target protein, without temporal or spatial control. However, advances in genetic manipulation in cells has 
led to being able to alter genes in a controlled and relatively easy manner. Chemical biology, or the use of 
small molecules to study cellular processes, has become increasingly powerful as the number of probes 
we have to study biological processes have increased. Small molecule probes can be designed to inhibit 
one function of a multi-functional protein and allows for temporal control; all advantages over genetic 






Small molecule modulation of cellular processes  
 Small molecules have been used extensively to study cell death. Rapamycin, a natural 
product isolated from soil samples from the island Rap Nui in 1972 (Sehgal et al., 1975), was 
found to inhibit cell growth in many organisms, including Saccharomyces cerevisiae (Heitman et 
al., 1991), Drosophila (Oldham et al., 2000; Zhang et al., 2000), Caenorhabditis elegans (Long 
et al., 2002), fungus (Cruz et al., 1999), plants (Menand et al., 2002) and mammals. 
Identification of the protein target of rapamycin, mTOR (mammalian Target Of Rapamycin), 
opened the doors for further elucidation of the complex TOR signaling pathway, which plays a 
part in cell proliferation, growth, motility and survival, protein synthesis, and transcription (Hay 
and Sonenberg, 2004).   
 More recently, identification of necrostatin-1 (Nec-1), a small molecule inhibitor of 
necroptosis, and its mechanism of action in cells led to the understanding of the genetic network 
involved in regulated necrosis (Degterev et al., 2005; Holler et al., 2000). Using Nec-1, 
involvement of RIP1 and RIP3 kinases in necroptosis was elucidated (Degterev et al., 2008).   
 Forward chemical genetics is one way to identify small molecules that modulate cell 
death. Chemical genetics uses chemical probes, or small molecules, to perturb protein function 
and to study its effect on cellular processes (Schreiber, 1998). Instead of screening a pool of 
randomly mutagenized mutants for a phenotype of interest, as in a classical genetic screen, 
forward chemical genetics uses a large selection of small molecules to mimic random 
perturbations to a protein and downstream cellular function (Stockwell, 2000). A disadvantage to 
this approach is that every protein in the cell does not have a small molecule binder; however, 
screening large libraries with a diverse range of chemical structures will increase the chances of 





identified, the mechanism by which they elicit the phenotype is identified (Walsh and Chang, 
2006). Target identification on its own is not a trivial matter and may require different techniques 
to identify the relevant target (Schenone et al., 2013). Common phenotypes studied using 
forward chemical genetics include cell viability and motility. 
 In reverse chemical genetics, a target protein of interest is defined from the beginning, 
and large numbers of small molecules are screened to identify modulators of the specific target 
(Walsh and Chang, 2006). The “hit” small molecule can then be used in cell lines or in 
organisms to probe the function of the target protein. These screens can be designed to target 
enzymatic functions (such as kinases) (von Ahsen and Bomer, 2005) and protein-protein 
interactions (such as the p53-Mdm2 interaction) (Aeluri et al., 2014).       
 
Genetic modulation of cell processes 
Modulation of the genome has gained interest from researchers in the last few decades as 
a means to study individual gene function in normal physiology and in the pathophysiology of 
disease. Genetic modulation in vivo in model organisms has led to identification of genes and 
mutations that are involved in key cellular processes, such as cell cycle regulators discovered in 
yeast (Hartwell et al., 1974), apoptosis regulators discovered in C. elegans (Horvitz, 1999), and 
genes essential for development of multicellular organisms discovered in D. melanogaster 
(Nusslein-Volhard and Wieschaus, 1980; St Johnston and Nusslein-Volhard, 1992). 
Many methods exist to manipulate the genome, from complete knockout methods (where 
the translated gene is completely ablated) to gene knockdown techniques where residual amounts 
of the product protein may be present. In vivo knockout methods exist, such as the Cre-loxP 





mechanisms (Kilby et al., 1993). More recently, knockout methods have included zinc-finger 
nucleases (Santiago et al., 2008), TALEN (Miller et al., 2011), and CRISPR-Cas9 systems (Mali 
et al., 2013). 
Techniques to transiently modulate gene expression were first identified in 1984 in C. 
elegans with the use of antisense RNA that inhibited thymidine kinase (Izant and Weintraub, 
1984). Work by Fire and Mello in 1998 used double-stranded RNAs to knockdown activity of 
individual genes, which led to the founding of the RNAi (RNA interference) field (Fire et al., 
1998). RNAi is advantageous compared to traditional genetic studies as it is more easily 
employed in organisms where genetic knockouts are difficult to create (especially in mammalian 
systems), and can be used to study temporal effects of gene inhibition. 
There are a few methods by which genes can be knocked down, including siRNA (short-
interfering), esiRNA (endonuclease-prepared siRNAs), shRNA (short-hairpin) and dsRNA 
(double-stranded). These reagents take advantage of an endogenous RNAi machinery, 
microRNAs, which exist in mammalian cells to regulate protein expression (Djuranovic et al., 
2012). In general, si- or sh-RNA reagents must be shorter than ~21 base pairs to avoid initiation 
of the non-specific interferon response and apoptosis (Elbashir et al., 2001). New algorithms are 
being developed to design better sequences specific for the target mRNA, decreasing the chances 
of off-target effects (Holen, 2006). The specifics of each type of RNAi reagent will be described 
in detail below, but in general, in mammalian cell culture, once the RNAi reagent is introduced 
into cells and processed (in the case of shRNAs) into single siRNAs, the most unstable 5’ end is 
incorporated into the RISC (RNA-induced silencing complex) (Figure 1.4). In the RISC 
complex, mRNA with complementary sequence to the siRNA is cleaved by the Argonaute 






Figure 1.4. Schematic of RNAi in cells.   
dsRNA introduced into the cytoplasm are cleaved by Dicer enzyme into small interfering RNA 
(siRNA). Synthetic siRNA can be introduced directly into the cell, oftentimes utilizing cationic 
transfection reagents. siRNA is then incorporated into RNA-inducing silencing complex (RISC), 
where siRNA duplex is unraveled and the sense strand cleaved. The RISC-siRNA complex then 
binds target mRNA complementary to the passenger siRNA strand, leading to the degradation of 
target mRNA. shRNA integrated into the genome can be expressed and exported from the 





siRNA’s are chemically synthesized, double stranded sequences designed to target 
specific mRNA. Chemical modifications on siRNA’s have led to decreased off-target effects 
(Jackson et al., 2006). Different delivery methods can be optimized for different cell types, but 
the most commonly used methods include electroporation and lipid-mediated transfections. 
Electroporation methods require upwards of ten times more siRNA per experiment compared to 
lipid-mediated transfections, making this method costly on a high-throughput scale (Echeverri 
and Perrimon, 2006). Lipid-transfection reagents take advantage of the negative charge of 
siRNAs and encapsulates the siRNA (Liu and Huang, 2010). The lipid casing then interacts with 
the cell membrane and is endocytosed. siRNA reagents produce a transient effect of 5-6 days.  
Each siRNA reagent can only target one sequence. To avoid observing phenotypes 
associated with off-target effects, three to six sequences are usually tested against each gene 
target, and sometimes up to 30 sequences per gene have been tested (Bassik et al., 2009; Silva et 
al., 2008). Multiple sequences can be tested in a pooled format, where all the sequences are 
transfected into cells in one well, or arrayed, where each sequence is separated out into different 
wells for testing. One way to facilitate the use of multiple sequences in a pooled fashion is 
through the use of endoribonuclease-prepared siRNAs (esiRNAs)  (Kittler et al., 2004; Yang et 
al., 2002). esiRNAs are produced from 200-500 bp dsRNAs that are cleaved by Dicer enzyme or 
bacterial RNase III. The resulting fragments are siRNA-like molecules that can target one 
mRNA sequence. Although only a few screens have been conducted using esiRNAs, this tool 
proves useful for easily testing many sequences targeting a gene (Ding et al., 2009; Kittler and 
Buchholz, 2005; Kittler et al., 2004).  
shRNAs have been widely used in pooled RNAi screens, where long-term silencing is 





through viral transduction, leading to shRNA construct integration into the chromosome 
(Echeverri and Perrimon, 2006). Positive screens lead to identification of specific genes that 
when knocked down lead to survival of cells treated with a lethal stimulus  (Kolfschoten et al., 
2005; Popov et al., 2007; Westbrook et al., 2005). For negative selection screens, where loss of 
shRNA’s are sought, barcodes (short unique artificial DNA sequences) are necessary to track 
which shRNA is present at the beginning of the study, and which is missing at the end. A 
barcode can be up to 60 nucleotides and is specific for each shRNA, and is detected through a 
microarray technique (Schlabach et al., 2008). shRNA vectors can be regenerated and used for 
different screens, as opposed to siRNAs that are a one-time use reagent, so may be more feasible 
than siRNAs to continue using for experiments.  
dsRNAs are used mainly when knocking down genes in D. melanogaster. dsRNAs are 
stable enough to be taken up by D. melanogaster through media (Clemens et al., 2000). dsRNAs 
are also endogenous to eukaryotes and require processing by Dicer, a dsRNA-specific RNase III, 
to form siRNAs, which are then loaded into RISCs to degrade target mRNA.  
Apart from loss-of-function studies, target genes can be overexpressed to observe what 
phenotypes would be present with excess protein. Certain mutations that lead to overexpression 
of proteins, such as in HER2, MYC, REL or AKT2, can lead to tumor formation and progression 
(Shastry, 1995). Overexpression studies can be carried out through forced expression of a 
plasmid containing the gene for the protein of interest, through introduction of mutations that 
cause overexpression, or through regulation of the gene of interest with an inducible promoter 
(Prelich, 2012). Recently, a method to deliver purified proteins through lipid-mediated 
transfection was reported, circumventing the need to modify the genome or express plasmids 





Drawbacks of RNAi technology 
 Shortcomings of RNAi technology have become more evident as the number of 
publications addressing the same questions using genome-wide RNAi screens increases. For 
example, in identifying genes involved in HIV host infection and replication, three studies used 
similar siRNA reagents, but only three hit genes overlapped between the screens involving over 
20,000 genes (Brass et al., 2008; Bushman et al., 2009; Konig et al., 2008; Zhou et al., 2008). In 
another example, a genome-wide shRNA screen was conducted to find synthetic lethal genes 
with oncogenic KRAS expression, and STK33 knockdown was found to inhibit tumor cell growth 
(Scholl et al., 2009). In attempts to design small molecule inhibitors of STK33 to treat KRAS-
driven tumors, scientists at Amgen found that STK33 is actually not essential for KRAS-driven 
tumors (Babij et al., 2011). These variable results suggest that despite controlling for as many 
variables as possible (including cell type and RNAi reagent used), results from genome-wide 
RNAi screens may be difficult to replicate. 
 One issue associated with RNAi technology is the off-target effects; 21 nucleotide 
sequences specific for one mRNA target may also target other mRNA’s, invariably knocking 
down other targets (Qiu et al., 2005). To decrease these off-target effects, better algorithms are 
being used to design and modify the siRNA molecules. Incorporation of passenger strand into 
the RISC can also lead to off-target effects. The strand with less stable 5’ end is preferentially 
loaded onto the RISC, so the guide strand is now designed to be less stable than the passenger 
strand (Khvorova et al., 2003).     
 In a large-scale screen, it is difficult to optimize conditions for each target protein/RNAi 
reagent used. Screens are optimized using a negative and positive control, but these reagents may 





the different half-lives of proteins. Many studies use RNAi technology to knockdown translated 
proteins, but because proteins have different half-lives, the degree to which target proteins are 
actually depleted differs from RNAi reagent used and target mRNA/protein stability 
(Schwanhausser et al., 2011).  
Another issue associated with using one concentration of RNAi reagent (for siRNA 
screens) is that some reagents are more efficient than others at knocking down target proteins, 
again related to target protein half-life and design of siRNA. Depending on how efficient the 
RNAi reagent is, the concentration of reagent can be minimized (even as low as 1 nM siRNA 
concentration), which leads to less change in the global mRNA landscape (Caffrey et al., 2011). 
RNAi technology takes advantage of the endogenous RNAi machinery, so introduction of too 
much RNAi reagent will alter processing of endogenous mRNA and alter the mRNA landscape 
of the cell.   
 Despite some inconsistencies in results from RNAi studies, there have been some 
successes, where findings from RNAi screens from one lab have led to confirmation in other labs 
and translation into therapeutics. For example, in 2006, CARD11 was identified from a loss-of-
function study to inhibit diffuse large B-cell lymphoma growth (DLBCL) (Ngo et al., 2006). 
Later in 2011, Dong et al. confirmed using somatic mutagenesis techniques that CARD11 
activates NF-κB in DLBCL (Dong et al., 2011).      
	  
Genome-wide RNAi in cell death research 
Genome-wide RNAi screens have been used to elucidate mechanism of action of small 
molecule therapeutics, as well as defining the regulatory network of different cell death 





regulatory network of necroptosis (Hitomi et al., 2008). Genes essential for necroptosis induced 
by a pan-caspase inhibitor, zVAD.fmk, or TNF-α in L929 mouse cells, or in other words genes 
that suppressed necroptosis when knocked down, were identified and classified according to 
their function. Networks related to innate immunity were identified to regulate necroptosis, as 
well as an active translational machinery.  
Neuroblastoma H4 cells were used by Lipinski et al in a genome-wide human RNAi 
screen to identify regulators of autophagy (Lipinski et al., 2010). Autophagy was detected by a 
GFP-reporter linked to the expression of LC3, a component of autophagic vacuoles. This high-
content screen identified extracellular factors, such as growth factors, cytokines and chemokines, 
as regulating autophagy in unstressed cells.  
To identify regulators of splicing of apoptotic genes, a genome-wide siRNA screen was 
conducted in HeLa cancer cells (Moore et al., 2010). In this high-throughput screen, Bcl-X 
splicing was measured by tagging to Venus fluorescent protein, while Mcl1 splicing was 
monitored through tagging to red fluorescent protein (RFP). Two splice variants of Bcl-X and 
Mcl1 exits; the longer variants are anti-apoptotic by preventing mitochondrial outer membrane 
permeabilization, while the shorter versions are pro-apoptotic (Bae et al., 2000). Cell cycle 
disruption was found to encourage alternative splicing to produce the short pro-apoptotic 
isoform.   
	  
Applying reverse chemical genetics and genome-wide RNAi methods to study 
cell death 
 In this thesis, both a small molecule and RNAi approach are taken to explore two types of 





suppressors of erastin-induced ferroptosis is described. In Chapter 3, a gene “hit”, CARS, from 
the siRNA screen is validated and its mechanism of action in suppressing ferroptosis is 
discussed. Chapter 4 looks at a reverse chemical genetic approach to studying cell death 
involving p53, and elaborates on the incidental discovery of a novel non-apoptosis inducing 










Genome-wide RNAi screen to identify suppressors of erastin-




In Chapter 1, I introduced the field of cell death and the progress made in research over 
the last few decades. In this chapter, I will describe a genome-wide siRNA screen to identify 
genetic suppressors of ferroptosis. The ultimate goal of this project is to identify methods that 
inhibit ferroptosis in cases where ferroptosis may be detrimental, such as in neurodegenerative 
diseases. This screen yielded several hits, one of which will be mechanistically explored in the 
following chapter.  
 
Ferroptosis RNAi screens 
 In the Stockwell lab, we have previously conducted RNAi screens to identify suppressors 
of ferroptosis using targeted RNAi libraries. We first screened a shRNA library that targeted 
1,087 genes predicted to encode mitochondrial proteins (Dixon et al., 2012). The mitochondria 
was of interest because one distinct morphological change in cells undergoing ferroptosis is 
smaller mitochondria and increased membrane density compared to normal cells and cells 
undergoing apoptosis and autophagic cell death. This suggested that mitochondrial dysfunction 
was responsible for induction of ferroptotic cell death. The screen was conducted in HT-1080 
                                                
1 The following chapter is adapted from a manuscript in preparation: Hayano M, Yang WS, Corn 
CK, Stockwell BR.  Loss of Cysteinyl-tRNA synthetase induces the transsulfuration pathway 





and Calu-1 cells, with three to five shRNA hairpins/gene. There was no correlation between 
genes that when knocked down suppressed erastin lethality versus genes that were required for 
apoptosis induced by a nonspecific kinase inhibitor, staurosporine. A cluster of genes that 
regulate mitochondrial fatty acid metabolism were shown to be needed for erastin’s lethality, 
suggesting that a lipid precursor specific for ferroptosis may be generated by the mitochondria.  
 This screen was done using shRNA’s, which require viral infection and antibiotic 
selection, which may stress cells and affect the result of the screening experiment. Moreover, the 
screen used a focused library of shRNA targeting mitochondrial genes. To cast a wider net and to 
find genes essential for erastin-induced ferroptosis on a whole genome scale, we decided to 
conduct a genome-wide siRNA screen. In this chapter, I describe screening optimization steps 
taken to set up a siRNA screen in 384-well format, a genome-wide screen for suppressor siRNAs 
against erastin lethality and experiments validating the hits. As a result, I identified CARS, or 
cysteinyl-tRNA synthetase, as a gene whose knockdown leads to suppression of erastin-induced 
ferroptosis. The ultimate goal of this project is to find new methods to suppress ferroptosis in 
contexts where it is detrimental.                                                                     
 
Results 
384-well screening optimization  
In order to identify genetic suppressors of erastin-induced ferroptosis, we decided to 
conduct a genome-wide siRNA screen. Previous work from our lab identified voltage-dependent 
anion channel 3 (VDAC3) as an essential gene for erastin’s lethality (Yagoda et al., 2007). We 
therefore decided to use siRNA targeting VDAC3 as a positive control for erastin suppressor to 





reagent, 2) transfection reagent concentration, 3) cell number, and 4) erastin concentration 
(Echeverri et al., 2006). We proceeded to use HT-1080 fibrosarcoma cell lines as they are 
sensitive to erastin and undergo ferroptosis, and grow rapidly and uniformly in 384-well assay 
plates.  
The first variable we optimized was the transfection reagent to use in HT-1080 cells to 
knockdown genes. We opted to use the reverse-transfection method instead of traditional 
transfection methods that requires one more day of preparation (Ziauddin and Sabatini, 2001). 
As an initial screening method, we used 10 nM siRNA per well. In some studies, siRNA 
concentration of 100 nM induced changes in expression that were unrelated to the target 
knockdown, while 5-20 nM siRNA concentration showed less change in global expression 
(Semizarov et al., 2003). We tested three different lipid transfection reagents; Lipofectamine 
RNAiMAX (LifeTechnologies), NeoFX (LifeTechnologies), and HiPerfect (Qiagen). Depending 
on the cell line, different transfection reagents may be more efficient at transfecting with siRNA 
(Borawski et al., 2007). Forty-eight hours after reverse transfection in six-well format according 
to their respective manufacturers’ protocol, cells were harvested and VDAC3 mRNA levels were 
detected using qPCR. VDAC3 mRNA levels were compared to non-targeting siRNA (siNT) 
treated cells. As shown in Figure 1A, Lipofectamine RNAiMAX was most effective at knocking 
down VDAC3 mRNA levels compared to siNT treated cells.  
We next determined the concentration of Lipofectamine RNAiMAX needed in 384-well 
format. We reverse transfected siNT into HT-1080 cells at three different cell concentrations; 
500, 1000, and 1250 cells per well, using three different concentrations of Lipofectamine; 0.1, 
0.15, and 0.2 µL per well. Viability was measured using alamar blue after 48 hours of 





control mock cells transfected with siNT. Cells reverse-transfected with 0.15 µL of lipofectamine 
showed the best viability across all cell concentrations compared to other concentrations of 
Lipofectamine tested (Figure 2.1B).  
Using 0.15 µL Lipofectamine per well, we further optimized cell concentration. For a 48-
hour small-molecule treatment in 384-well format, our lab has traditionally used 1000 cells/well. 
However, the screening protocol we wanted to follow from the NYU RNAi Core suggested 72 
hours for knockdown. The extent of protein knockdown depends on the half-life of the protein, 
so at 72 hours, long-lived proteins may show more of a depletion compared to a shorter 
knockdown time frame (Sharma and Rao, 2009). We decided to test seeding 500 and 1000 
cells/well, as the 1250 cells/well used in Figure 2.1B was already visually overgrown. Testing 
two concentrations of erastin and two concentrations of cells, we found that 1000 cells/well 
showed the best separation between siNT-erastin treated cells and siVDAC3-erastin treated cells 
(Figure 2.1C). Using 500 cells/well, erastin, even at 10 µg/mL, did not force all the cells to die, 
while 1000 cells/well were more sensitive to erastin treatment. Sensitivity was determined as 
percent growth inhibition compared to vehicle treatment.  
Lastly, we optimized the concentration of erastin to use. Erastin was treated at a single-
dose in the screen. We wanted to use the minimum concentration possible to see the greatest 
difference between siNT transfected and siVDAC3 transfected cells. Using 4 µg/mL of erastin 







Figure 2.1. Optimization parameters for screening.  
A) Transfection reagent – three types of transfection reagent were tested in 6-well format. 10 nM 
siVDAC3 was reverse transfected using 2.5 µL Lipofectamine RNAiMAX. 100,000 HT-1080 





before cell harvesting and mRNA isolation. RT-qPCR was conducted using primers for actin as 
control and VDAC3. B) Optimization of Lipofectamine RNAiMAX volume. 0.1, 0.15 and 0.2 µL 
Lipofectamine RNAiMAX was used in a well in a 384-well plate, with siNT transfection. Cells 
were seeded in media containing 2X serum. After 72 hours, viability was measured with alamar 
blue and normalized to wells without Lipofectamine. C) HT-1080 cell number optimization. 
Using 0.15 µL Lipofectamine RNAiMAX per well and 9 nM siVDAC3 as a positive control, 500 
and 1000 cells were seeded per well in 384-well plate. Knockdown was allowed to proceed for 
72 hours, before addition of 7 µM erastin. After 24 hours, viability was measured using alamar 
blue. Compound treated cells were normalized to DMSO vehicle treated cells. D) Different 
concentrations of erastin were tested. 1000 cells/well of HT-1080 cells were transfected using 10 
nM siVDAC3 or siNT. Seventy-two hours later, different concentrations of erastin were added, 
and after 24 hours, viability measured. Z’ was calculated with the following equation: Z’ = 1-
((3(standard deviation positive control + standard deviation negative control))/absolute value (mean positive 
control - mean negative control).  

















Primary screen in HT-1080 cells 
 We worked in collaboration with the RNAi Core facility at NYU to conduct our genome-
wide siRNA screen. We utilized the Ambion Silencer siRNA library, where three siRNA 
sequences per gene are pooled together into one well in a 384-well plate. Using siRNA targeting 
VDAC3 as our positive control (Figure 2.2A, top graph % growth inhibition, bottom VDAC3 
mRNA fold change), we screened pools of siRNA targeting 21,687 genes. The screening cascade 
is shown in Figure 2.2B. Four identical plates (two for DMSO treatment and two for compound 
erastin treatment) were reverse transfected with a final concentration of siRNA in each well 
being 9.5 nM. After 72 hours of incubation, media containing either 7 µM erastin or equal 
volume of DMSO was added for 24 hours, after which viability was assessed using alamar blue. 
Percent growth inhibition of each siRNA pool was calculated using erastin treatment and their 
corresponding DMSO treated wells. Data were analyzed using CellHTS2, an R package that 






Figure 2.2. Genome-wide siRNA screening cascade.  
A) Screening was done with siVDAC3 as a positive control, knockdown for 72 hours before 
treatment with 7 µM erastin for 24 hours, then viability was assessed. One hundred percent 
growth inhibition means all cells are dead, while 0% growth inhibition means all cells are alive. 







Figure 2.3. Primary screen normalization data.  
A) Raw %GI information imputed into CellHTS2. Along the x-axis is plate number, and y-axis 
is distribution of raw %GI values on each plate. B) Normalized %GI values. Values were 
normalized to positive and negative controls on each plate and converted to z-score and the 
median of duplicates were taken. C) Normalized z-score values of controls on each plate. Blue 
labels are negative controls and red positive controls. D) Z’ calculated for the entire screen was 





 Figure 2.3 shows the data analysis progression used with CellHTS2. Panel A shows the 
distribution of raw percent growth inhibition calculated per well on each plate. In Panel B, the 
raw data was normalized to the positive control (average of six wells of siVDAC3 treated wells), 
where HT-1080 cells were rescued, and negative control (average of six siNT treated wells), 
where HT-1080 cells were mostly dead on each plate using the NPI (normalize percent 
inhibition) method. In the NPI method, each measurement is subtracted from the average of the 
plate positive controls, and divided by the difference between the means of the measurement of 
the positive and negative controls on the plate. Using CellHTS2, there are other methods of 
normalizing for plate-to-plate variations, including POC (percent of control) and B-score (Demir 
and Boutros, 2012). We tested these other normalization methods, but found the best Z’ factor 
when the NPI method was used. This could be because the NPI methods takes into account both 
positive and negative controls (POC only relies on positive controls), and the negative controls 
may also be variable from plate-to-plate because the amount of Lipofectamine RNAiMAX could 
be different when prepared at different times, and a slight increase in concentration could lead to 
cell death on its own.  
 Figure 2.3C shows the normalized data, where the blue dots are the negative controls on 
each plate, and red dots the positive controls. The separation between the averages of the two 
controls were summarized into the Z’ factor, which overall in the screen was 0.21. Although this 
Z’ factor is lower than the desired value for a small molecule screen (usually 0.5, higher the 
better), for an siRNA screen, which has more variability due to the difference in knockdown 
efficiency from different runs, this value was acceptable (Birmingham et al., 2009). The 
normalized values were then computed into Z scores for comparison across all the plates (Figure 





(MAD) from the median (1,426 genes) were selected to be re-evaluated in BJeLR fibroblast cells 




Figure 2.4. Summary of primary screen in HT-1080 cells.  









Figure 2.5. Secondary screen in BJeLR cells.  
A) Validation of VDAC3 as a positive control in BJeLR cells. 7 µM erastin treatment can be 
suppressed with VDAC3 knockdown (%GI on left, VDAC3 mRNA on right). B) Calculated %GI 






One thousand four hundred twenty-six genes with pools of siRNA were re-screened in 
BJeLR cells. BJeLR cells were chosen because, like HT-1080 cell, they undergo ferroptosis and 
grow uniformly in 384-well format. siVDAC3 was used as a control again (Figure 2.5A). Each 
pool of siRNA was screened in a similar manner to in HT-1080 cells. Out of the top 1,426 pools 
of siRNA tested, many did not rescue from erastin’s lethality in BJeLR cells, but some did, so we 
decided to select 250 genes that rescued from erastin’s lethality the most (i.e., smaller % GI) and 
whose knockdown on its own did not cause lethality on its own (viability of gene knockdown on 
DMSO treated plates >90%)  (Figure 2.5B).  
 
Gene selection and secondary screen in HT-1080 and Panc-1 cells 
 We decided to perform the next step of the screen, which involved testing three siRNA 
sequences for each gene with each sequence in individual wells, in both HT-1080 and Panc-1, a 
pancreatic cancer cell line. We decided to use another cell line so as to decrease the chances of 
finding a cell-line specific genetic modulator of ferroptosis.   
We confirmed that Panc-1 cells undergo ferroptosis by co-treating with ferroptosis 
inhibitors and erastin. As seen in Figure 2.6A, erastin lethality was suppressed with ferroptosis 
inhibitors α-tocopherol, ferrostatin-1 and the iron chelator deferoxamine. Using the 384-well 
screening conditions optimized for HT-1080 and BJeLR cells, we were able to see inhibition of 
the suppressive effects of VDAC3 knockdown on erastin’s lethality in Panc-1 cells (Figure 2.6B).  
Toxic siRNAs that decreased viability to < 30% of control were not further evaluated. Of 
the 250 genes selected, 15 genes reproducibly suppressed erastin-induced ferroptosis upon 





siRNA), and of these 15 genes, 11 reproduced in Panc-1 cells (3 sequences, t-test, p-value < 
0.05) (Table 2.1). This method relies on the fact that each siRNA sequence knocks down the 
target mRNA effectively, so chances of false-negatives may be increased if the siRNAs are not 
effective at knocking down the target. The 11 genes identified in HT-1080 and Panc-1 cells were 
associated with distinct pathways. Knockdown of CARS had by far the most robust suppressive 
effect, so we further investigated the function of this gene in ferroptosis (Figure 2.7). 
 
 
Figure 2.6. Panc-1 cells undergo ferroptosis.  
A) Erastin is inhibited by ATOC, Fer-1 and DFOM. Lethal compound was added to cells in a 
two-fold, 12-point dilution series and co-treated with 100 µM ATOC, 1.5 µM Fer-1, and 152 µM 



















% GI C P-value 
MAN2A2 84.3 59.0 54.0 0.03 14.3 6.5 22.7 0.00 
CARS 32.3 19.7 29.2 0.00 -2.0 3.9 18.1 0.00 
GTF3C3 49.6 65.9 76.2 0.02 5.9 22.0 15.7 0.01 
CGI-143 37.7 73.9 8.3 0.04 28.7 15.3 10.6 0.01 
p44S10 49.5 14.0 36.0 0.01 -12.7 14.3 -9.1 0.01 
TFIP11 55.8 78.3 33.7 0.04 -17.6 15.5 -7.4 0.02 
SRRM1 85.4 91.9 94.1 0.03 15.6 22.4 2.5 0.02 
TUBGCP3 24.2 41.7 47.7 0.01 -0.2 8.7 -26.4 0.02 
SAGE1 2.9 49.9 34.3 0.02 -11.4 33.1 16.9 0.03 
DNTT 61.1 44.0 84.5 0.04 45.4 0.3 12.2 0.04 
LYPLA1 79.9 41.7 17.0 0.05 -0.7 34.5 -7.4 0.04 
 
Table 2.1. Hits from secondary screen.  
Percent GI measured in both HT-1080 and Panc-1 cells, and P-values calculated from t-test 
compared to non-targeting siRNA treated cells for the three siRNA sequences targeting each 
gene (A, B and C sequences). These genes were the ones that rescued from erastin’s lethality 







Figure 2.7. Top 250 hits.  
From the 250 genes tested in a deconvoluted manner in HT-1080 cells, knockdown of 11 genes 
also rescued from erastin’s lethality in Panc-1 cells. Log(p-value) in HT-1080 cells shown on y-
axis, and log(p-value) in Panc-1 cells on x-axis.  
 
CARS knockdown inhibits erastin-induced ferroptosis in diverse cell contexts 
CARS encodes the cysteinyl-tRNA synthetase, an enzyme involved in the charging of 
tRNAs with cysteine for protein translation (Yao and Fox, 2013). We first validated the ability of 
CARS knockdown to prevent erastin-induced ferroptosis using three additional sequences of 
Ambion Silencer Select siRNAs targeting CARS (Figure 2.8A). These siRNA sequences knocked 
down CARS protein and mRNA levels as determined through immunoblotting and qPCR (Figure 
2.8B). Independent shRNA constructs targeting CARS also showed a suppressive phenotype, 










Figure 2.8. Knockdown of CARS rescues from erastin’s lethality.  
A) %GI and mRNA knockdown levels associated with each CARS siRNA sequence. B) CARS 
protein knockdown as determined by western blotting. C) shRNA’s targeting CARS also rescues 
from erastin’s lethality. The degree of rescue correlates to degree of CARS knockdown in the 
cells (shCARS-754, shCARS-756, and shCARS-757 knockdown CARS the best, and also 





To further confirm that the rescuing effect of CARS siRNA was through knockdown of 
the CARS mRNA, we examined the specificity of the CARS siRNAs using mutagenesis. The 
third codon of the siRNA target sequence was mutated to a degenerate nucleotide, and 
overexpressed in HT-1080 cells using a CARS cDNA overexpression plasmid in LentiORF 
backbone (Figure 2.9). Sequence 1 and 2 were used for the mutational and overexpression 
studies. As shown in Figure 2.10 left panel, gray lines, CARS overexpression was still sensitive 
to erastin. Knockdown of CARS using sequences 1 and 2 (siCARS.1 and siCARS.2, respectively, 
mRNA levels on bottom bar graph) suppressed erastin lethality. When HT-1080 cells expressed 
CARS with the target sequence of siCARS.1 mutated, CARS was no longer knocked down with 
the siRNA (Figure 2.10 middle panel, bottom graph), and the siCARS.1’s ability to suppress 
erastin was reverted, restoring sensitivity to erastin (Figure 2.10 middle panel, top graph). 
Likewise, when the target sequence of siCARS.2 was mutated, CARS was no longer knocked 
down with siCARS.2, while siCARS.1 was still able to knockdown the mutated form of CARS 
(Figure 2.10, right panel, bottom graph). CARS knockdown levels correlated to the cell’s ability 








Figure 2.9. Schematic of rescue experiment.   
Cells are transfected with CARS overexpression plasmids. Right side; site-directed mutagenesis 
is performed on overexpression plasmids so as to be unable to be targeted by siRNA. The third 
codon is mutated to a degenerate codon so the expressed protein is not altered in structure or 
function. Cells overexpressing wild-type CARS will respond to siCARS (left side of figure) and 
target gene expression is decreased, leading to the phenotype of rescuing erastin lethality. Cells 
overexpressing mutant CARS will not be sensitive to siCARS treatment, allowing for expression 







Figure 2.10. CARS rescue experiments.  
HT-1080 cells were transfected with CARS overexpression plasmids in the LentiORF backbone. 
Overexpressed CARS could still be knocked down with siRNA (bottom left panel). CARS 
knockdown led to resistance from erastin lethality. Overexpression of CARS with the target 
sequence of the first siRNA mutated led to siCARS.1’s inability to knockdown CARS mRNA, 
leaving cells sensitive to erastin (middle panels). This is in comparison to siCARS.2, which can 
still knockdown CARS mRNA, leading to resistance to erastin. The right panels show cells 
expressing CARS with the target of the second siRNA mutated, inhibiting its ability to 








CARS overexpression on its own (Figure 2.11, left panel qPCR data) did not sensitize to 
erastin-induced lethality, suggesting that the abundance of CARS is above the saturating levels 
needed for sensitivity to erastin under normal cellular conditions (Figure 2.11). These 
experiments established that CARS expression is essential for erastin-mediated ferroptosis.  
 
Figure 2.11. CARS cDNA overexpression does not sensitize to erastin.  
LentiORF containing the CARS construct was transfected into HT-1080 cells. LentiRFP was 
used as a control. Both cells are equally sensitive to erastin.  
 
 Erastin is lethal to many cell lines (Dixon et al., 2012). To ensure that the suppressive 
effect of CARS knockdown was not specific to HT-1080, Panc-1 and BJeLR cells, we knocked 
down CARS in two additional erastin-sensitive cell lines—A673 (Ewing’s sarcoma) and 143B 
(osteosarcoma) cells. CARS knockdown indeed prevented erastin-induced ferroptosis in all these 
cell lines, providing further evidence that CARS is required for ferroptosis in diverse cell 






Figure 2.12. Cell line selectivity of CARS knockdown to suppress erastin’s lethality.  
A) CARS was knocked down in HT-1080, Panc-1, 143B and A673 cells for 48 hours. 5 µM 
erastin was added for 24 hours before viability was assessed using ViCell cell count. Knockdown 
of CARS led to suppression of erastin lethality. B) qPCR validation of CARS knockdown.  
 
CARS knockdown selectively suppresses lethality induced by system xc- inhibition 
 We evaluated the specificity of the suppressive effect of CARS knockdown on lethal 
insults other than erastin. Specifically, we tested two other compounds that induce ferroptosis 
through distinct mechanisms: (1S,3R)-RSL3, hereafter referred to as RSL3, which inhibits GPX4 
directly, and FIN56, which causes depletion of GPX4 protein (Shimada et al., Nature Chemical 
Biology, under review), and on the lethality of the apoptosis inducers doxorubicin (a DNA-
damaging agent and topoisomeriase inhibitor) and rotenone (an inducer of mitochondrial ROS 
generation), in HT-1080 cells. CARS knockdown did not suppress the lethality of any of these 
compounds (Figure 2.13A), indicating that the suppressive effect of CARS is likely specific for 
ferroptosis induced by system xc- inhibition. In support of this observation, the lethality of ME II 
and PE, two erastin analogs that also inhibit system xc-, was suppressed by CARS knockdown. 





lipid peroxides and execution of ferroptosis (Yang et al., 2014), we hypothesized that CARS 
knockdown inhibits erastin’s lethality upstream of GPX4. CARS knockdown did not suppress the 
lethality of buthionine sulfoximine (BSO), an inhibitor of γ-glutamylcysteine synthetase, the 
rate-limiting enzyme in GSH synthesis, in HT-1080 cells, suggesting that CARS knockdown may 
not protect from lethality in response to inhibiting this step in glutathione synthesis (Figure 
2.13B). BSO, however, has been documented to induce ferroptosis, apoptosis and necrosis in 
different contexts, potentially complicating the interpretation of this result (Armstrong et al., 
























Figure 2.13. CARS knockdown rescues from system xc- inhibition.  
A) CARS suppressive effect on different lethal agents. Ferroptosis inducers RSL3 and FIN56’s 
lethality is not suppressed with CARS knockdown, as well as apoptosis inducers doxorubicin and 
rotenone. Erastin and its analogs, ME2 and PE, all system xc- inhibitors, are inhibited by CARS 
knockdown. CARS was knocked down in 6-well format, and after 48 hours, was re-seeded into 
384-well format. After 24 hours, lethal compounds were added in a 2-fold, 12-point dose curve. 
The highest concentrations of compound used were: erastin (37 µM), PE (15 µM), ME2 (3 µM), 
RSL3 (10 µM), FIN56 (41 µM), doxorubicin (36.8 µM), and rotenone (1.25 mM). AUC of each 
dose curve was calculated, then normalized to DMSO (vehicle) treatment, from which ΔAUC 
was calculated and compared to DMSO. Data are from four biological replicates, one-way 
ANOVA compared to vehicle treatment, Bonferroni correction, *** p-value <0.001, ** p-value 








In this chapter, a genome-wide siRNA screen was conducted to identify genetic inhibitors 
of erastin’s lethality. Ferroptosis, which can be induced with erastin, has been implicated in 
neurodegenerative disorders and a host of other diseases (Dixon et al., 2012; Skouta et al., 
2014a). Development of methods to inhibit ferroptosis may be beneficial in contexts where it is 
detrimental. Identification of genes essential for ferroptosis may lead to development of a small 
molecule inhibitor of the target protein, or may elucidate pathways that may be inhibited, to 
suppress ferroptosis. 
Loss-of-function screens using shRNA targeting kinases and mitochondrial genes have 
previously been conducted to elucidate erastin’s mechanism of action (Dixon et al., 2012). These 
studies led to the identification of mitochondrial lipid biosynthesis as playing an important role 
in ferroptosis. However, these screens focused on a subset of genes encoded in the human 
genome. To identify genes outside of the mitochondria and kinases that may be essential for 
ferroptosis, we decided to conduct a genome-wide siRNA screen.  
After optimization of the siRNA transfection in 384-well format in HT-1080 cells, we 
screened siRNA targeting over 20,000 genes. Potential hits were then re-screened in BJeLR 
cells, then genes whose knockdown rescued from erastin lethality the most were tested in a de-
convoluted format in HT-1080 and Panc-1 cells. From this screening cascade, we identified 
CARS, or cysteinyl-tRNA synthetase, as essential for erastin’s lethality.  
We determined that CARS is essential for erastin’s lethality in a panel of cell lines, 
including pancreatic cancer cell line Panc-1, osteosarcoma 143B and Ewing’s sarcoma A673. 
Overexpression of CARS in HT-1080 cells did not sensitize to erastin. Interestingly, knockdown 





induced by RSL3 and FIN56 were not affected. This suggests that the mechanism by which 
CARS knockdown is suppressing erastin’s lethality is upstream of the target of RSL3 and FIN56, 
which is GPX4. The next chapter will explore the mechanism by which CARS knockdown is 




Methods and Materials 
siRNA screening 
A pooled collection of siRNA’s targeting 21,687 genes (Ambion V3) was screened in 
conjunction with the RNAi core at New York University Langone Medical Center. Three 
sequences targeting each gene were pooled into 384-well format and screened in duplicate (for 
each DMSO and erastin treatments). HT-1080 cells were reverse-transfected using 
Lipofectamine RNAiMAX (Invitrogen, 13778150) with a final concentration of 9.5 nM siRNA 
in each well. siRNA targeting VDAC3 (Qiagen, SI00302155) was used as a positive control on 
all plates. 1.5 pmol siRNA was resuspended in 15 uL serum free OptiMEM in each well. 0.15 µL 
of Lipofectamine RNAiMAX was mixed with 15 µL of serum free OptiMEM in a polypropylene 
reservoir, and after 5 minutes, was transferred to each well containing the siRNA/OptiMEM 
mixture. After waiting for 30 mintues at room temperature, cells were added in 30 µL of media 
containing 2X serum and placed in the cell culture incubator. After 72 hours of knockdown, cells 
were treated with 7 µM erastin or DMSO. 24 hours later, cell viability was measured using 
Alamar Blue. Growth inhibition was calculated for each erastin treated well based on the average 
of the corresponding DMSO wells. The data was then analyzed using CellHTS2 (Boutros et al., 





controls on each plate), then the mean of the duplicates were calculated before conversion to a z-
score. The genes that rescued more than 3 median absolute deviation (MAD) from the median 
against erastin’s lethality based on z-score were re-screened in BJeLR cells using the same 
format as in H-1080 cells. 
 
Chemicals 
Erastin and RSL3 were synthesized as previously described in (Yagoda et al., 2007; Yang et al., 
2014). Doxorubicin was purchased from Tocris. Unless otherwise noted, all chemicals were 
purchased form Sigma-Aldrich (St. Louis, USA).  
 
Cell lines and media 
HT-1080, A673 and Panc-1 cells were from obtained from the American Type Culture 
Collection. BJeLR cells were obtained form Robert Weinberg (Whitehead Institue). 143B cells 
were obtained from Eric Schon (Columbia University Medical Center). BJeLR cells were grown 
in DMEM (Gibco/Life Technologies Corp.) plus 20% M199 (Sigma), 15% heat-inactivated fetal 
bovine serum (FBS) and 100 µg/mL penicillin/streptomycin (P/S). HT-1080 cells were grown in 
DMEM supplemented with 15% FBS, 1% non-essential amino acids (Gibco) and P/S. A673, 
Panc-1 and 143B cells were grown in DMEM with 10% FBS and P/S. All human cancer cells 
were grown in humidified 37°C, 5% CO2.  
 
siRNA reverse transfection 
Reverse transfection using siRNA’s were performed as follows for 6 well plates. siRNA was 
diluted in OptiMEM (250 µL) to a final concentration of 10 nM in the wells, and 250 uL of 





for 30 minutes. 100,000 cells were added to each well in regular growth media (200,000 for 
Panc-1 cells) and knockdown was allowed to proceed for 48 hours before re-seeding for dose 
curves, or harvested for qPCR. For transfection reagent optimization studies, siVDAC3 or non-
targeting siRNA was diluted in OptiMEM (250 µL) to a final concentration of 10 nM in the 
wells, and 250 uL of OptiMEM with 2.5 µL transfection reagent was added and incubated at 
room temperature for 30 minutes. 100,000 HT-1080 cells were added to each well in regular 
growth media and knockdown was allowed to proceed for 48 hours before harvesting mRNA. 
HiPerfect (Qiagen, 301702) and siPORT NeoFX (Ambion, AM4510) were tested alongside 
Lipofectamine RNAiMAX.  
 
shRNA knockdown in HT-1080 cells 
HT1080 cells were infected with lentiviruses that contain shRNA expression plasmids as 
previously described (Yang and Stockwell, 2008a). The clones used target CARS: 
TRCN0000045753, TRCN0000056865, TRCN0000056866, TRCN0000045756, 
TRCN0000045757, from Sigma Aldrich. Lentiviral shRNA were made following the protocol 
from The RNAi Consortium. Briefly, 280,000 293-T cells were seeded in each well of a 6-well 
plate the day before plasmid transfection. The next day, cells were transfected using X-
tremeGENE HP DNA transfection reagent (Roche, 06366244001) with shRNA plasmid (450 
ng), viral packaging plasmid (p-Δ8.9, 400 ng) and viral envelope plasmid (p-VSV-G, 45 ng). 
After 24 hours, media was replaced with viral collection media (293-T media with 30% FBS). 
Every 12 hours, media was replaced and collected over 36 hours and pooled. For lentiviral 
shRNA infection into HT-1080 cells, on the day before infection, for 384-well format, 400 cells 





supplemented with polybrene (8 µL/mL) and 2 µL of viral supernatant. Plates were centrifuged 
at 2,250 rpm for 90 minutes at room temperature. Plates were then incubated for 48 hours at 
37°C humidified incubator, before replacing media with media containing 1.5 µL/mL 
puromycin. After 24 hours, media was changed again to incorporate erastin in a two-fold, 
twelve-point dose curve. Plates were incubated for another 24 hours before viability was 
assessed by alamar blue. For qPCR studies to confirm knockdown, lentivirus infection was 
carried out in 6-well format. 30,000 cells/well were seeded the day before the infection, and on 
the day of the experiment, media was exchanged to incorporate polybrene and 150 µL viral 
supernatant. Spin infection and puromycin selection were carried out as in 384-well format. Cells 
were then harvested for mRNA extraction and qPCR.  
 
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
RNA was extracted using the Qiashredder and Qiagen RNeasy Mini kits (Qiagen) according to 
the manufacturer’s protocol. 1-2 µg total RNA was used for each reverse transcription reaction 
performed using the TaqMan RT kit (Applied Biosystems). Primer pairs were designed for target 
transcripts using Primer Express 3.0 (Applied Biosystems). Quantitative PCR reactions were 
performed using the Power SYBR Green PCR Master Mix (Applied Biosystems). Reactions 
were run and analyzed on a ViiA 7 (Life Technologies) qPCR instrument using absolute 
quantification settings. mRNA levels were normalized to ACTB internal control levels, and 
differences computed between samples using the ΔΔCt method. 
  Forward Reverse 













To conduct rescue experiments, a point mutation in the third codon of an amino acid at the target 
site of the siRNA was introduced through mutagenesis. Target sequences of two siRNA’s 
targeting CARS was used; seq 1 (Ambion Silencer Select Cat. # S2404), and seq 2 (Ambion 
Silencer Select Cat. # S2405).  
 
siRNA sequences and primers for each mutagenesis were as follows:   
CARS siRNA seq 1: GC AUG AAC AUU ACG GAU AU  
siRNA seq 1 forward primer: CAA ATT TGA TGT CTT TTA TTG CAT GAA CAT CAC AGA 
CAT TGA TGA CAA GAT CAT CAA GAG GGC CCG  
siRNA seq 1 reverse primer: CGG GCC CTC TTG ATG ATC TTG TCA TCA ATG TCT GTG 
ATG TTC ATG CAA TAA AAG ACA TCA AAT TTG 
 
CARS siRNA seq 2: C AAU GGG UCU GUC UAC UUU TT  
siRNA seq 2 forward primer: GGTTAC GGCTAT GTC TCC AAC GGATCC GTC TACTTT 
GAT ACA GCG A 
siRNA seq 2 reverse primer: TCG CTG TAT CAA AGT AGA CGG ATC CGTTGG AGA CAT 






Mutagenesis was conducted on Sigma LentiORF CARS (Clone 100998721) overexpression 
constructs. Mutagenesis was done using the following reaction mixture: 10 µL 5X buffer, 1 µL 
25 mM dNTPs, 25 µM of each primer, 1 µL of template (from miniprep), 3 µL DMSO, 31 µL 
water and 0.5 µL Phusion enzyme generously donated by Dr. Liang Tong at Columbia 
University.  
PCR reaction conditions:  
98° C 1 min 
98°C  30 sec 
65°C 1.5 min 
68°C 15 min 
X 25 times 
68°C  10 min 
PCR reactions were confirmed through sequencing. 
Three cell lines were constructed; one overexpressing wild-type CARS, another with siRNA seq 
1 sequence mutated, and a third with siRNA seq 2 sequence mutated. The LentiORF plasmids 
were infected into HT-1080 cells as lentivirus as described above with shRNA production. 10 
µg/mL of blasticidin was used to select for stably-transfected cells instead of puromycin. Once 
stably-transfected cell lines were constructed, siRNA-mediated gene knockdown was conducted 
as described above and tested for sensitivity to erastin.  
   
Immunoblotting  
Cells were lysed in lysis buffer consisting of 50 mM HEPES, 40 mM NaCl, 2 nM EDTA, 0.5% 





glycerophosphate and 1 tablet of protease inhibitor (Roche). Cell lysates were separated on a 4-
25% Tris-gel and transferred to nitrocellulose membrane. Primary antibodies were used at the 
following concentration: CARS (AbCam, ab69454) 1:500, Actin 1:1000 (Santa Cruz, sc-1616), 
overnight at 4°C. Blots were incubated with 1:2000 HRP-conjugated secondary before 







Elucidation of CARS knockdown as a suppressor of erastin-induced 
ferroptosis: Importance of the transsulfuration pathway 
 
Introduction 
In the last chapter, I conducted a genome-wide siRNA screen to identify genetic modulators of 
ferroptosis, and identified loss of CARS to suppress erastin-induced ferroptosis. In this chapter, I 
will elucidate the mechanism by which loss of CARS leads to suppression of ferroptosis.  
 
tRNA synthetases 
 Aminoacyl-tRNA synthetases (ARSs) are a family of enzymes that catalyze the ligation 
of amino acids to their cognate tRNA in the process of protein translation. This family of 
enzymes has been well conserved throughout evolution, mainly due to its essential function in 
cell homeostasis (Guo et al., 2009). Mammalian cells contain cytosolic and mitochondrial ARSs, 
one for each amino acid, with some ARS being able to identify and bind multiple amino acids, 
such as EPRS (glutamyl-prolyl-tRNA synthetase), which binds both glutamine and proline. 
Glycyl- and lysyl- tRNA synthetases are the only ARS that can function in both cytosol and 
mitochondria (Konovalova and Tyynismaa, 2013). The mitochondria synthesizes proteins 
essential in the oxidative phosphorylation system, and requires protein synthesis components to 
be inside the mitochondria even though mitochondrial ARS are encoded by nuclear genes 
distinct from cytosolic ARSs.  In the first step of ligation by ARS, an amino acid is charged with 
                                                
2 The following chapter is adapted from a manuscript in preparation: Hayano M, Yang WS, Corn 
CK, Stockwell BR.  Loss of Cysteinyl-tRNA synthetase induces the transsulfuration pathway 





adenylate, forming aminoacyl-AMP, requiring ATP. In the second step, the activated amino acid 
is delivered to the acceptor 3’ end of tRNAs. Some ARS have evolved to include editing 
functions, which prevents ligating tRNA with an incorrect amino acid (Guo et al., 2010a). Post-
charging editing functions exist as well, all to make sure incorrect amino acids are not 
incorporated into translated proteins, which, depending on amino acid change, could be 
catastrophic to the cell.    
 ARSs have evolved to incorporate about 20 different domains, such as glutathione S-
transferase (GST)-like and WHEP-domains, which allow them to possess functions other than in 
protein translation (Guo et al., 2010b; Kim et al., 2011). For example, seryl-tRNA synthetase 
(SARS) in humans and zebrafish contains a UNE-S domain, which dictates nuclear localization 
and is essential for cardiovascular development (Fukui et al., 2009; Herzog et al., 2009). The 
WHEP domain of tryptophanyl-tRNA synthetase (TARS) acts to bridge DNA-dependent protein 
kinase (DNA-PKcs) to poly(ADP-ribose) polymerase 1 (PARP-1) to activate p53 in response to 
IFN-γ stimulation (Sajish et al., 2012). 
 Some ARSs are involved in diseases. Charcot-Marie-Tooth (CMT) disease is caused by a 
heritable mutation in glycyl-tRNA synthetase (GARS) and tyrosyl-tRNA synthetase (YARS) 
(Antonellis et al., 2003; Jordanova et al., 2006). The disease causing mutations do not inhibit 
aminoacylation activity of GARS and YARS, but may alter other protein-protein interactions 
(Nangle et al., 2007). Methionyl-tRNA synthetase (MARS) has been shown to be mis-expressed 
in a variety of cancers, including colon cancer, Burkett’s lymphoma, breast cancer, and 
colorectal adenocarcinoma (Sang Won Lee, 2006). The aminoacylation activity of MARS is 
increased in some colon cancers (Kushner et al., 1976), but the relationship of different MARS 





ARS knockouts are embryonic lethal as ARSs transcribe essential proteins. Inhibitors 
against mammalian ARSs may be too toxic to use in the clinic; however, there are ARS 
inhibitors used as antimicrobials (Hurdle et al., 2005). Bacterial ARS have evolved over time to 
be divergent enough for small molecule inhibitors of eukaryotic ARS to be developed as 
therapeutics, such as mupirocin which targets isoleucine ARS and is used to treat both gram-
positive and –negative pathogens (Wuite et al., 1985). Some inhibitors of mammalian ARSs have 
been documented as a probe to study ARS functions. Histidinol is commonly used to study the 
function of histidyl-tRNA synthetase (HARS) (Hansen et al., 1972; Tsui et al., 1985), and 
halofuginone inhibits EPRS (Keller et al., 2012). Halofuginone was used to inhibit 
differentiation of TH17 cells through activation of the general amino acid control response (see 
below) (Sundrud et al., 2009).  
 
CARS – cysteinyl-tRNA synthetase 
 CARS encodes the protein responsible for charging cysteine-tRNA. Human CARS has 
evolved to contain three extra domains; the UNE-C1, UNE-C2 and GST domains (Guo et al., 
2010b). The function of these extra domains is currently unknown. CARS is expressed as a 
fusion protein to anaplastic lymphoma kinase (ALK) in some cancers (Cools et al., 2002; 
Debelenko et al., 2003). Again, the function of CARS-ALK fusion in cancer is unknown but may 
work to promote tumorigenesis.    
 
Amino acids 
 Amino acids are needed not only for synthesis of proteins but for synthesis of metabolites 





are essential in our diets, while the other amino acids can be synthesized from essential amino 
acid precursors and other metabolites (Kopple and Swendseid, 1975; Rose, 1949). Amino acids 
cannot be stored, so close regulation of the levels of amino acid intake and synthesis is needed. 
Precise control of amino acid levels is maintained through sensors that either allows cells to take 
up more amino acids or break them down.  
The general amino acid control (GAAC) and mammalian target of rapamycin (mTOR) 
pathways both sense nutrient status (Figure 3.1). The mTOR pathway is inhibited by amino acid 
restriction, and with excess amino acid activates mTORC1 signaling, which activates 4EBP1 and 
S6 kinase activation, allowing for translation of ribosomal proteins and enhancing protein 
translation (Efeyan et al., 2012; Peng et al., 2002; Sancak et al., 2008). Recently, excessive 
amino acid was shown to be taken up by the lysosome and to activate the v-ATPase-Ragulator 
complex, followed by activation of Rag GTPases, which recruit mTORC1 to lysosomal surface 
and allows for activation by the Rheb GTPase (Ras homolog enriched in brain) (Efeyan et al., 
2013). GAAC detects uncharged tRNAs as a consequence of low amino acids, and induces a 
signaling cascade for cells to cope with the stress. The two pathways are regulated differently 
and induce different downstream signaling cascades (Palii et al., 2009). For example, in response 
to leucine deprivation in mouse embryonic fibroblasts (MEFs), 420 genes were found to be up-
regulated and 311 genes down-regulated, with genes associated with serine family amino acid 
biosynthetic process and cholesterol biosynthetic process most enriched (Deval et al., 2008). 
Signaling through GAAC accounted for some of the downstream gene regulation, and mTORC1 






Figure 3.1. Amino acid sensing by mTORC1 and GCN2.  
In homeostatic state or with excess nutrients, such as amino acids, mTORC1 is recruited to the 
lysosomal surface and activated. mTORC1 signaling activates 4EBP1 and S6K, which support 
translation, while activation of ULK1 and TFEB both inhibit protein degradation (top panel). 





onto tRNA synthetases. Unloaded tRNA synthetases in the cytoplasm bind to GCN2 kinase and 
activates signaling. Downstream signaling events include phosphorylation of eIF2α, a 
transcriptional regulator of ATF4. P- eIF2α leads to inhibition of global translation, while 
allowing for translation of ATF4 targets which help cells cope with the amino acid deprivation 
stress.      





General amino acid control 
The general amino acid control (GAAC) response, also known as the amino acid 
response, is a conserved mechanism from yeasts to mammals that has been extensively studied in 
different organisms (Dever and Hinnebusch, 2005). When cells face stressors such as nutrient 
deprivation, the GAAC is activated to conserve energy and materials to survive until the stressor 
is removed. During amino acid deprivation, tRNA’s are not charged with their respective amino 
acids and deacylated tRNA’s accumulate. Deacylated tRNA’s bind to the regulatory domain 
related to histidyl-tRNA synthetase (HARS) on general control nonderepressible 2 (GCN2) 
kinase (Dong et al., 2000). GCN2 phosphorylates the α subunit of eIF2 upon binding of 
deacylated tRNA’s to GCN2.  
Phosphorylated eIF2α inhibits the general translational activity eIF2 and upregulation of 
a subset of genes under the control of ATF4. Global protein synthesis is turned off, and 
translation of mRNAs with C/EBP-ATF response element is initiated (Fawcett et al., 1999). eIF2 
in its heterotrimeric form is essential for general translation as it delivers charged methionyl 
initiator tRNA (Met-tRNAiMet) to the small (40S) ribosomal subunit along with GTP for 
initiation of translation (Hinnebusch and Natarajan, 2002). The resulting 43S preinitiation 
complex binds mRNA and forms the 43S complex, along with other eukaryotic initiation factors. 
Once the 48S complex finds the start codon on the mRNA, eIF2 is released by a GTPase, eIF5. 
The released eIF2-GDP is inactive for binding Met-tRNAiMet, and GDP to GTP exchange occurs 
through eIF2B. Phosphorylation on the α subunit of eIF2 results in its inability to recharge with 
GTP, inhibiting general translation (Proud, 1992).     
ATF4 is a transcriptional activator that activates stress-inducible transcription factor 





(Harding et al., 2000). There are two upstream ORFs (uORFs) in the 5’ leader of ATF4 mRNA. 
In non-stressed cells, eIF2-GTP guides the ribosome to translate uORF1 to uORF2, which forces 
the ribosome to dissociate and ATF4 mRNA is not translated. In stressed cells, eIF2-GTP is 
scarce, causing a delay in reinitiation and translation of ATF4 (Vattem and Wek, 2004). A 
negative feedback loop exits to re-activate global translation when the stress is removed. A 
downstream target of ATF4 is GADD34, which targets protein phosphatase 1α, which promotes 
dephosphorylation of the α subunit of eIF2 (Brush et al., 2003; Novoa et al., 2001; Novoa et al., 
2003).         
  eIF2α can be phosphorylated by three other kinases, PRKR-like endoplasmic reticulum 
kinase (PERK), protein kinase R (PKR) and heme-regulated eIF2α kinase (HRI), that respond to 
different stressors. PERK responds to ER stress such as with thapsigargin treatment, PKR 
responds to dsRNA as with viral infection, and HRI responds to heme limitation (Kilberg et al., 
2009). The yeast ortholog of ATF4, Gcn4, can be induced under conditions other than amino 
acid deprivation, such as growth in high salt medium, glucose limitation and treatment with 
rapamycin (Harding et al., 2000).    
ATF4 increases transcription of stress response genes by binding to C/EBP-ATF 
(CCAAT-enhancer binding protein-activating transcription factor) response element (Fawcett et 
al., 1999; Gjymishka et al., 2008). Genes upregulated in response to amino acid starvation 
include membrane amino acid transporters and ribosomal proteins. Apart from protein synthesis, 
amino acids are used for synthesis of other molecules that are required for cell homeostasis, such 
as glutathione (GSH). GSH is a tripeptide composed of glycine, glutamate and cysteine, and is 






Transsulfuration pathway  
 
Figure 3.2. Transsulfuration pathway and methionine metabolism in mammalian cells.  
AdoMet, S-adenosylmethionine; AdoHcy, S-adenosylhomocysteine; MAT, methionine 
adenosyltransferase; GNMT, glycine N-methyltransferase; MTs, AdoMet-dependent 
methaltransferases; SAHH, AdoHcy hydrolase; CBS, cystathionine β-synthase; CSE, γ-
cystathionase. Figure modified from Baric et al (Baric et al., 2004).   
 
In humans, sulfur must be obtained from the diet to be used in protein synthesis. Two 
amino acids account for sulfur incorporation into proteins; cysteine and methionine (Brosnan and 
Brosnan, 2006). The transsulfuration pathway allows for the synthesis of cysteine from 





transsulfuration pathway is a method of converting homocysteine (produced from methionine) to 
cystathionine, then to cysteine and α-ketobutyrate (Figure 3.2). The forward transsulfuration 
pathway exists in mammals (Mudd et al., 1965), archaebateria (Zhou and White, 1991) and yeast 
(Cherest and Surdin-Kerjan, 1992). Reverse transsulfuration pathway exists in bacteria (Cohen, 
1987) and plants (Macnicol et al., 1981), where cystathionine is formed from cysteine and O-
succinylhomoerine using complementarily functioning enzymes to the forward transsulfuration 
pathway. Homocysteine is derived from S-adenosylhomocysteine, and is found elevated in 
disease pathologies, including cardiovascular disease (Refsum et al., 1998), neural tube defects 
(Mills et al., 1995; Steegers-Theunissen et al., 1994) and Alzheimer’s disease (Clarke et al., 
1998).      
Cystathionine β-synthase (CBS) is the first enzyme in the transsulfuration pathway, 
converting homocysteine and serine into cystathionine. CBS is a homotetramer that binds two 
cofactors, pyridoxal 5’-phosphate (PLP) and heme (Kery et al., 1994; Skovby et al., 1984). After 
binding the substrates, CBS is further regulated by S-adenosyl-L-methionine, an allosteric 
activator. Heme’s role in the activity of CBS is unknown and may not be essential; yeast CBS 
functions similarly to mammalian CBS but does not contain heme (Jhee et al., 2000; Maclean et 
al., 2000). However, the heme may be a sensor of the cell redox state, as FeIII CBS is more active 
in vitro than FeII CBS (Cherney et al., 2007).  
γ-cystathionase (CSE) is the enzyme responsible for the second step in the 
transsulfuration pathway, converting cystathionine into cysteine and α-ketobutyrate, and also 
requires PLP. Propargylglycine (PPG) is a competitive inhibitor of CSE, competing with PLP. 
Although CSE and CBS both require PLP as cofactors, PPG only targets CSE (Asimakopoulou 





Some genes regulated by ATF4 feed into GSH biosynthesis by providing enzymes for 
cysteine formation; cysteine is usually not an essential amino acid as it can be synthesized from 
the transsulfuration pathway. PSAT1, PSPH and PHGDH, genes involved in serine biosynthesis, 
have been shown to be activated by ATF4 (Krug et al., 2014). Transsulfuration gene CTH 
(cystathione γ-lyase, protein known as CSE) is also thought to be activated by ATF4 (Dickhout 
et al., 2012). 
 
Results 
CARS knockdown induces general amino acid control stress response 
CARS encodes cysteinyl-tRNA synthetase, a protein that is used in protein translation. 
CARS functions to charge tRNA’s with the amino acid that it encodes for, using ATP as a 
cofactor (Yao and Fox, 2013). We first hypothesized that knockdown of CARS, similarly to 
inhibition of a tRNA synthetase by small molecules such as halofuginone (targets glutamyl-
prolyl-tRNA synthetase, or EPRS) (Keller et al., 2012), would induce the general amino acid 
response.  
 mRNA levels for ATF4 transcription factor, as well as downstream target Chac1, were 
indeed increased with CARS knockdown (Figure 3.3, A - CARS mRNA, B - ATF4 mRNA, C - 
Chac1 mRNA). Chac1 is a biomarker for ferroptosis (Dixon et al., 2014). On the protein level, 
along with CARS knockdown and increase in ATF4 levels, eIF2α, the kinase that activates 
ATF4, was phosphorylated on serine 51, indicative of GAAC activation (Figure 3.3D). GCN2, 








Figure 3.3. CARS knockdown induces ATF4 signaling.  
A) CARS mRNA knockdown using the three sequences targeting CARS. B) With knockdown of 
CARS, ATF4 mRNA is induced. C) With knockdown of CARS, Chac1, a biomarker for 
ferroptosis, is induced. qPCR data from biological triplicates. D) Overexpression of ATF4 
protein in response to CARS knockdown. eIF2α is also phosphorylated in response to the 
knockdown. Table shows fold change in protein abundance from CARS knockdown normalized 
to siNT treated cells, as determined by densitometry. E) The kinase upstream of eIF2α and 







 One of the downstream targets of GAAC and ATF4 activation is SLC7A11, a component 
of system xc- (Sato et al., 1999). System xc- is inhibited by erastin, and overexpression of 
SLC7A11 leads to suppression of erastin-mediated ferroptosis (Dixon et al., 2012). With CARS 
knockdown, SLC7A11 mRNA levels increased (Figure 3.4A CARS mRNA, Figure 3.4B 
SLC7A11 mRNA). The knockdown of SLC7A11, as previously seen, sensitized to erastin’s 
lethality (Figure 3.4D, gray lines with X marks) (Dixon et al., 2012). The sensitization effect 
seen with SLC7A11 knockdown was associated with inhibition of system xc- activity. Combining 
knockdown of SLC7A11 and CARS led to a rescue of SLC7A11 mRNA levels compared to 
SLC7A11 knockdown alone, which corresponded to a rescue of system xc- activity as determined 
from a glutamate release assay (Figure 3.4B for mRNA levels, Figure 3.4C for glutamate release 
assay). Although the functional activity of system xc- was restored following combined 
knockdown of both SLC7A11 and CARS, the suppressive effect of CARS knockdown on erastin’s 
lethality was not restored (Figure 3.4D). Taken together, we conclude that CARS knockdown’s 
ability to induce upregulation of SLC7A11 mRNA is not the cause of resistance to erastin in cells 






Figure 3.4. SLC7A11 induction by CARS knockdown does not suppress erastin’s lethality.  
A) CARS mRNA levels in response to CARS and SLC7A11 knockdown. B) SLC7A11 mRNA 
levels in response to CARS and SLC7A11 knockdown. Knockdown of CARS induces a 2.5 fold 
increase in SLC7A11 mRNA levels. Combined knockdown of CARS and SLC7A11 result in 
restoration of SLC7A11 mRNA levels to cells treated with non-targeting siRNA. Biological 
triplicates, one-way ANOVA, Bonferroni correction, ** p-value <0.01, ns = not significant in 
relation to indicated treatment. C) System xc- activity measured by glutamate release into media. 
HT-1080 cells were treated with siRNA for 48 hours, before glutamate release assay was 
conducted and activity normalized to cell number. Knockdown of SLC7A11 leads to inhibition of 





non-targeting siRNA treated cells. System xc- activity assay and qPCR data from biological 
triplicates. One-way ANOVA, Bonferroni correction, **** p-value <0.0001, ns = not-significant 
in relation to indicated treatment. D) Erastin dose-response curve with CARS and/or SLC7A11 
knocked down.   SLC7A11 knockdown leads to a slight sensitization to erastin, while knockdown 
of CARS leads to suppression of lethality. The combined knockdown leads to suppression of 
erastin lethality, similarly to CARS alone. Dose-response curve representative of biological 
triplicates.    





CARS knockdown does not alter intracellular iron homeostasis 
Treatment of cells with the iron chelator deferoxamine or knockdown of iron-regulating 
genes, such as the transferrin receptor, inhibits ferroptosis, as iron is required to induce the lipid 
peroxidation that is involved in the execution of ferroptosis (Yang and Stockwell, 2008a). We 
therefore sought to determine whether CARS knockdown elicits its suppressive effects by 
modulating iron levels. Using calcein-acetoxymethyl ester (calcein-AM) to measure intracellular 
labile iron levels, we observed no difference in calcein-AM staining between CARS knockdown 
and control cells (Figure 3.5A) (Tenopoulou et al., 2007). Likewise, mRNA expression levels of 
iron-regulating genes were not altered (Figure 3.5B). These data suggest that CARS knockdown 
does not affect iron homeostasis in cells.   






Figure 3.5. Intracellular iron levels are not affected by CARS knockdown.  
A) Intracellular iron levels were measured using Calcein AM. CARS was knocked down in HT-
1080 cells for 48 hours before staining with Calcein AM. Fluorescence was measured by flow 
cytometry. Biological duplicates. B)  Levels of iron regulating genes were not altered with CARS 
knockdown. Genes regulated by iron or proteins that regulate iron’s mRNA were quantified from 
HT-1080 cells after 48 hours of CARS knockdown. There were no differences between control 
cells and siCARS treated cells in the amount of mRNA. mRNA from biological triplicates. 





         
Lipid ROS generation in response to erastin is inhibited by CARS knockdown 
 Lipid ROS accumulates when GPX4 is inhibited, and this leads to the cell death 
phenotype that is observed in ferroptosis. GPX4, as mentioned in Chapter 2, can be inhibited 
directly with RSL3 or indirectly by depleting GSH with compounds such as erastin. We assayed 
for lipid ROS levels in response to erastin treatment in the context of CARS knockdown using 
C11-conjugated BODIPY. C11-BODIPY (581/591) is a dye that reports on lipid ROS. BODIPY 
can be oxidized by reactive oxygen species, resulting in a shift in fluorescence, and the 11-
carbon saturated fatty acid modification to the BODIPY dye allows it to insert into lipid 
environments. As expected, CARS knockdown inhibited erastin’s ability to induce C11-BODIPY 
oxidation (Figure 3.6A, left panel), but did not have an effect on RSL3’s ability to induce C11-
BODIPY oxidation (Figure 3.6A, right panel). Similar trends in intracellular ROS were observed 
using H2DCFDA (DCF) stain (Figure 3.6B, erastin left panel, RSL3 right panel). These data 
suggest that CARS knockdown inhibits the ferroptotic mechanism upstream of GPX4 inhibition, 






Figure 3.6 Knockdown of CARS inhibits lipid and intracellular ROS formation in response to 
erastin but not RSL3.  
A) Lipid ROS levels were measured with C11-conjugated BODIPY. Erastin treatment (left 
panel) and RSL3 treatment (right panel) both induce an increase in C11-BODIPY staining. This 
increase was inhibited with CARS knockdown in erastin treated cells, but did not affect C11-
BODIPY levels with RSL3 treatment. B) Intracellular ROS levels were monitored with 





RSL3 (right panel), DCF staining increases in cells. With CARS  knocked down, this increase is 
inhibited, while RSL3 induced DCF staining is unaltered. Biological triplicates, two-way 
ANOVA with Bonferroni correction. *** p-value <0.001, ** p-value <0.01, * p-value <0.05, ns 
= not significant compared to indicated treatment.  






Transsulfuration pathway is upregulated in response to CARS knockdown 
 Since CARS uses cysteine in a conjugation reaction with uncharged tRNAs, we 
hypothesized that CARS knockdown might elevate intracellular cysteine levels, which might in 
turn alter intracellular glutathione levels. We performed a global metabolite analysis to detect 
alterations in over 300 metabolites upon CARS knockdown (see Appendix I). There was a 
modest detectable increase in intracellular free cysteine (Figure 3.7, leftmost panel); however, 
there was no change in the level of reduced or oxidized intracellular GSH (Figure 3.7, right two 
panels). The most increased metabolite upon CARS knockdown was in fact cysteine-glutathione 
disulfide (CSSG), which would likely form upon an increase in cysteine levels (Figure 3.7, 
second from left panel). We hypothesized that CSSG could serve as a source of glutathione in 
times of stress, such as upon loss of cellular cysteine. Indeed, there was a slight, but significant 
(t-test, p-value <0.05), increase even in reduced and oxidized GSH upon erastin treatment in the 
presence of CARS knockdown.  







Figure 3.7. Intracellular metabolite levels.  
Global metabolomics studies were done with HT-1080 cells with or without 5 µM erastin, and 
with CARS knockdown or control non-targeting siRNA treated cells. Over 300 metabolites were 
detected by Metabolon, Inc. Data from five biological replicates. T-test ** p-value <0.01, * p-
value <0.05.  
 
 We also determined from this experiment that cystathionine, a central metabolite in the 
transsulfuration pathway, was increased upon CARS gene knockdown (Figure 3.8). We 
wondered if, upon CARS knockdown, cells might become dependent upon the transsulfuration 
pathway to generate cysteine, leading to resistance to erastin. We examined changes in the 
transcriptome using RNA sequencing (RNA-seq) to determine whether genes involved in the 
transsulfuration pathway may be induced upon CARS knockdown (see Appendix II). Indeed, 
compared to non-targeting-siRNA-treated cells, siCARS induced genes involved in serine 
biosynthesis and transsulfuration (Figure 3.8); thus, we further investigated this pathway’s 







Figure 3.8. RNA-seq and metabolite analysis of the transsulfuaration pathway. Metabolites are in 
black, and fold change in metabolite abundance in CARS knockdown cells compared to non-
targeting-siRNA treated cells are shown. mRNA transcripts detected with RNA-sequencing are 
shown in gray. The numbers following indicate fold change in FPKM from CARS knockdown 
cells compared to control cells. RNA-seq data from biological triplicates.      
 
In order to probe the involvement of the transsulfuration pathway in leading to resistance 
to erastin, we first co-treated siCARS-transfected cells with a small molecule inhibitor of the 
transsulfuration pathway. Propargylglycine (PPG) is an inhibitor of cystathionine γ-lyase, the 





Walsh, 1973). As expected, PPG treatment on its own had no effect on erastin’s lethality (Figure 
3.9A, left panel). However, co-treatment of siCARS with PPG re-sensitized cells to erastin, 
suggesting that the transsulfuration pathway is necessary for siCARS’s ability to suppress 
erastin’s lethality (Figure 3.9A, right panel). To ensure that PPG was not acting through other 
mechanisms known to suppress erastin, we co-treated PPG with the antioxidant α-tocopherol 
(ATOC) or with the iron chelator deferoxamine (DFOM). Neither ATOC nor DFOM’s ability to 
suppress erastin was altered upon co-treatment with PPG, suggesting that the re-sensitization 
effect seen with PPG in the presence of CARS knockdown is specific to the suppressive effect of 
CARS, likely due to activation of the transsulfuration pathway (Figure 3.9B). We confirmed 
PPG’s ability to re-sensitize cells to erastin after CARS knockdown in 143B cells (Figure 3.9C).   
Instead of small molecule inhibition of the transsulfuration pathway, we also knocked 
down a gene associated with the pathway simultaneously with CARS knockdown to see if indeed 
the upregulation of the transsulfuration pathway was leading to suppression of erastin’s lethality. 
We knocked down cystathionine β synthase (CBS) simultaneously with CARS, and saw a re-
sensitization to erastin (Figure 3.9D viability assay, 3.9E for mRNA levels). The small molecule 
and genetic inhibition of the transsulfuration pathway re-sensitizing CARS knockdown cells to 
erastin suggests that cells that can up-regulate the transsulfuration pathway can become resistant 













A) Treatment with 2 mM propargylglycine (PPG) in the presence of CARS knockdown 
resensitizes cells erastin (right panel). PPG treatment on its own has no effect on erastin’s 
lethality. CARS was knocked down for 48 hours in 6 well format, followed by re-seeding into 
384 well format with 2 mM PPG. After 24 hours, erastin was added in a two-fold, 12-point 
dilution series. Data representative of biological triplicates. B) PPG has no effect on suppressive 
effects of small molecule suppressors of erastin. HT-1080 cells were seeded with ferroptosis 
inhibitors α-tocopherol or deferoxamine, with or without 2 mM PPG in 384 well format. After 
24 hours, erastin was added in a two-fold, 12-point dilution series. Data representative of 
biological triplicates. C) PPG can resensitizes 143B cells to erastin with CARS knocked down. In 
non-targeting siRNA treated cells, treatment with PPG did not have an effect on 143B cells’s 
sensitivity to 5 µM erastin. With CARS knocked down, cells were no longer sensitive to erastin 
(middle panel). However, with co-treatment with PPG, cells were resensitized to erastin. CARS 
was knocked down in 12-well format for 48 hours, before addition of 5 µM erastin and/or 2 mM 
PPG. After 24 hours, viability was accessed by ViCell cell counting. Biological triplicates, two-
way ANOVA, Bonferroni correction. *** p-value <0.001, ** p-value <0.01, ns = not significant 
compared to designated treatment. D) Simultaneous knockdown of CARS and CBS resensitize 
cells to erastin.  HT-1080 cells were treated with 2.5 nM siCARS and/or 7.5 nM siCBS for 48 
hours, before treatment with 5 µM erastin for 24 hours. Viability was assessed by ViCell cell 
count. E) Knockdown of CARS and CBS in HT-1080 cells.    








 Induction of the integrated stress response has been shown to induce cystathionine γ-
lyase to assist cells in maintaining their redox state (Dickhout et al., 2012). tRNA synthetase 
inhibition leads to phosphorylation of eIF2α and activation of the transcription factor ATF4, 
inducing a similar transcriptional mechanism to the integrated stress response (Keller et al., 
2012). CARS knockdown by siCARS induced ATF4 through phosphorylation of eIF2α (as 
shown in Figure 3.3D), which may be the mechanism responsible for induction of the 
transsulfuration pathway.  
 We expected that knockdown of other tRNA synthetases would inhibit translation and 
induce the general amino acid control response, regardless of specific amino acid tRNA 
synthetase knockdown; CARS is part of a family of tRNA synthetases. In mammals, there are 
tRNA synthetases for specific amino acids, with some tRNA synthetases able to charge multiple 
amino acids (Guo et al., 2010b). We knocked down other tRNA synthetases to determine if 
charging of other amino acids is essential for the suppressive effect of erastin-induced 
ferroptosis: MARS, methionyl-tRNA synthetase; HARS, histidyl-tRNA synthetase; CARS2, the 
mitochondrial cysteinyl-tRNA synthetase; EPRS, the dual glutamyl-prolyl-tRNA synthetase; and 
SARS, seryl-tRNA synthetase. Knockdown of HARS and EPRS had rescuing effects in response 
to erastin lethality, while MARS, SARS and CARS2 knockdown did not (Figure 3.10A, left 
panel). None of these tRNA synthetase knockdowns suppressed RSL3-induced ferroptosis 
(Figure 3.10A, right panel). Among the other 15 tRNA synthetases, knockdown of KARS, NARS, 
QARS, VARS also suppressed erastin’s lethality, suggesting that the effects seen with CARS 
knockdown are not generalizable to all tRNA synthetases. The specificity of each tRNA 
synthetase knockdown’s ability to rescue from erastin’s lethality could be attributed to different 





speculated, in addition, that the effectiveness of each tRNA synthetase knockdown was due to a 










Figure 3.10. A few other tRNA synthetase knockdowns rescue from erastin-induced lethality.  
A) CARS, HARS and EPRS knockdown rescue from erastin-induced lethality (left panel). RSL3 
lethality was unaffected by these tRNA synthetase knockdowns (right panel). tRNA synthetases 
were knocked down in 6-well format in HT-1080 cells for 48 hours. Cells were then re-seeded 
into 384-well format, then after 24 hours, erastin was added in a two-fold, 12-point dilution 
series for 24 hours before viability was assessed with alamar blue. Negative ΔAUC indicates 
suppression of % growth inhibition dose-curves. Four biological replicates, one-way ANOVA, 
Bonferroni correction. ** p-value <0.01, *** p-value <0.001. B) Confirmation of tRNA 
synthetase knockdowns using qPCR. Data from biological triplicates. C) Rest of tRNA 
synthetase knockdown’s effect on erastin’s lethality. Experiment done in same manner as in 
panel A. On average four biological replicates, one-way ANOVA, Bonferroni correction, * p-
value <0.05, ** p-value <0.01, **** p-value <0.0001 compared to siNT. D) qPCR confirmation 
of target tRNA knockdown with siRNA.         




















To determine the basis for the difference in tRNA synthetase knockdown suppressive 
activity, we conducted quantitative RT-qPCR on mRNAs involved in the transsulfuration 
pathway to determine whether their upregulation was different between knockdown of different 
tRNA synthetases. Using MARS knockdown as a negative control and CARS and EPRS 
knockdown as positive controls for suppression of erastin lethality, we performed RT-qPCR on 
cells upon knockdown of these genes. Indeed, we found that upon EPRS knockdown, the 
transsulfuration pathway genes CBS, CTH, PSAT1, and PSPH were upregulated, while MARS 
knockdown had no effect on the mRNA levels of these genes (Figure 3.11A, tRNA synthetase 
knockdown confirmation in Figure 3.11B). The precise mechanism by which knockdown of 
some tRNA synthetases leads to induction of genes associated with transsulfuration is not 
known. Nonetheless, upregulation of transsulfuration genes was predictive of the knockdown of 
tRNA synthetases to cause resistance to erastin-induced ferroptosis, suggesting that this is a key 







Figure 3.11. Differential upregulation of transsulfuration genes upon tRNA synthetase 
knockdown in HT-1080 cells.  
A) CBS was up-regulated in CARS and EPRS knockdown cells. These tRNA synthetase 
knockdowns suppress erastin’s lethality. MARS knockdown, which does not suppress erastin’s 
lethality, did not induce expression of this gene. Serine biosynthesis genes were also upregulated 





correction. * p-value <0.05, ** p-value <0.01, *** p-value <0.001, ns = not significant compared 
to indicated treatment. B) Confirmation of tRNA synthetase knockdown in cells used in panel A.  





CARS knockdown suppresses ferroptosis in other systems 
To expand on the ability of CARS knockdown to inhibit ferroptosis in different contexts, 
we utilized PC12 rat pheochromocytoma cells. In a glutamate-induced excitotoxic rat brain-slice 
model, ferroptosis inhibitors were able to suppress cell death (Dixon et al., 2012). We wondered 
if glutamate-induced toxicity could be rescued with Cars knockdown. PC12 cells are sensitive to 
glutamate-induced toxicity, which can be rescued with antioxidants (Pereira and Oliveira, 1997). 
We first tested to see if PC12 cells undergo ferroptosis in response to erastin and glutamate. 
PC12 cells were sensitive to both erastin and glutamate, and both toxicities were rescued with 
ferroptosis inhibitors Fer1, deferoxamine (DFO), and α-tocopherol (ATOC) (Figure 3.12A). 
Etoposide, a topoisomerase inhibitor that causes apoptosis, was not suppressed by these 
modulators. Glutamate and erastin’s toxicities were also associated with increased lipid ROS 
levels (Figure 3.12B). Chac1 mRNA was previously shown to be a biomarker for ferroptosis 
(Dixon and Stockwell, 2014). In PC12 cell, Chac1 was also upregulated in response to erastin 
and glutamate (Figure 3.12C). These data suggest that PC12 cells can undergo ferroptosis, and 
that glutamate induces ferroptosis. To confirm that glutamate was inducing cell death through 
depletion of cysteine, similar to erastin, we co-treated PC12 cells with glutamate and β-
mercaptoethanol (BME). BME can rescue system xc- inhibition by promoting cystine uptake 
through an alternative pathway (Ishii et al., 1981).   Indeed, glutamate lethality was rescued by 
co-treatment with BME, suggesting that its lethal mechanism in part involves inhibition of 
cystine import (Figure 3.12D).  
Confirming that PC12 cells undergo ferroptosis in response to erastin and glutamate, we 
employed shRNA against rat Cars gene. We saw a suppressive effect of erastin and glutamate 





suggest that inhibition of CARS may be beneficial in disease contexts, such as in 
neurodegenerative disorders like Huntington’s.  







Figure 3.12. PC12 cells undergo ferroptosis in response to glutamate, whose toxicity can be 
rescued by Cars knockdown.  
A) Erastin and glutamate induce ferroptosis in PC12 cells. PC12 cells were seeded in 384-well 
format with ferroptosis inhibitors Fer1, DFOM and ATOC. Lethal compounds were added in a 
two-fold, six-point dilution series. After 48 hours, viability was assessed using alamar blue. 
Etoposide was used as a non-ferroptosis inducing lethal compound. Graph representative of 
biological triplicates. B) Erastin and glutamate treatment leads to increased C11-BODIPY 





correction. *** p-value <0.001. C) Erastin and glutamate induce Chac1 mRNA expression as 
determined by RT-qPCR. D) Glutamate induces cell death through cystine-deprivation. Co-
treatment with β-mercaptoethanol (BME), rescues PC12 cells form glutamate induced lethality. 
Biological triplicates, one-way ANOVA, Bonferroni correction. *** p-value <0.001. E) 
Knockdown of rat Cars in PC12 cells suppresses erastin and glutamate induced lethality. PC12 
cells were electroporated with shRNA targeted Cars, allowed to recover for 48 hours, selected 
for transfected cells for 24 hours, before addition of lethal compounds in a two-fold, seven-point 
dilution series. Graph representative of biological triplicates. F) Confirmation of Cars 

































Another method to expand upon CARS knockdown’s ability to rescue from ferroptosis 
was to utilize ATF4-/- mouse embryonic fibroblasts (Hettmann et al., 2000). ATF4-/- MEF’s 
undergo cell death in the absence of reducing agent BME. These cells produce reactive oxygen 
species (DCF detectable) and can be rescued with DFO, similar to ferroptosis (Harding et al., 
2003). Mouse Cars knockdown in ATF4-/- cells cultured without BME were rescued compared 
to ATF4-/- cells transfected with non-targeting siRNA (Figure 3.13A, qPCR in Figure 3.13B). 
This data suggests that ferroptosis-like cell death in MEF’s can be rescued with Cars 
knockdown, and rescuing effects can be independent of ATF4. It is a possibility that in these 
MEF’s other stress responses may compensate for the lack of ATF4. Another possibility is that 
since ATF4 mRNA levels are detected through qPCR in ATF4-/- cells (Figure 3.13C, ATF4 
panel, third bar from left), ATF4 may actually be present in these cells and is enough to induce 
genes associated with the transsulfuration pathway and serine biosynthesis. Indeed, CBS, PSAT1 







Figure 3.13. ATF4-/- MEF lethality can be rescued with Cars knockdown.  
Cells were deprived of β-mercaptoethanol (BME) for 48 hours before viability was assessed with 
ViCell cell counting. In non-targeting siRNA transfected cells, ATF-/- cells died without BME, 
while having no affect on ATF+/- MEF’s. The lethality seen in ATF-/- cells with BME starvation 
was rescued with mouse Cars knockdown. One-way ANOVA, Bonferroni correction, * p-value 
<0.05. B) Confirmation of Cars knockdown in MEF’s. C) Confirmation of Atf4 mRNA levels, 
along with transsulfuration and serine biosynthesis genes in MEF’s. t-test, * p-value < 0.05, ns = 







Ferroptosis is a regulated cell death mechanism that can be induced with small molecules, 
and may occur in degenerative disease contexts. The death process involves lipid peroxidation; 
lipid peroxides are involved in diseases such as periventricular leukomalacia (PVL), ischemia 
reperfusion injury, and Huntington’s disease (HD). Methods to inhibit or monitor this form of 
cell death may be useful in these contexts.  
 In the previous chapter, we screened for genes essential for erastin-induced ferroptosis 
and identified CARS, a cysteinyl-tRNA synthetase. In this chapter, we elucidated the mechanism 
by which CARS knockdown was leading to suppression of erastin-induced lethality. CARS 
knockdown inhibited lipid ROS generation upon erastin treatment, but did not have an effect on 
intracellular iron levels. CARS is involved in cysteine metabolism, which is the rate limiting 
reagent for the synthesis of glutathione, an important molecule in the regulation of the oxidative 
environment of cells and ferroptosis. Upon CARS knockdown, we found an increase in 
intracellular cysteine and also an increase in reduced and oxidized glutathione with erastin 
treatment, leading to maintenance of GPX4 activity and to the rescue of erastin-induced 
ferroptosis.       
 Specific tRNA synthetase knockdown, such as for CARS, HARS, EPRS, NARS, QARS, 
VARS and KARS, caused suppression of erastin’s lethality, while other ARS knockdowns did not. 
We determined that this difference was due to each ARS knockdown’s ability to induce genes 
associated with the transsulfuration pathway. Specifically, CBS, which is involved in the 
conversion of cystathionine to cysteine, was upregulated by ARS knockdowns that suppressed 
erastin’s lethality. The basis for the specificity of some ARS knockdowns’ ability to induce 





expression to different extents (Palii et al., 2009). Another possibility is that cells are more 
sensitive to accumulation of, or incorporation into proteins, of cysteine, histidine and 
proline/glutamate.  
 There are different domains associated with some ARSs that may have functions apart 
from tRNA charging (Guo et al., 2010b). CARS may have an alternative function that allows 
cells to remain sensitive to ferroptosis, such as partaking in generation of lipid ROS. However, 
there are no overlapping domains between CARS, HARS, EPRS and KARS.  
 The ability of CARS knockdown to suppress ferroptosis induced by erastin, through 
activation of the transsulfuration pathway, explains the observation that CARS knockdown does 
not suppress the lethality of RSL3 or BSO. GPX4 inhibition by RSL3 cannot be rescued by 
increasing the pool of CSSG, GSH or cysteine, as RSL3 directly inhibits GPX4 biochemical 
activity. In addition, increasing the pool of intracellular cysteine would not suppress the lethality 
of BSO, which acts at the stage of inhibiting the conjugation of cysteine to the g-carboxyl group 
of glutamate. Thus, activation of the transsulfuration pathway by CARS knockdown is only 
expected to suppress the ferroptosis induced by cysteine depletion, caused by inhibiting the 
cystine-glutamate exchanger, system xc-.  
GPX4 activity has been shown to be neuroprotective in Huntington’s disease models 
(Mason et al., 2013). In addition, supplementation of cysteine to mouse diets was recently shown 
to delay neurodegeneration in mouse models of the disease (Paul et al., 2014). The deficiency of 
cystathionine γ-lyase in Huntington’s disease models was suggested to mediate the 
pathophysiology of the disease. tRNA synthetase inhibitors exist as anti-microbial agents 
(Hurdle et al., 2005); however, development of a mammalian CARS inhibitor may be too toxic, 





may be beneficial in slowing cell death in certain physiological conditions, such as Huntington’s 
disease or ischemia-reperfusion injury. Irrespective of this, the knowledge that ARS activity and 
the transsulfuration pathway regulate sensitivity to ferroptosis may aid in understanding and 
regulating this form of cell death in diverse contexts. 
 
Methods and Materials 
Chemicals 
Erastin and RSL3 were synthesized as previously described in (Yagoda et al., 2007; Yang et al., 
2014). Doxorubicin was purchased from Tocris. Unless otherwise noted, all chemicals were 
purchased form Sigma-Aldrich (St. Louis, USA).  
 
Cell lines and media 
HT-1080, A673 and Panc-1 cells were from obtained from the American Type Culture 
Collection.     BJeLR cells were obtained form Robert Weinberg (Whitehead Institue). 143B 
cells were obtained from Eric Schon (Columbia University Medical Center). BJeLR cells were 
grown in DMEM (Gibco/Life Technologies Corp.) plus 20% M199 (Sigma), 15% heat-
inactivated fetal bovine serum (FBS) and 100 µg/mL penicillin/streptomycin (P/S). HT-1080 
cells were grown in DMEM supplemented with 15% FBS, 1% non-essential amino acids 
(NEAA) (Gibco) and P/S. A673, Panc-1 and 143B cells were grown in DMEM with 10% FBS 
and P/S. All human cancer cells were grown in humidified 37°C, 5% CO2. PC12 cells were 
purchased from American Type Culture Collection and grown in humidified 37°C, 9.5% CO2, in 
DMEM (Corning, 15-013) supplemented with 10% Cosmic calf serum (HyClone, SH30087), P/S 





David Ron (University of Cambridge) and Scott Vafai (Massachusetts General Hospital). Cells 
were grown in complete medium consisteing of DMEM plus 10% FBS, P/S, 2 mM L-glutamine, 
55 µM β-mercaptoethanol and 1% NEAA. MEFs were grown in humidified 37°C, 5% CO2 
conditions.        
 
siRNA reverse transfection 
Reverse transfection using siRNA’s were performed as follows for 6 well plates. siRNA was 
diluted in OptiMEM (250 µL) to a final concentration of 10 nM in the wells, and 250 uL of 
OptiMEM with 2.5 µL Lipofectamine RNAiMAX was added and incubated at room temperature 
for 30 minutes. 100,000 cells were added to each well in regular growth media (200,000 for 
Panc-1 cells) and knockdown was allowed to proceed for 48 hours before re-seeding for dose 
curves, or harvested for qPCR. MEFs were reverse transfected in a similar manner using pooled 
siRNA targeting mouse Cars (Ambion, #s77612, #s77613, #s77614)  
 
Growth inhibition measurements 
Cells were grown in 384 well format and treated with compound for indicated times. Alamar 
blue was added to each well at a final concentration of 10% for 6 hours before reading the 
fluorescence (ex/em 530/590) on a fluorescence plate reader (Victor3). For ΔAUC calculations, 
cells were treated with lethal compounds in a 12-point, 2-fold dilution series. The highest 
concentrations used were erastin (36.6 µM), RSL3 (10 µM), doxorubicin (18.4 µM), rotenone 
(25.4 µM), ME2 (3 µM), PE (15.5 µM) and sulfasalazine (4 mM). Cells were treated with lethal 





AUC determined from dose-response curves. ΔAUC was calculated based on non-targeting 
siRNA treated or vehicle-treated dose curves.  
 
Lipid ROS measurements 
100,000 HT-1080 cells were seeded in 6 well plates (Corning) after reverse transfection using 2 
µL Lipofectamine RNAiMAX and 10 nM siRNA. 48 hours later, cells were treated with 10 µM 
erastin, 625 nM RSL3 or DMSO for 8 hours. BODIPY-C11 (Invitrogen, D-3861) was added to a 
final concentration of 1.5 µM for 20 minutes before cells were harvested by trypsinization, 
washed and strained through a 40 µM cell strainer (BD Falcon). Cells were analyzed using a 
flow cytometer (Accuri C6, BD Biosciences) equipped with a 488 nm laser for excitation.  Data 
were collected from the FL1 channel, with a minimum of 10,000 cells per sample. Data were 
analyzed as in (Dixon et al., 2012). H2DCFDA (Molcular Probes) staining was done in a similar 
manner.  
 
Reverse transcription-quantitative polymerase chain reaction (RT-qPCR) 
RNA was extracted using the Qiashredder and Qiagen RNeasy Mini kits (Qiagen) according to 
the manufacturer’s protocol. 1-2 µg total RNA was used for each reverse transcription reaction 
performed using the TaqMan RT kit (Applied Biosystems). Primer pairs were designed for target 
transcripts using Primer Express 3.0 (Applied Biosystems). Quantitative PCR reactions were 
performed using the Power SYBR Green PCR Master Mix (Applied Biosystems). Reactions 
were run and analyzed on a ViiA 7 (Life Technologies) qPCR instrument using absolute 
quantification settings. mRNA levels were normalized to ACTB internal control levels, and 





    Forward Reverse 
Human Actin GCGCGGCTACAGCTTCA CTTAATGTCACGCACGATTTCC 
  CARS AGCTTGCCACAGAGCCAC GTTGACTTCCTCTCCCGTGAGTTT 
  TFRC CCTGCAGCACGTCGCTTA GGTGAAGTCTGTGCTGTCCAGTT 
  IREB2 AGGAATAGTGCTGCCGCTAAGT TCGAGCTCCGTAAGAGTTGAATT 
  ISCU CGTGAAACTGCACTGCTCCAT CCAGGGCGGCCTTGAT 
  FTH1 CAGATCAACCTGGAGCTCTAC CTTCAAAGCCACATCATCGC 
  FTL ACCCCAGACGCCATGAAA AGGGCCTGGTTCAGCTTTTT 
  FBXL5 TGCAGTCCACCAAGCAGTATG ATTTCTTCTCCAATGCCCTTGTT 
  DMT1 GCAGGACAGAGCTCCACCAT GGAATCCCTCCATGACAAACTG 
  MARS CACCCAATGCCCAGTTTATCA GTTATGCAGCGTGGCTTGAG 
  HARS TTAAACGCTACCACATAGCAAAGG TCGGCCACGGGTCAT 
  CARS2 AGGCAATGTCTACTTCGATCTGAA ACCACGCCGACCAATTTG 
  SARS GCTCGCCGGCTTCGA CTCCACCTTGTCCATCATCTTCT 
  DARS TGGCGGTGGGAGACCAT TTTGTTGATGTTGGCAGCAAA 
  EPRS GACGCTCTCTCTGACCGTGAA ACGTGTTCTACTGCCAGCAAAG 
  GARS AGACCCCCCACACTGCAA TCTGCTCTTATCTGCCGCATT 
  LARS AAGGCACTGGTGTGGTTACAAGT TCTCTGAGGGCAGCAATATCATC 
  AARS GGCCGGCCTGACAACA GGCGGAGAATCCGTCTCAA 
  IARS GGCCACGGCCCTCTTT GACAAGCCCATTCACAATTACG 
  KARS CGGCGAATCAACATGGTAGA TTCGTTTCTGGCAGCTTCATC 
  RARS TGAAGGTGAACATGTGGCGTAT CAAACCCCTTGGCCATGAC 
  TARS GCGATTGGGCGGTACCA GATGGGCAACTGGAAATCCA 
  YARS TGAGGAGTGCATCGCACAGT AAATGGAGCCCAGCTTGGT 
  WARS GCCTTATCCCATGTGCCATT GGCGACGTCCCTTGTCAT 





  HARS TTAAACGCTACCACATAGCAAAGG TCGGCCACGGGTCATG 
  FARSA TCACCCGCTGCTCAAGGT GTGAACCCCATCTCCAGGAA 
  NARS GTGTGTCTTGGCGGATGAGTT TGCTCTCCGTGGACAAGAGA 
  QARS CCCTGGGTTCCACCATTG GGGAGGCCAAGCCATATAACA 
  VDAC3 AATTTCGCCCTGGGTTACAA AATTCAGTGCCATCGTTCACAT 
    
Rat Actin TTCAACACCCCAGCCATGT CAGAGGCATACAGGGACAACAC 
  Cars GATGCGTCTCACATGGGACAT CCCTCCGCAGGATATCGA 
  Chac1 TTGCTTGCCGAGGCTTCT TCTGCCAAACGCAACAAGTATT 
Mouse Actin CGATGCCCTGAGGCTCTTT TGGATGCCACAGGATTCCA 
 Cars GCGGATCCAGAACTCTGTGAA GATCGCACAGCCTGTTCCA 
 
RNA sequencing 
RNA was isolated from siRNA and compound-treated HT-1080 cells as described above for RT-
qPCR reactions. Poly-A pull-down was used to enrich mRNAs from total RNA samples (1 µg 
per sample, RIN>8 on Bioanalyzer) and libraries were prepared using Illumina TruSeq RNA 
prep kit. Libraries were sequenced using an Illumina HiSeq 2000 instrument (Columbia Genome 
Center, Columbia University). Short reads were mapped to the human reference genome using 
Tophat, and relative abundance of genes and splice isoforms were determined using Cufflinks.   
 
Metabolomic profiling 
1.5 million HT-1080 cells were reverse transfected with siNT or siCARS in 15 cm tissue culture 
dish and incubated for 48 hours. DMSO (vehicle), 10 µM erastin (7 hours) or 500 nM RSL3 (2 





pelleted, washed with PBS and flash frozen. Samples were processed by Metabolon Inc. The 
experiment was done in biological quintuplicate.      
 
Calcein-AM staining 
To detect intracellular iron levels, CARS was knocked down in cells for 48 hours. On the day of 
assay, cells were harvested in HBSS and incubated with 10 nM Calcein AM (Invitrogen, C3099) 
for 10 minutes at 37 °C. Cells were then washed and analyzed through an Accuri C6 flow 
cytometer.         
 
Immunoblotting  
Cells were lysed in lysis buffer consisting of 50 mM HEPES, 40 mM NaCl, 2 nM EDTA, 0.5% 
Triton X-100, 1.5 mM Na3VO4, 50 mM NaF, 10 mM sodium pyrophosphate, 10 mM sodium 
beta-glycerophosphate and 1 tablet of protease inhibitor (Roche). Cell lysates were separated on 
a 4-25% Tris-gel and transferred to nitrocellulose membrane. Primary antibodies were used at 
the following concentrations: ATF4 (Santa Cruz, sc-200) 1:100, phosphor-eIF2α (Cell Signaling, 
3597) 1:200, eIF2α (Cell Signaling, 5324) 1:1000, CARS (AbCam, ab69454) 1:500, overnight at 
4°C. Blots were incubated with 1:2000 HRP-conjugated secondary before development with 
SuperSignal West Pico Substrate (Pierce, 34080).      
 
PC12 modulator treatment 
7,500 PC12 cells were seeded in 384 well format with fer1 (1.5 µM), ATOC (100 µM) and DFO 
(152 µM). Lethal compounds were added in 2-fold, 6-point dilution series, with the highest 






shRNA knockdown in PC12 cells 
Cars was knocked down in PC12 cells using shRNA targeting rat sequences (Qiagen, 
KR46003P, Clone 2 (insert sequence CAGTATGATGTCTTTTACTGC) and 3 (insert sequence 
CCATTCTCAGTCAAGTTAAGT)). On the day of experiment, 2 million PC12 cells were 
mixed with 2 µg of shRNA construct and nucelofected using Nucelofection reagent V (Lonza, 
VACA-1003). Nucelofected cells were plated in 384-well format. After 48 hours, puromycin (2 
µg/mL) was added to select for cells expressing the shRNA. After 24 hours, lethal compounds 
were added for 24 hours before viability measurements. To confirm knockdown of Cars, 
nucleofected cells were seeded in 6 well plate, and knockdown allowed to proceed for 48 hours 
and puromycin selection for 24 hours, before harvesting cells for qPCR analysis.           
 
Statistical analysis 
All experiments were done in three biological replicates unless otherwise noted. Prism 6.0b was 







Small molecule probes for cell death: development of a Mdm2 
inhibitor and RAS synthetic lethal compounds 
 
In the last two chapters, I developed a genome-wide RNAi screen to identify genetic modulators 
of ferroptotic cell death and elucidated the mechanism by which CARS knockdown leads to 
upregulation of the transsulfuration pathway, thereby allowing cells to buffer against cysteine 
depletion and suppress ferroptosis. In this chapter, I study two types of cell death using chemical 
probes; an Mdm2 inhibitor to study Mdm2-regulated apoptosis, and a novel ferroptosis inducer.  
 
Introduction 
p53 and cell death 
p53 was first discovered in 1979 and thought to be an oncogene due to its high mutation 
rate; it is now one of the most well studied tumor suppressors in cancer biology (DeLeo et al., 
1979; Kress et al., 1979; Lane and Crawford, 1979; Linzer and Levine, 1979). Roughly 50% of 
cancers have mutated or deleted p53, and often even in wild-type expressing cells, the p53 
signaling pathway is somehow disrupted (Harris and Levine, 2005; Soussi, 2005). p53 itself is a 
transcription factor that responds to stress and oncogenic signals and induces transcription of 
                                                
3 Data from this chapter have been published. The data on MEL compounds were published in: 
Herman AG, Hayano M, Poyurovsky MV, Shimada K, Skouta R, Prives C, Stockwell BR. 
Discovery of Mdm2-MdmX E3 Ligase Inhibitors Using a Cell-Based Ubiquitination Assay. 
Cancer Discovery, 2011 Sep; 1(4):312-25. 
Data from Compound 27 were published in: Skouta R, Hayano M, Shimada K, Stockwell BR. 
Design and synthesis of Pictet-Spengler condensation products that exhibit oncogenic-RAS 






genes involved in cell death and cell cycle regulation. Given the tumor suppressive function and 
high frequency of perturbation in cancer, activators of p53 have been pursued as potential 
chemotherapeutics.  
Genotoxic stresses can also activate p53 signaling. DNA can be damaged by oxidative 
free radicals, UV irradiation, alkylation of bases and more. Each type of DNA damage is 
repaired by different sets of proteins, but all report to the p53 pathway (Giaccia and Kastan, 
1998; Gudkov and Komarova, 2003; Oren, 2003). When adequate repairs are not made, the p53 
pathway ensures that those cells are eliminated. Stressors other than DNA damage also signal to 
activate p53: hypoxia, glucose starvation, faulty chromosome segregation, denatured protein 
response, and nitric oxide, to name a few. When cells become abnormal they signal to p53, 
allowing the p53 pathway to act as a checkpoint to prevent growth of abnormal cells. For this 
reason, p53 has been coined the “Guardian of the Genome”(Lane, 1992).  
 p53 activity is heavily regulated through several mechanisms. For example, p53 has a 
relatively short half-life of 6-20 minutes in many cell lines, mainly due to the ubiquitin ligase 
activity of Mdm2. Recently, two other ubiquitin ligases, COP1 and PIRH2, have been shown to 
regulate p53 (Dornan et al., 2004; Leng et al., 2003). p53 can be regulated post-translationally by 
other factors that allow it to bind p53 DNA response elements (Appella and Anderson, 2001). 
Serine and threonine residues on p53 are phosphorylated by multiple kinases, including ATM. 
Several other modifications to p53 have also been reported; it can be acetylated by histone 
acetyltransferases, ubiqutinated, SUMOylated, NEDDylated and methylated (Brooks and Gu, 
2003; Xirodimas et al., 2004; Xu, 2003). Although these modifications regulate protein function, 
they may not be essential for p53 activation. For example, while gamma radiation activates 





significantly affect the p53 response. Likewise, Nutlin, a small molecule that inhibits p53-Mdm2 
interaction and stabilizes p53, activates p53 without phosphorylation (Vassilev et al., 2004). 
Further research is underway to determine what functional alterations of p53 protein signaling 
occurs with post-translational modifications.  
 Target genes of p53 encompass three general functional domains: cell cycle arrest, 
apoptosis, and senescence. p53-regulated genes in cell cycle arrest include p21, 14-3-3 sigma, 
and GADD-45. In its apoptosis-regulatory function, p53 can upregulate Fas production, as well 
as killer-DR5, which induces the extrinsic apoptotic machinery. p53 can also upregulate genes 
involved in the intrinsic apoptotic pathway, including Bax, Noxa and Puma. A third set of genes 
regulated by p53 are involved in senescence, such as p21. While these three outputs have been 
well studied, recent research has shown certain p53 target genes to be involved in other areas of 
cell function. For example, Sestrins are a set of p53 regulated genes and can counter the presence 
of reactive oxygen species in cells (Budanov et al., 2004).  
Many of the p53 target genes are involved in a positive or negative feedback loop with 
p53, including Mdm2, Cop1 and PIRH2. These regulatory loops provide integration of stress 
signaling and makes sure p53 is tightly regulated, as too much p53 can be lethal, but too little can 
lead to uncontrolled growth.  
 
Mdm2 
 Mdm2 is the murine double minute 2 protein, first discovered in the late 1980s as an 
amplified factor in the spontaneously transformed 3T3 mouse cell line. Its importance in cancer 
was realized with the discovery of Mdm2 amplification in various tumors, with some tumors, 





Furthermore, a single nucleotide polymorphism in the Mdm2 promoter (SNP309) leads to a 2-3 
fold increase in Mdm2 expression, which correlates with accelerated tumor formation (Levine et 
al., 2006). More importantly, Mdm2 knockout is embryonic lethal in mice, pointing to the 
significance of Mdm2 in normal physiology (Montes de Oca Luna et al., 1995). However, in the 
background of p53 knockout, Mdm2 knockout mice are viable, pointing to the importance of 
Mdm2 in blocking p53-mediated cell death in development.  
 Mdm2 is a protein of 491 amino acids with three well-conserved domains: an N-terminal 
domain important in binding p53, a Zinc-finger domain, and a C-terminal RING domain (Toledo 
and Wahl, 2007). The C-terminal RING domain is essential for Mdm2 to form homodimers and 
also heterodimers with MdmX. The RING domain in Mdm2 is responsible to for its E3 ubiquitin 
ligase activity.  
 Ubiquitination is a post-translation modification that requires three enzymes to modify 
target proteins with ubiquitin (Sun, 2003). The events involved are: 1) E1 activation of ubiquitin, 
2) transfer onto a cysteine residue by an E2 conjugating enzyme, and 3) E3 mediated formation 
of an isopeptide bond between ubiquitin and a lysine on the target protein. Poly-ubiquitinated 
proteins on lysine 48 and lysine 11 of ubiquitin are often targeted for degradation through the 
26S proteasome. Target proteins can be mono- or poly-ubiquitinated on other lysines, leading to 
altered activity or localization of proteins. In mammals, there are two known E1 enzyme, tens of 
E2’s and hundreds of E3’s. E3’s can be classified into two structurally distinct categories: 
HECT-domain containing and RING-domain containing enzymes. The RING domain E3 ligases 
do not form covalent links between the ubiquitin and active site on E3 ligases, contrary to 





Mdm2 is an auto-regulatory transcriptional target of p53, but it takes hours for p53 
activation to increase Mdm2 protein levels in the cells. Once the Mdm2 protein is produced, it 
works to inhibit p53 through two mechanisms; one, it binds to p53 and inhibits its transcriptional 
activity; and two, Mdm2 ubiquitinates p53 and enhances its proteolytic degradation (Lahav et al., 
2004; Lev Bar-Or et al., 2000). This negative feedback loop keeps p53 levels in check in normal 
cells and allows for control of p53 activation under stress. Mdm2 interacts with p53’s 
transactivation domain, preventing p53 from interacting with the transcriptional machinery and 
co-activators such as p300.  
Mutations in p53 and Mdm2 were once thought to be mutually exclusive; however, some 
tumors exhibit both mutant p53 and Mdm2 overexpression (Cordon-Cardo et al., 1994). Mdm2 
has been shown to have p53-independent functions, which include regulation of the target of 
retinaoblastoma susceptibility gene (pRB), as well as transcription factor E2F-1 (Ganguli and 
Wasylyk, 2003). Mdm2 can target phosphorylated Foxo3a, a regulator of the cell cycle, in 
response to Erk signaling, for degradation (Fu et al., 2009; Yang et al., 2008). E-cadherin has 
also been shown to be marked for degradation by Mdm2 (Yang et al., 2006). E-cadherin loss is 
involved in epithelial-to-mesenchymal transition, which allows solid tumors to become more 
malignant and metastasize.  Some p53-independent functions of Mdm2 have been studied using 
Nutlin, a small molecule that binds Mdm2 and disrupts p53 interactions. In this case, isogenic 
Hct116 cells engineered to express p53 or not were used to study p53-dependent and –
independent functions of Mdm2 in response to Nutlin treatment (Valentine et al., 2011).  Even in 
the p53-/- cells, Nutlin treatment was able to induce cell cycle arrest. More p53-independent 
Mdm2 functions may exist, and continued research in the field will continue to elucidate new 







 MdmX was identified as a p53 binding partner and later discovered to share sequence and 
structural similarity to Mdm2. MdmX knockout mice are embryonic lethal, but can be rescued in 
a p53 knockout background, similar to Mdm2 (Parant et al., 2001). This points to MdmX being 
as important as Mdm2 in regulating p53 in mouse development. MdmX is overexpressed or 
amplified in 10-20% of over 800 diverse tumors (Toledo and Wahl, 2006).  
 MdmX is a protein of 490 amino acids long and contains the same three structural 
domains as Mdm2. Although MdmX also contains the RING domain, it is not an active E3 ligase 
and therefore can only affect other proteins through direct binding. MdmX can bind to p53 in a 
similar manner to Mdm2 and inhibit p53’s transactivation domain. MdmX also contains a p53 
responsive element similar to Mdm2’s, however, it is induced by p53 under different conditions 
(Barak et al., 1994; Phillips et al., 2010). Even though MdmX has an inactive E3 ligase, it was 
recently shown that MdmX promotes genomic instability independent of p53 and Mdm2 
(Carrillo et al., 2014). The MdmX functions independent of p53 and Mdm2 will continue to be 
elucidated with development of better genomic and chemical tools.      
 
Mdm2/MdmX 
 After a stress signal is sensed, Mdm2 polyubiquitination of Mdm2 and MdmX results in 
their degradation, increasing p53 levels. Until recently, it remained unclear if the Mdm2/MdmX 
hetero-complex was more important in regulating p53 levels, or if the two proteins worked 
independently to suppress p53. A first line of evidence suggesting that the heterocomplex may 





be in complex with MdmX (Kawai et al., 2007), which was the formation favored over the 
homocomplex in in vitro structural studies (Linke et al., 2008). Mdm2 also was shown to be less 
effective at ubiquitinating p53 than the heterocomplex (Gu et al., 2002; Kawai et al., 2007; 
Linares et al., 2003; Poyurovsky et al., 2007; Uldrijan et al., 2007). Recently, two studies showed 
the importance of the heterocomplex in vivo. One demonstrated this using transgenic mice where 
the MdmX protein was engineered with a point-mutation (MdmXC462A) that disabled it from 
interacting with Mdm2 (Huang et al., 2011). The MdmXC462A mutation did not interfere with 
MdmX’s ability to interact with p53 and left Mdm2 unaltered. MdmXC462A homozygous mice 
were embryonic lethal, but could be rescued with concomitant p53 deletion, suggesting that the 
Mdm2/MdmX interaction is necessary to regulate p53 in mouse development. Another study 
engineered mice to conditionally express MdmX lacking the RING domain and showed that 
MdmX is essential for early development but not for Mdm2 or p53 protein stability in adult mice 
(Pant et al., 2011). These data combined show the importance of Mdm2/MdmX heterocomplex 
in regulating p53 in development, suggesting that inhibiting this complex could lead to re-
activation of p53 in oncogenic contexts.  
 The p53-independent functions of Mdm2/MdmX heterocomplex is less well studied, but 
further work using knock-in mice models like the ones described in the previous paragraph, or 
development of small molecule inhibitors of the heterocomplex, will help elucidate the function 
of the heterocomplex in normal physiology and in disease contexts.    
 
Inhibitors of p53, Mdm2 and Mdm2/MdmX 
 Mdm2 and MdmX inhibitors, or therapeutics that reactivate p53, are of paramount 





characterized of these is Nutlin 3a, whose derivative RG7112 is in Phase I clinical trials 
(Vassilev et al., 2004). Nutlin 3a binds to Mdm2 in the N-terminal and inhibits its interaction 
with p53, thereby releasing p53 to activate its tumor-suppressive effects. Nutlin 3a has also been 
used in research laboratories to probe the importance of Mdm2-p53 interaction in development 
and tumor progression. Other small molecule inhibitors of the Mdm2-p53 interaction include 
MI-219 (Ding et al., 2006) in preclinical development, and RITA (Appella and Anderson, 2001; 
Issaeva et al., 2004).  
Small molecule Mdm2 E3 ligase inhibitors have also been developed, such as HLI98 
(Yang et al., 2005) and its derivative MPD (Roxburgh et al., 2012). HLI98 compounds were 
discovered in an in vitro high-throughput Mdm2 ubiquitination assay (Davydov et al., 2004). 
However, relatively high concentrations of HLI98 (5-20 µM) were necessary to induce apoptosis 
in cells. Because of this, HLI98 suffers from off-target affects by also inhibiting Nedd4 E3 ligase 
activity. MPD compounds were discovered as analogs of HLI98 compounds, but also required 
low µM concentrations in cells to induce cell cycle arrest, which was not shown to correlate with 
cell death induction, as would be predicted with p53 stabilization and activation.  
More recently, non-small molecule inhibitors of Mdm2/MdmX have been described. An 
Mdm2/MdmX inhibitory peptide was shown to stabilize p53 and induce cell death in breast 
cancer cell lines MCF-7 and ZR-75-30 (Geng et al., 2013). Despite the importance of the 
Mdm2/MdmX heterocomplex, no small molecule inhibitor of the complex has been described. 
This could be due to the fact that a well-characterized crystal structure of the heterocomplex is 







 As p53 is regulated by ubiquitin modification, the Stockwell lab sought to identify small 
molecules that would inhibit Mdm2’s E3 ligase activity, inhibiting p53 ubiquitin modification 
and thereby stabilizing p53. Over 270,000 small molecules were screened in a cell-based assay 
where Mdm2 protein stability was monitored through a luminescence tag on the Mdm2 protein 
(Herman et al., 2011). Compounds were counter screened in a mutant cell line where the E3 
ligase activity was ablated with introduction of a C464A mutation in the Mdm2 RING domain. 
Hit compounds were defined as compounds that increased luminescence in wild-type cells, while 
having no effect on luminescence in the mutant cell line.  
After confirmation of primary hits, two analogs with indole scaffolds, which we named 
Mdm2 E3 Ligase 23 and 24, were pursued (Herman et al., 2011). The MEL compounds 
stabilized Mdm2, MdmX and p53 in cells by inhibiting ubiquitination of these proteins, and in 
vitro ubiquitination reactions suggested that the compounds worked through inhibition of the 







Figure 4.1 MEL24 – discovery and in cell activity 
A) Structure of MEL24.  B) Discovery of the compound in a high-throughput screening assay. 
Hits were identified as compounds that increased stability of the Mdm2 protein in cells, as 
determined by luminescence produced by luciferase-tagged Mdm2, while having no effect on a 
mutant Mdm2 (C464A) expressing cells, which is catalytically inactive. C) MEL23 and MEL24 
stabilize p53 and Mdm2 in RKO cells. D) p53 stabilization in cells in response to MEL23 and 
MEL24 treatment seems to be due to inhibition of p53 ubiquitination. MG132 is a proteasomal 





MEL co-treatment with MG132, poly-ubiquitinated p53 levels is less than in MG132 only 
treated cells.  Figures from Herman et al, 2011.        
 
Indole derivatives and RAS synthetic lethality 
 
MEL is an indole derivative (Figure 4.2). Indoles are a privileged scaffold in that these 
scaffolds are enriched in natural products and synthetic compounds that have been described to 
target receptors and proteins in cells (Welsch et al., 2010). Examples of indole containing small 





Figure 4.2 Indole. Example of indoles in natural products with biological functions.  Vinblastine 
is derived from plants and is an antimicrotubule drug used to treat Hodgkin’s lymphoma, non-
small cell lung cancer, breast cancer, and head and neck cancer (Gigant et al., 2005). Nostodione 
A was first isolated from cyanobacterium and found to inhibit mitotic spindle formation (Kery et 






RSL3, a ferroptosis inducer, also contains an indole that is critical for activity (Yang and 
Stockwell, 2008b). RSL3 was initially discovered as a RAS-synthetic lethal compound; a 
compound that kills cells that harbor mutant RAS, while not having an effect on wild-type cells. 
Isogenic cell lines derived from BJ fibroblasts were used to discover RSL3. BJ-TERT is 
transformed with hTERT, BJ-TERT/LT/ST is further transformed with simian virus 40 large and 
small oncoproteins, BJ-TERT/LT/ST/RASV12 is transformed to additionally express mutant 
RasV12 (Hahn et al., 1999) and DRD are cells transformed to harbor an HRAS mutation instead 
(Hahn et al., 2002). These isogenic cell lines have been used in the past to identify small 
molecules that are lethal in the presence of mutant RAS compared to cells that express wild-type 
RAS. These same lines were used for the discovery of erastin. Erastin and RSL3, therefore, were 
discovered as mutant RAS synthetic lethal molecules; that is, the compounds kill cells only in the 
presence of mutant RAS.    
 
The goal of this chapter is to determine the mechanism of action of the MEL compounds 
in cells and to investigate whether inhibition of Mdm2/MdmX E3 ligase activity in vivo is 
therapeutically viable. The MEL compounds could then be used as a probe to study the 
significance of the Mdm2/MdmX heterocomplex in tumor development in vivo. Through this 
project, we also identified RAS synthetic lethal compounds based on MEL’s indole scaffold that 







MEL inhibits p53 and Mdm2 ubiquitination in cells 
Preliminary cell culture work showed that the MEL compounds stabilized p53 and Mdm2 in 
cell culture. In RKO (colon carcinoma) cells, we showed that the increase in p53 and Mdm2 by 
MEL23 was dose-dependent (Figure 4.3A). The increase in p53 protein was not due to an 
increase in p53 mRNA levels, as determined by qPCR (Figure 4.3B). This suggested that the 
stabilization of p53 was not due to an upregulation of transcription, as would be the case with 
doxorubicin and other genotoxic drugs. Genotoxic drugs induce p53 transcription through 
phosphorylation of stress-mediating proteins, such as histone H2A.X. We observed no 
phosphorylation of histone H2A.X with MEL compound treatment, but phosphorylation was 
observed with doxorubicin treatment (Figure 4.3C). These results show that MEL compounds 
stabilize p53 independent of de novo p53 transcription.  
Since the screen was set up to identify Mdm2 E3 ligase inhibitors, we sought to determine 
MEL23’s ability to inhibit ubiquitination in cells. Higher molecular weight smears, indicative of 
poly-ubiquitination modification to proteins, was evident on Mdm2 and p53 in cells (Herman et 
al., 2011). The poly-ubiquitination was more evident with co-treatment with a proteasome 
inhibitor, MG132. With addition of MEL23 or 24, the higher molecular weight bands 
disappeared, suggesting the ubiquitination mechanism was inhibited. We performed a 
cycloheximide pulse-chase experiment to determine if the half-life of p53 and Mdm2 was 
increased with MEL treatment. In RKO cells, p53 and Mdm2 had half-lives of about an hour 
(Figure 4.3D). With treatment of MEL23, the half-life of p53 and Mdm2 was greater than 6 and 





with MG132 co-treatment, suggesting that Mdm2 may be degraded in another fashion or may be 
a substrate for another E3 ligase.  
In order to determine specificity of the MEL compounds, we performed in vitro 
ubiquitination reactions using another RING-domain containing E3 ligase. BRCA1/BARD1 is a 
heterocomplex E3 ligase. BRCA1 is a RING-domain E3 ligase, and interaction with BARD1 
enhances the activity of the ligase (Wu-Baer et al., 2010). We performed in vitro ubiquitination 
reactions using 50 and 100 µM MEL23 and purified BRCA1/BARD1 complex. Even at 100 µM 

















Figure 4.3. MEL compounds stabilize p53 and Mdm2 in a dose-dependent manner without 
affecting other E3 ligases.  
A) RKO cells were treated with decreasing concentrations of MEL23 starting at 28 µM in a 2-
fold, 5-point dilution series for 6 hours. Cells were then harvested and immunoblotted with 
indicated antibodies. B) p53 mRNA levels after treatment with lethal compounds. RKO cells 
were treated with indicated compounds for indicated times before cells were harvested and 
mRNA isolated. RT-qPCR was performed to detect p53 transcript levels. C) RKO cells were 
treated with 14 µM MEL23, 15 µM MEL24, 10 µM MG132, or 0.9 µM doxorubicin for 6 hours. 
Cells were lysed and analyzed using western blotting against anti-H2A.X and anti-phospho-
ser139 H2A.X antibodies. D) Half-life determination of Mdm2 and p53 proteins after MEL23 
treatment. RKO cells were treated with 15 µM MEL24 for 6 hours, then treated with 18 µM 
cycloheximide for indicated times before harvesting cells for western blot samples. E) MEL23 





ubiquitnation reactions. MEL23, even at concentrations of 100 µM, did not inhibit ubiquitination 
of BRCA1.  





MEL requires Mdm2 and MdmX for optimal cellular activity 
In vitro ubiquitination reactions showed that for MEL activity, MdmX had to be present. In 
order to show that MdmX was indeed essential for MEL activity, we knocked down MdmX in 
RKO cells to probe its effect on MEL activity. MEL23 treatment of cells transfected with non-
targeting siRNA increased p53 protein levels by 20 fold as determined by western blotting. 
When cells were transfected with siRNA targeting MdmX, MEL23’s ability to increase p53 
stability was less than in control cells, increasing p53 levels by about 5 fold (Figure 4.4A). We 
also performed experiments with doxorubicin, a compound that is thought to not act through 
interaction with p53 or Mdm2, to make sure we were not saturating the p53 levels in the cells. As 
seen in Figure 4.3A, bottom right panel, doxorubicin could induce p53 levels further in cells 
where MdmX was knocked down. This experiment showed that MdmX is needed for efficient 
p53 stabilization by MEL23 in cells.  






Figure 4.4. MEL requires Mdm2 and MdmX for activity, but does not inhibit Mdm2/p53 
interaction.  
A) MdmX is required for optimal MEL23 activity. MdmX was knocked down in cells RKO cells 
and treated with 15 µ MEL23 for 6 hours before harvesting. p53 stabilization (bottom left graph, 
gray bars) upon MEL23 treatment was hindered with MdmX knockdown. Bottom right graph 
shows p53 levels with doxorubicin treatment to show that p53 stabilization is not saturated. B) 
MEL23 does not inhibit p53/Mdm2, p53/MdmX, or Mdm2/MdmX interaction. Top blot shows 
co-ip with endogenous p53, bottom blot show co-ip with Flag epitope in MCF7 cells transfected 
with Flag-Mdm2. 24 hours after transfection, cells were treated with 28 µM MEL23, 10 µM 









 The MEL compounds could be disrupting the Mdm2 interaction with MdmX or with p53 
to exert its E3 ligase inhibitory effects. We performed co-immunoprecipitation studies in MCF7 
cells to determine if MEL23 was disrupting any Mdm2 protein-protein interactions. To see if 
interactions with p53 were disrupted, we immunoprecipitated p53 using anti-p53 antibodies and 
subjected pull-down products to western blotting with antibodies against Mdm2 and MdmX. 
Nutlin is a p53-inhibitor that binds to the N-terminal of Mdm2, thereby inhibiting Mdm2-p53 
interaction. As seen in the third column of Figure 4.4B top panel, Nutlin disrupted p53-Mdm2 
interaction. On the other hand, MEL23 did not disrupt this interaction. To probe if MEL23 was 
disrupting the Mdm2-MdmX interaction, MCF7 cells were transfected with FLAG-Mdm2, and 
FLAG-epitope immunoprecipitated. MEL23 had no effect on the Mdm2-MdmX, or Mdm2-p53 
interaction. These results suggest that MEL23 requires MdmX for efficient activity, but does not 
inhibit the Mdm2-MdmX interaction. The MEL compounds could, therefore, be binding to the 
RING domain, or could be binding to a cofactor that regulates the Mdm2/MdmX heterocomplex.  
 
MEL induces apoptosis and has a therapeutic window 
 p53 is a tumor suppressor that is often associated with induction of apoptosis. In order to 
determine if p53 stabilization was leading to cell death that was apoptotic, we performed 
TUNEL staining on cells treated with MEL23. Terminal deoxynucleotidyl transferase dUTP nick 
end labeling (TUNEL) staining detects terminal ends of nucleic acids and is useful for detecting 
fragmented DNA that is characteristic of apoptosis (Gavrieli et al., 1992). MEL23 treatment 
resulted in TUNEL positive cells in a similar manner to doxorubicin treatment, indicating 





 Small molecules must have a therapeutic window to be potentially useful in the clinic. In 
order to probe the therapeutic window of MEL23, we treated a panel of tumorigenic and non-
tumorigenic cells in a two-fold, five-point dilution series of MEL23. The dose-response curves 
associated with blue lines are cells derived from patient tumors, while the green lines are not 
(Figure 4.5B). MCF10a cells are mammary cells derived from a patient with fibrocystic disease, 
while BJeH cells are BJ fibroblasts transformed with hTERT. A small window of selectivity was 
seen in tumorigenic cells compared to non-tumorigenic cells, providing a basis for further work 






Figure 4.5. MEL induces apoptosis and has a therapeutic window.  
A) MEL23 induces TUNEL staining. HT-1080 cells were seeded and treated with 14 µM 
MEL23 or 920 nM doxorubicin for two days. Cells were fixed, permeabilized and stained, and 
fluorescence visualized with a fluorescence microscope. B) MEL23 has a small therapeutic 
window. Cells were seeded in 384-well format and treated with MEL23 in a two-fold, 5-point 
dilution series. Non-transformed cell lines are represented in green, while tumor-derived cells are 
in blue. C) MEL23 inhibits colony formation. RKO cells were used in a colony formation assay 





 Colony formation assays have been used in preclinical drug development to gauge the 
ability of cytotoxic compounds to inhibit colony formation (Shoemaker et al., 1985). We utilized 
this assay to determine MEL23’s cytotoxic potential in soft agar. RKO cells were plated in a 
monolayer of soft agar, and were treated with three concentrations of MEL23. MEL23 inhibited 
colony formation in a dose-dependent manner, as visualized by crystal violet (Figure 4.5C).  
These data suggest that the MEL compounds could be beneficial as potential therapeutics 
in oncology by stabilizing and allowing for increased activity of the tumor suppressor p53. 
Development of a more water-soluble analog would allow for testing in vivo in xenograft studies 
to further validate this thought.  
      
Indole derivatives 
In order to identify a more soluble analog of MEL compounds that may be more suitable for 
animal testing, we synthesized analogs of MEL24. We synthesized 34 analogs of MEL24, 
modifying areas that were known to be non-essential for MEL24 function (Herman et al., 2011). 
Unfortunately, the 34 analogs did not show any activity in the Mdm2-luciferase cell lines in 
stabilizing Mdm2 protein (Figure 4.6, compound 1 is MEL24). However, since indole’s are a 
privileged scaffold, we tested the analogs in a panel of cell lines to see if there was any cell line 








Figure 4.6. MEL analogs do not stabilize Mdm2 in cells.  
Compound 1 (MEL24) stabilizes Mdm2 in Mdm2 (WT) Luc cells, but does not stabilize Mdm2 
in mutant Mdm2 (C464A) Luc cells. MEL analogs tested do not show stabilization of Mdm2. 





 The 34 analogs were tested in a panel of seven cell lines; MCF7 (breast cancer), HT-1080 
(fibrosarcoma), U2OS (osteosarcoma), RKO (colon cancer), H1299 (lung cancer) and a pair of 
engineered isogenic cell lines, BJeH and BJeLR. MEL24 was lethal across all cell lines (Table 
4.1). Most of the analogs had no activity in cells; however, compound 27, 29 and 34 were 
interesting in that they were lethal to some cell lines and were selectively lethal towards 
oncogenic KRAS expressing BJeLR cells compared to BJeH cells (Figure 4.7A). We had 
previously seen similar selectivity trends in ferroptosis-inducing compounds (Dolma et al., 
2003b). We therefore decided to further characterize one representative compound, compound 











Table 4.1. Lethality of MEL24 analogs. Breast cancer (MCF7), fibrosarcoma (HT-1080), 
osteosarcoma (U2OS), colon cancer (RKO), lung cancer (H1299) and a pair of engineered 
isogenic cell lines, BJeH and BJeLR, were treated with compound in a two-fold, five-point 
dilution series starting at 20 µg/mL. EC50 values are shown in µM. Blank well represents no 





Compound 27 exhibits non-apoptotic, RAS-synthetic lethality 
 We first wanted to elaborate on the data gathered in the initial multi-cell line screening. 
We utilized two more cell lines derived from BJ fibroblasts to look for mutant RAS synthetic 
lethality. BJ-TERT and BJ-TERT/LT/ST harbor wild-type RAS, while BJ-TERT/LT/ST/RASV12 
and DRD are transformed to express mutant and oncogenic RAS. Compound 27 was selectively 
more toxic to BJ cells that expressed mutant RAS (20 µM in BJ-TERT/LT/ST/RASV12 and 102 
µM in DRD) compared to BJ cells that expressed wild-type RAS (178 µM in BJ-TERT and 266 
µM in BJ-TERT/LT/ST) (Figure 4.7B). The BJ cell line selectivity was similar to that of other 
ferroptosis inducers, RSL3 and erastin, that were initially discovered in the BJ cell series (Figure 
4.67). Kinetic analysis revealed that Compound 27 was inducing complete lethality in BJ-







Figure 4.7. Compound 27 exhibits RAS synthetic lethality and induces non-apoptotic cell death 
in a mechanism similar to RSL3.  
A) Compound 27 selectively reduces the viability of oncogenic-RAS expressing cells. B) Top – 
cells were treated in a two fold, 7-point dilution series for 48 hours before Alamar blue reading 
of viability. SEM of triplicates are shown. Bottom – table of EC50 and maximum growth 
inhibitory efficacy in four cell lines ± SEM of triplicates. C) Photograph of BJ-TERT and BJ-
TERT/LT/ST/RASV12 cells treated with Compound 27 (30 µM), RSL3 (568 nM), erastin (10 
µM) or staurosporine (1 µM) for 24 hours. D) Kinetic-analysis of Compound 27 induced cell 





Compound 27 (30 µM) or RSL3 (568 nM). Data representative of duplicate experiments. E) 
Compound 27 does not induce caspase activation. BJ-TERT and BJ-TERT/LT/ST/RASV12 cells 
were treated with Compound 27 for 28 hours in a two-fold, 14-point dilution series before 
Alamar blue addition and detection of caspase activation by Apo-ONE. F) Compound 27 
lethality is rescued by deferoxamine (Deferox) and α-tocopherol (Atoc), but not z-VAD-fmk 
(zVAD) or Boc-D-fmk (BocD). HT-1080 cells were treated with Compound 27 in the presence 
of Deferox (152 µM), Atoc  (100 µM), zVAD (45 µM) or BocD (50 µM). 





Since some other BJ-cell line selective lethals have also been ferroptosis inducers, we 
wondered if Compound 27 was also inducing ferroptosis. Using a fluorogenic substrate of 
caspase 3/7 to detect caspase activation, Compound 27 was found not to activate caspases, 
similar to erastin and RSL3, but unlike MEL24, which we showed to be an inducer of caspase-
dependent apoptosis (Figure 4.7E). We further confirmed that the cell death induced by 
Compound 27 was ferroptosis through co-treatment with suppressors of ferroptosis, namely α-
tocopherol and deferoxamine. Boc-D-fmk and z-VAD-fmk, both inhibitors of caspases, had no 
affect on Compound 27 induced death, while α-tocopherol and deferoxamine were able to 
suppress lethality, similar characteristics to ferroptosis inducer RSL3 (Figure 4.7F). These data 
suggest that Compound 27 is a low µM inducer of ferroptosis. 






Aberrations in Mdm2 expression have been implicated in many types of cancers. Mdm2 
exerts its oncogenic potential by inactivating the tumor suppressor p53, but Mdm2 itself may 
have other targets that contribute to tumor growth. Studies using genetic modification of Mdm2 
have been done, including studies to probe the significance of the E3 ligase function of Mdm2 in 
vivo (Itahana et al., 2007). However, genetic modifications are often not amenable to temporal 
and spatial control. Small molecule probes allow for complementary studies of proteins of 
interest, especially when more than one protein is involved, for example in the case of 
Mdm2/MdmX heterocomplex. 
We discovered MEL23 and MEL24 in a high-throughput phenotypic screen that 
evaluated over 200,000 compounds. The two MEL compounds consistently stabilized p53 and 
Mdm2 protein levels in multiple cell lines. We showed that in in vitro ubiquitination reactions, 
Mdm2 and MdmX were needed for MEL activity. This was validated in cells where MdmX 
knockdown led to inefficient p53 stabilization. We also showed MEL treatment induces 
apoptosis and has a small window of selectivity for oncogenic cell lines.  
MEL compounds show promise as inhibitors of Mdm2/MdmX E3 ligase activity. 
Although the poor solubility in water of the original compounds prevented their use in mice to 
study the significance of Mdm2/MdmX in tumor progression, more analogs can be tested to 
identify compounds that have better physicochemical properties and may be more viable as 
research tools in vivo.  
We had shown that MEL compounds require MdmX for in vitro ubiquitination reactions 
and that MdmX is needed in cells for maximal activity; however, the in vitro reactions required 





concentrations used in cells (Gavrieli et al., 1992). More evidence to show MEL binding to 
Mdm2/MdmX RING domain would be informative in cases where MEL will be used as a tool to 
probe the heterocomplex. Further studies could involve crystallization of the MEL compound 
with purified heterocomplex, and performing binding studies such as surface plasmon resonance 
(SPR) or microscale thermopheresis (MST).  
Indole derivatives are considered privileged scaffolds in that the scaffold is enriched in 
compounds that are biologically active. We found through testing of MEL analogs, an indole 
itself, of compounds that were not Mdm2 E3 ligase inhibitors, but compounds that induced cell 
death similar to ferroptosis. Although the mechanism by which these compounds induce cell 
death was not elucidated, this work adds to the list of indole-containing molecules that have 
biological activity, providing a basis for further elaboration of the molecules to probe different 
biological functions.  
	  
Methods and Materials 
Chemicals and reagents 
MG132 (Sigma, C2211), doxorubicin hydrochloride (Sigma, D1515), z-VAD-fmk (TOCRIS, 
2163), Boc-D-fmk (MP Biomedicals, FK011), α-tocopherol (Sigma, T3251), deferoxamine 
(Sigma, D9533), cycloheximide (Sigma, C7698), staurosporine (Sigma, S6942). 
 
Cell culture 
H1299 (non-small cell lung carcinoma), MCF7 (mammary gland adenocarcinoma) and MCF10a 
were grown in Dulbecco’s modified Eagle’s medium (Fisher, MT-15-018-CM), with 10% fetal 
bovine serum (FBS) and 100 µg/mL penicillin/streptomycin (P/S). RKO (colon carcinoma) and 





M5650) with 10% FBS and 100 µg/mL P/S. U2OS (osteosarcoma) and HCT116 (colorectal 
carcinoma) were maintained in McCoy’s 5a Medium (Invitrogen, 16600-108) with 10% FBS and 
100 µg/mL P/S. HT1080 (fibrosarcoma) cells were grown in DMEM 10% FBS, 100 µg/mL P/S 
and 1% non-essential amino acids (Invitrogen, 11140-050). BJeH and BJeLR fibroblasts were 
grown in 210 mL M199, 150 mL IFS, 10 mL P/S and 730 mL DMEM. All cells were grown at 
37°C and 5% CO2.  
 
Alamar blue viability dose-response assay 
Cells were seeded in 384-well black clear-bottom plates (Corning, 3712). Cells were then treated 
with indicated concentrations of compound for 48 hours in a two-fold, five-point (for MEL 
treatment) or seven-point (for Compound 27) dose response curve. Alamar blue (Invitrogen, 
DAL1100) was added to each well to a final concentration of 10% and incubated at 37°C for 6 
hours. Fluorescence intensity was determined using the Victor3 Plate Reader (PerkinElmer). 
Median percent survival was calculated and normalized to no treatment control.  
 
siRNA transfection 
50,000 H1299 cells were plated in 6-well dishes the day before transfection. On the day of 
transfection, siRNA (final concentration 25 nM) was mixed with 2 µL DharmaFECT1 (GE 
Healthcare, T-2001) and incubated at room temperature for 20 minutes. Afterwards, the mixture 
was added to cells. After 48 hours of knockdown, cells were treated with the indicated 
compounds before harvesting for western blot. siRNA constructs used:       
siLuc (AACTTACGCTGAGTACTTCGA)  







Cells were harvested on the day of experiment in lysis buffer (50 mM TrisHCl, pH 7.5, 200 mM 
NaCl, 0.5% NP-40, and 1 complete mini EDTA-free protease inhibitor cocktail tablet per 10 mL 
of buffer (Roche, 8360170). Proteins in the lysates were separated by gel-electrophoresis, 
followed by transferring to a nitrocellulose membrane. The membrane was then blocked in 5% 
milk and incubated with primary antibody overnight at 4°C. The membrane was then incubated 
with HRP-conjugated secondary and developed with SuperSignal West Pico Substrate (Pierce, 
34080). Antibodies used were: BRCA1 (Calbiochem, OP92), Flag IP antibody (Sigma, F1804), 
p53 antibody for WB (Calbiochem, OP43) and IP (Calbiochem, OP03), p-histone H2AX 
(Millipore, 05-636), histone H2AX (Millipore, 07-627), Mdm2 (Calbiochem, OP115), MdmX 
(Bethyl, A300-287A), eIF4E (BD Transduction Laboratories, 610270). 
 
Plasmid transfection 
Flag-Mdm2 in pcDNA3 (Poyurovsky et al., 2003) was a kind gift from Dr. Carol Prives at 
Columbia University. MCF7 cells were transfected using FuGENE 6 (Roche, 814-442-001) 
according to manufacturer’s protocol. Transfections were performed in 15 cm dishes. 
 
Immunoprecipiation 
MCF7 cells were lysed in lysis buffer (150 mM NaCl, 10 mM TrisHCl pH 7.5, 0.5% NP-40, 
10% glycerol, 1 mM EDTA, 1 mM DTT, and 1 complete mini EDTA-free protease inhibitor 
cocktail tablet. FLAG-tagged Mdm2 immunoprecipitation experiments were performed by 
incubating lysates with anti-M2 (FLAG) antibody for 2 hours at 4°C before binding to Protein-
A/G sepharose beads (Pierce, 20421) for 1 hour at 4°C. p53 immunoprecipitation studies were 





agarose beads for 1 hour at 4°C. All lysates were washed three times with lysis buffer before 
eluting protein with SDS sample buffer and analysis by immunoblotting.  
 
In vitro ubiquitination assay 
His-BARD1/BR304 was incubated with 5 pmol UbcH5c and 0.2 pmol E1 enzyme (Boston 
Biochem) with 300 pmol of ubiquitin in reaction buffer for 2 hours at 37°C. The products were 
resolved by SDS-PAGE and analyzed by immunoblotting with anti-BRCA1 antibody. 
BRCA1/BARD1 (BARD1/BR304) protein was a kind gift from Dr. Richard Baer at Columbia 
University.  
 
Cycloheximide chase - Mdm2 and p53 half-life calculations 
To determined the half-life of Mdm2 and p53 in cells treated with MEL23. On the day before the 
experiment, 750,000 RKO cells were seeded in 6-well plates. On the day of the experiment, cells 
were treated with 14 µM MEL23, vehicle or 10 µM MG132 (as a positive control) for 4 hours 
before addition of 18 µM cycloheximide for 30 minutes or 1, 2, 4, or 6 hours. Cell lysates were 
analyzed by western blotting for p53, Mdm2 and eIF4E proteins.        
 
RNA extraction and qRT-PCR analysis 
RNA was extracted using RNeasy Mini kit (Qiagen, 74104) and 2 µg of RNA was converted to 
cDNA using TaqMan Reverse Transcription Reagents (Applied Biosystem, N8080234) 
according to manufacturers protocol. Samples were analyzed using quantitative real-time PCR 
on an ABI 7300 Real-Time PCR instrument (Applied Biosystems) using ΔΔCT method and 1X 





µM primers per well. Cycle times of the p53 transcripts were normalized to in house loading 









Soft agar colony formation assay 
0.6% agar solution made with media, serum and P/S were added to 6 well plates in a volume of 2 
mL’s. 5,000 cells were mixed with 0.3% agar and added on top of the 0.6% agar solution and 
allowed to rest. Media containing compound was exchanged every other day. After 12 days, 
colonies were stained with 0.005% crystal violet for 30 minutes and washed with water.  
 
TUNEL staining 
Cells were seeded overnight on cover slips and treated with compounds for indicated time. Cells 
were fixed in 3.2% paraformaldehyde (Electron Microscopy, 15714) and permeabilized in 0.1% 
Triton X-100 (Sigma, 234729) in 0.1% sodium acetate (Sigma, 4641). They were then stained 
with TMR RED (Roche, 12156792910) according to manufacturers protocol. Samples were 
counterstained with Hoechst 33342 (Molecular Probe, H1399) and viewed on a Diaphont 300 






Mdm2 activity assay 
The Mdm2 assay was performed as previously described (Herman et al., 2011). 7,500 
Mdm2(WT) and Mdm2(C464A) cells were seeded in 384-well white plates. After 24 hours, cells 
were treated with compounds at a concentration of 20 µg/mL for 2 hours at 37°C. Cells were 
then lysed with addition of 30 µL luminescence buffer (PerkinElmer, 6016989) and incubated for 
30 minutes before analysis on a Victor3 Plate Reader.  
 
Modulator treatment 
For RSL3 and Compound 27 co-treatment with cell-death modulators, 1,000 HT-1080 cells were 
seeded in 384-well format with lethal compound in a two-fold, 12-point dose curve. Cells were 
co-treated with modulator; deferoxamine (152 µM), α-tocopherol (100 µM), z-VAD-fmk (45 
µM) or Boc-D-fmk (50 µM) for 48 hours before viability assessed with Alamar blue.      
 
Apo-ONE caspase-3/7 activation assay 
Caspase activity was measured using Apo-ONE Homogeneous Caspase-3/7 assay kit (Promega, 
G7797) according to manufacturers protocol. Briefly, 1,000 HT-1080 cells were seeded in each 
well of a 384-well plate and lethal compound added for 18 hours in a total volume of 40 µL. 
After compound treatment, 15 µL was removed from each well, then 5 µL of the lysis buffer and 
fluorogenic substrate was added. Plates were kept in the dark for 16 hours before fluorescence 






CHAPTER FIVE:  
Perspectives and Future Directions 
 
This thesis used chemical and genetic modulators of cell death to investigate mechanisms 
of apoptosis and ferroptosis. In the first two chapters, a genome-wide siRNA screen was 
conducted to identify suppressors of erastin-induced ferroptosis. Loss of CARS, or cysteinyl-
tRNA synthetase, rendered cells insensitive to erastin treatment. The resistance mechanism was 
due to upregulation of the transsulfuration pathway, allowing cells to rely more on methionine as 
a source of cysteine over imported cysteine. In the following chapter, small molecule indole 
derivatives were used to study Mdm2-mediated apoptosis, and separately identified a new 
ferroptosis inducer. 
 
Genome-wide RNAi to identify mechanisms to suppress ferroptosis 
Summary 
A genome-wide RNAi screen was conducted in cells to identify suppressors of erastin-
induced lethality, and loss of CARS, or cysteinyl-tRNA synthetase, was identified to suppress 
erastin-induced ferroptosis. Loss of CARS did not alter iron homeostasis or activity of system xc-, 
but did inhibit lipid ROS generation upon erastin treatment. Interestingly, loss of CARS did not 
suppress RSL3 or FIN56 induced ferroptosis, suggesting that the mechanism by which cells 
became resistant to erastin is upstream of GPX4 (the target of RSL3 and FIN56), but 
downstream of system xc- inhibition. Unbiased RNA sequencing and metabolomics analysis 
suggested that the transsulfuration pathway was upregulated upon CARS knockdown. Using 





erastin treatment in the presence of CARS knockdown. These results suggest that upregulation of 
the transsulfuration pathway could lead to suppression of ferroptosis where it is involved in 
detrimental phenotypes, or could serve as a predictor of response to ferroptosis-inducing agents.             
 
Significance 
Identifying mechanisms to induce and inhibit alternative, non-classical apoptosis is 
important in treating diseases where aberrant cell growth is a problem, like in cancers, and in 
situations where too much cell death leads to disease, such as in ischemia and neurodegenerative 
disorders. Ferroptosis is distinct from previously defined cell death pathways including 
apoptosis, necroptosis and autophagic cell death (Dixon et al., 2012). Ferroptosis can be induced 
with small molecules, including erastin and RSL3, leading to the possibility of inducing 
ferroptosis to treat uncontrolled cell growth in patients. Upregulation of the transsulfuration 
pathway leads to suppression of erastin-induced cell death, leading to the possibility of using the 
activity of this pathway as a predictive marker to ferroptosis-inducing agents. These data also 
open the door for exploration of methods to inhibit ferroptosis in the clinic, as ferroptosis was 
demonstrated to be involved in disease models of Huntington’s, periventricular leukomalacia, 
glutamate induced toxicity and kidney dysfunction (Linkermann et al., 2014; Skouta et al., 
2014a).   
 
Future directions 
 The main future directions for this project involve further defining the significance of the 
transsulfuration pathway as a resistance mechanism to ferroptosis, and to translate these findings 





the transsulfuration pathway can be measured through use of radiolabeled methionine. Detection 
of radiolabeled glutathione after incubation with [35S] methionine signifies an intact 
transsulfuration pathway, and increased [35S] labeled glutathione would mean upregulation of the 
pathway (Vitvitsky et al., 2006). In cells with CARS knockdown cultured with [35S] methionine,  
[35S] glutathione should be increased. This increase should be concomitantly decreased upon 
propargylglycine (PPG) treatment and CBS knockdown. PPG binds to the PLP-cofactor binding 
pocket of cystathionine γ lyase, and since there are many known enzymes that use PLP, PPG 
may be acting promiscuously (Percudani and Peracchi, 2003). Thus, correlation of PPG 
treatment and inhibition of the transsulfuration pathway, and further correlation with re-
sensitization of CARS knockdown cells to erastin, will provide stronger evidence that 
upregulation of the pathway indeed leads to suppression of system xc- induced death. 
 Overexpression of genes involved in the transsulfuration pathway could lead to increased 
cysteine synthesis from methionine (Wang et al., 2004). Cells stably transfected with plasmids 
that overexpress CTH or CBS could be tested to see if they are more resistant to erastin-induced 
ferroptosis compared to cells with basal levels of transsulfuration activity.  
 If overexpression of transsulfuration genes in cells leads to suppression of ferroptosis, 
then overexpression plasmids can be used to test if upregulation of this pathway can lead to 
suppression of cell death observed in disease models. For example, in Huntington’s disease rat-
brain slice models, ferrostatin was shown to rescue cells from death induced by poly-glutamine 
expression (Skouta et al., 2014b). Perhaps in this model, overexpression of CBS or CTH could 
also lead to rescue from cell death. Depletion of CTH was recently observed to be associated 





phenotype (Paul et al., 2014). These data suggest that overexpression or induction of the 
transsulfuration pathway could potentially be therapeutic in neurodegenerative disorders.  
 Small molecule inducers of ATF4 and the transsulfuration pathway may be used to 
rescue cells from ferroptosis. tRNA synthetase inhibitors halofuginone (Keller et al., 2012) and 
histidinol (Hansen et al., 1972; Tsui et al., 1985) were tested in HT-1080 cells to mimic 
knockdown of EPRS and HARS, respectively. Knockdown of both EPRS and HARS led to 
suppression of erastin’s lethality, however, pre-treatment with both halofuginone and histidinol 
gave variable effects on erastin’s lethality. Both treatments also induced transsulfuration genes to 
variable degrees, making drawing a conclusion difficult. The small molecules could be inducing 
a slightly different stress response to tRNA synthetase knockdown, similar to how only some 
tRNA synthetase knockdown suppressed erastin’s lethality. Instead, a direct inducer of the 
transsulfuration pathway may provide more convincing results supporting the notion that the 
pathway leads to suppression of ferroptosis. Salvianolic acid A was shown to increase activity of 
CBS and increase cysteine concentration in rats (Zhang et al., 2013). If pre-treatment with this 
molecule leads to suppression of erastin-induced lethality, this will provide further proof that 
targeting this pathway could be of therapeutic benefit.  
 Instead of targeting the transsulfuration pathway as a method to rescue cells from excess 
cell death, the pathway could be used as a predictive marker for treatments that induce 
ferroptosis. Sorafenib, an anti-cancer FDA approved drug, was recently shown to inhibit system 
xc- and induce an iron dependent death (Dixon et al., 2014; Louandre et al., 2013). It would be 
interesting to see if upregulation of the transsulfuration pathway, perhaps by looking at 





Viswanathan has undertaken looking at cystathionine levels in over 800 cell lines that are part of 
CTD2 to correlate to erastin sensitivity.   
 As a final future direction, other hits from the genome-wide RNAi screen can be further 
studied to elucidate the genetic network modulating ferroptosis. One of the hits from the screen 
was CGI-143, which encodes the protein BOLA1 (see Table 2.1). Not much is known about this 
protein, but it is thought to be a mitochondrial protein that counteracts the effect of BSO, a GSH 
depleting compound, and overexpression of BOLA1 leads to suppression of BSO (Willems et al., 
2013). Although this is contrary to what we observe, where loss of BOLA1 suppresses GSH 
depletion induced by erastin, there may be an unknown function of BOLA1 that is important in 
regulating GSH levels in cells.     
 
Small molecule inducer of apoptosis and non-apoptotic cell death 
Summary 
Using a targeted, reverse chemical genetic approach, small molecule regulators of cell 
death can be identified. Using this method, a Mdm2 E3 ligase inhibitor, or MEL, was discovered 
through a high-throughput screen designed to identify Mdm2 stabilizing compounds. MEL was 
found to mediate p53-associated cell death, requiring both Mdm2 and MdmX in cells to be most 
effective. This is the first reported small molecule inhibitor of the Mdm2/MdmX heterocomplex. 
The E3 ligase inhibitor inhibits cell growth in soft agar colony formation assays, and has a 
marginal selectivity window towards tumor cells compared to non-cancer derived cells, 
providing argument for further testing in animal models. MEL has an indole scaffold, which has 





the indole scaffold, we identified another ferroptosis inducing compound, confirming the notion 
that indoles are enriched in bioactive molecules.  
 
Significance  
 Well-defined chemical probes are useful for studying the biological significance of target 
proteins. Distinct advantages exist to using chemical probes compared to genetic modifications 
to study proteins, including spatial and temporal control. There is also the small possibility that a 
well-characterized chemical probe can be translated into use in the clinic. p53 is one of the most 
well-studied proteins in oncology. It is involved in countless cellular processes and has hundreds 
of interacting proteins. Identification of chemical probes for the p53 negative regulator, Mdm2, 
will allow scientists to elucidate the importance of Mdm2 in regulating p53 during certain stages 
of development and in disease progression. The Mdm2/MdmX heterocomplex has gained 
interest as the more dominant regulator of p53 compared to Mdm2 homocomplex. Genetic 
methods to address the question of which complex of Mdm2 is more relevant in regulating p53 
during development has been explored, but the lack of a specific chemical probe has impeded 
investigating the question in disease contexts. Using MEL, the importance of the Mdm2/MdmX 
heterocomplex E3 ligase activity on p53 activity can be probed throughout development, 
including in aging, as well as disease contexts. Also Mdm2/MdmX heterocomplex E3 ligase 
targets can be identified through use of MEL.   
 Development of a drug-like molecule that induces ferroptosis may be beneficial in 
targeting tumors that have become resistant to apoptosis inducing agents. Derivatives of current 
ferroptosis inducing agents are being pursued in clinical development; however, these 





Even if compounds do make it into the clinic, tumors may become resistant to ferroptosis 
induced by that compound, and another compound that targets a different molecule in the 
ferroptotic pathway may be used instead.   
 
Future directions 
 Future directions for development of MEL as a chemical probe include identifying a 
more soluble and potent analog to use in in vivo studies, and to use MEL to identify 
Mdm2/MdmX heterocomplex targets in cells.   
In vivo studies were impeded by the fact that both MEL23 and MEL24 were highly 
insoluble; solubility in DMSO was around 5 µg/mL, and in media 10 µg/mL. We hypothesized 
that the barbituric acid moiety on the indole ring was leading to the insoluble nature of MEL 
analogs. Testing of more analogs with similar activity to the original MEL compounds but with 
higher solubility will allow us to use the compound in animal testing. If the compound is found 
to be metabolically stable in animals, it will be interesting to see if inhibition of the 
Mdm2/MdmX E3 ligase activity leads to regression of xenografts and genetically engineered 
tumors, and if both p53-dependent and p53-null tumors respond to compound treatment. We 
hypothesize that inhibition of the heterocomplex will lead to activation of p53 and subsequent 
tumor regression or halt its proliferation; however, it will be interesting to see if tumors will 
respond in a p53-independent manner. This is one way the MEL analog can be used as a probe to 
study the significance of Mdm2/MdmX heterocomplex in regulating tumor-associated proteins 
that are less understood.  
MEL can be used in cells to identify targets of Mdm2/MdmX E3 ligase activity. By 





proteins in whole-cell lysate by LC-MS, we may be able to identify targets of Mdm2/MdmX. For 
whole-cell lysate, p53 could serve as a control, as we have shown p53 stabilization in response to 
MEL treatment via qPCR and western blotting. Background noise may be high using this whole-
cell lysate approach; instead, targets can be enriched by using poly-ubiquitination antibodies (for 
example, antibodies specific for ubiquitin connecting through lysine-48 or lysine-68, or using 
tandem-repeated ubiquitin-binding entities, or TUBEs (Hjerpe et al., 2009)) to pull down only 
proteins that are poly-ubiqutinated in cells. Targets can then be analyzed by LC-MS. If targets 
other than p53 are identified through this work, the significance of Mdm2’s regulation of the 
target protein can be further elucidated.     
Future directions for Compound 27, the novel ferroptosis inducer, include identification 
of the target in cells. Several methods exist for target identification, including yeast three-hybrid 
screens (Licitra and Liu, 1996), genetic modulator screens (Giaever et al., 1999) and affinity 
chromatography (Burdine and Kodadek, 2004). Once the target is identified through in vitro 
studies, the mechanism by which inhibition of the target leads to ferroptosis can be elucidated. 
There is a possibility that Compound 27 does not inhibit a protein, but may actually activate or 
enhance lipid peroxidation and accumulation of ROS. Discovery of ways to sensitize cells to 
ferroptosis will be interesting to pursue, as it may help identify patients that could benefit from 
ferroptosis-inducing therapeutics, or a ferroptosis inducing agent may be co-administered with 
the a sensitizing agent to increase efficacy of treatment.       
 
 In summary, through the use of genetic and chemical modulatory studies, we have 
discovered a new resistance mechanism to system xc- inhibition-induced ferroptosis, a novel 





activity. The transsulfuration pathway as a resistance mechanism to ferroptosis can be 
extrapolated into the clinic to identify tumor populations that my be sensitive to ferroptosis 
inducing agents, as well as inducing the pathway to inhibit excess cell death in certain contexts, 
such as in neurodegenerative disorders and ischemia. The Mdm2/MdmX inhibitor may be useful 
as a p53-stabilizing therapeutic, but will also be useful as a tool to probe the significance of the 











Abeles, R. H., and Walsh, C. T. (1973). Acetylenic enzyme inactivators. Inactivation of gamma-
cystathionase, in vitro and in vivo, by propargylglycine. Journal of the American Chemical 
Society 95, 6124-6125. 
 
Aeluri, M., Chamakuri, S., Dasari, B., Guduru, S. K., Jimmidi, R., Jogula, S., and Arya, P. 
(2014). Small molecule modulators of protein-protein interactions: selected case studies. 
Chemical reviews 114, 4640-4694. 
 
Albrecht, P., Lewerenz, J., Dittmer, S., Noack, R., Maher, P., and Methner, A. (2010). 
Mechanisms of oxidative glutamate toxicity: the glutamate/cystine antiporter system xc- as a 
neuroprotective drug target. CNS & neurological disorders drug targets 9, 373-382. 
 
Anglade, P., Vyas, S., Javoy-Agid, F., Herrero, M. T., Michel, P. P., Marquez, J., Mouatt-
Prigent, A., Ruberg, M., Hirsch, E. C., and Agid, Y. (1997). Apoptosis and autophagy in nigral 
neurons of patients with Parkinson's disease. Histology and histopathology 12, 25-31. 
 
Antonellis, A., Ellsworth, R. E., Sambuughin, N., Puls, I., Abel, A., Lee-Lin, S. Q., Jordanova, 
A., Kremensky, I., Christodoulou, K., Middleton, L. T., et al. (2003). Glycyl tRNA synthetase 
mutations in Charcot-Marie-Tooth disease type 2D and distal spinal muscular atrophy type V. 





Appella, E., and Anderson, C. W. (2001). Post-translational modifications and activation of p53 
by genotoxic stresses. Eur J Biochem 268, 2764-2772. 
 
Armstrong, J. S., Steinauer, K. K., Hornung, B., Irish, J. M., Lecane, P., Birrell, G. W., Peehl, D. 
M., and Knox, S. J. (2002). Role of glutathione depletion and reactive oxygen species generation 
in apoptotic signaling in a human B lymphoma cell line. Cell death and differentiation 9, 252-
263. 
 
Ashkenazi, A. (2008). Targeting the extrinsic apoptosis pathway in cancer. Cytokine & growth 
factor reviews 19, 325-331. 
 
Asimakopoulou, A., Panopoulos, P., Chasapis, C. T., Coletta, C., Zhou, Z., Cirino, G., Giannis, 
A., Szabo, C., Spyroulias, G. A., and Papapetropoulos, A. (2013). Selectivity of commonly used 
pharmacological inhibitors for cystathionine beta synthase (CBS) and cystathionine gamma lyase 
(CSE). British journal of pharmacology 169, 922-932. 
 
Babij, C., Zhang, Y., Kurzeja, R. J., Munzli, A., Shehabeldin, A., Fernando, M., Quon, K., 
Kassner, P. D., Ruefli-Brasse, A. A., Watson, V. J., et al. (2011). STK33 kinase activity is 
nonessential in KRAS-dependent cancer cells. Cancer research 71, 5818-5826. 
 
Bae, J., Leo, C. P., Hsu, S. Y., and Hsueh, A. J. (2000). MCL-1S, a splicing variant of the 
antiapoptotic BCL-2 family member MCL-1, encodes a proapoptotic protein possessing only the 






Barak, Y., Gottlieb, E., Juven-Gershon, T., and Oren, M. (1994). Regulation of mdm2 expression 
by p53: alternative promoters produce transcripts with nonidentical translation potential. Genes 
& development 8, 1739-1749. 
 
Baric, I., Fumic, K., Glenn, B., Cuk, M., Schulze, A., Finkelstein, J. D., James, S. J., Mejaski-
Bosnjak, V., Pazanin, L., Pogribny, I. P., et al. (2004). S-adenosylhomocysteine hydrolase 
deficiency in a human: a genetic disorder of methionine metabolism. Proceedings of the National 
Academy of Sciences of the United States of America 101, 4234-4239. 
 
Bassik, M. C., Lebbink, R. J., Churchman, L. S., Ingolia, N. T., Patena, W., LeProust, E. M., 
Schuldiner, M., Weissman, J. S., and McManus, M. T. (2009). Rapid creation and quantitative 
monitoring of high coverage shRNA libraries. Nat Methods 6, 443-445. 
 
Beaulaton, J., and Lockshin, R. A. (1977). Ultrastructural study of the normal degeneration of 
the intersegmental muscles of Anthereae polyphemus and Manduca sexta (Insecta, Lepidoptera) 
with particular reference of cellular autophagy. Journal of morphology 154, 39-57. 
 
Bergsbaken, T., Fink, S. L., and Cookson, B. T. (2009). Pyroptosis: host cell death and 
inflammation. Nature reviews Microbiology 7, 99-109. 
 
Berry, D. L., and Baehrecke, E. H. (2007). Growth arrest and autophagy are required for salivary 






Birmingham, A., Selfors, L. M., Forster, T., Wrobel, D., Kennedy, C. J., Shanks, E., Santoyo-
Lopez, J., Dunican, D. J., Long, A., Kelleher, D., et al. (2009). Statistical methods for analysis of 
high-throughput RNA interference screens. Nat Methods 6, 569-575. 
 
Borawski, J., Lindeman, A., Buxton, F., Labow, M., and Gaither, L. A. (2007). Optimization 
procedure for small interfering RNA transfection in a 384-well format. Journal of biomolecular 
screening 12, 546-559. 
 
Boutros, M., Bras, L. P., and Huber, W. (2006). Analysis of cell-based RNAi screens. Genome 
biology 7, R66. 
 
Brass, A. L., Dykxhoorn, D. M., Benita, Y., Yan, N., Engelman, A., Xavier, R. J., Lieberman, J., 
and Elledge, S. J. (2008). Identification of host proteins required for HIV infection through a 
functional genomic screen. Science 319, 921-926. 
 
Brooks, C. L., and Gu, W. (2003). Ubiquitination, phosphorylation and acetylation: the 
molecular basis for p53 regulation. Curr Opin Cell Biol 15, 164-171. 
 
Brosnan, J. T., and Brosnan, M. E. (2006). The sulfur-containing amino acids: an overview. The 






Brush, M. H., Weiser, D. C., and Shenolikar, S. (2003). Growth arrest and DNA damage-
inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and 
promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. 
Molecular and cellular biology 23, 1292-1303. 
 
Budanov, A. V., Sablina, A. A., Feinstein, E., Koonin, E. V., and Chumakov, P. M. (2004). 
Regeneration of peroxiredoxins by p53-regulated sestrins, homologs of bacterial AhpD. Science 
304, 596-600. 
 
Burdine, L., and Kodadek, T. (2004). Target identification in chemical genetics: the (often) 
missing link. Chem Biol 11, 593-597. 
 
Bushman, F. D., Malani, N., Fernandes, J., D'Orso, I., Cagney, G., Diamond, T. L., Zhou, H., 
Hazuda, D. J., Espeseth, A. S., Konig, R., et al. (2009). Host cell factors in HIV replication: 
meta-analysis of genome-wide studies. PLoS pathogens 5, e1000437. 
 
Caffrey, D. R., Zhao, J., Song, Z., Schaffer, M. E., Haney, S. A., Subramanian, R. R., Seymour, 
A. B., and Hughes, J. D. (2011). siRNA off-target effects can be reduced at concentrations that 
match their individual potency. PloS one 6, e21503. 
 
Carrillo, A. M., Bouska, A., Arrate, M. P., and Eischen, C. M. (2014). Mdmx promotes genomic 






Cauwels, A., Janssen, B., Waeytens, A., Cuvelier, C., and Brouckaert, P. (2003). Caspase 
inhibition causes hyperacute tumor necrosis factor-induced shock via oxidative stress and 
phospholipase A2. Nature immunology 4, 387-393. 
 
Chang, K., Elledge, S. J., and Hannon, G. J. (2006). Lessons from Nature: microRNA-based 
shRNA libraries. Nat Methods 3, 707-714. 
 
Chautan, M., Chazal, G., Cecconi, F., Gruss, P., and Golstein, P. (1999). Interdigital cell death 
can occur through a necrotic and caspase-independent pathway. Current biology : CB 9, 967-
970. 
 
Cherest, H., and Surdin-Kerjan, Y. (1992). Genetic analysis of a new mutation conferring 
cysteine auxotrophy in Saccharomyces cerevisiae: updating of the sulfur metabolism pathway. 
Genetics 130, 51-58. 
 
Cherney, M. M., Pazicni, S., Frank, N., Marvin, K. A., Kraus, J. P., and Burstyn, J. N. (2007). 
Ferrous human cystathionine beta-synthase loses activity during enzyme assay due to a ligand 
switch process. Biochemistry 46, 13199-13210. 
 
Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., and Chan, F. K. 
(2009). Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed 






Clarke, P. G. (1990). Developmental cell death: morphological diversity and multiple 
mechanisms. Anatomy and embryology 181, 195-213. 
 
Clarke, R., Smith, A. D., Jobst, K. A., Refsum, H., Sutton, L., and Ueland, P. M. (1998). Folate, 
vitamin B12, and serum total homocysteine levels in confirmed Alzheimer disease. Archives of 
neurology 55, 1449-1455. 
 
Clemens, J. C., Worby, C. A., Simonson-Leff, N., Muda, M., Maehama, T., Hemmings, B. A., 
and Dixon, J. E. (2000). Use of double-stranded RNA interference in Drosophila cell lines to 
dissect signal transduction pathways. Proceedings of the National Academy of Sciences of the 
United States of America 97, 6499-6503. 
 
Cohen, G., Saint-Girons, I (1987). Biosynthesis of threonine, lysine and methionine  In 
Escherichia coli and Salmonella typhimurium, F. Neidhart, ed. (Washington, DC: American 
Society for Microbiology), pp. 429-444. 
 
Cools, J., Wlodarska, I., Somers, R., Mentens, N., Pedeutour, F., Maes, B., De Wolf-Peeters, C., 
Pauwels, P., Hagemeijer, A., and Marynen, P. (2002). Identification of novel fusion partners of 
ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory 






Cordon-Cardo, C., Latres, E., Drobnjak, M., Oliva, M. R., Pollack, D., Woodruff, J. M., 
Marechal, V., Chen, J., Brennan, M. F., and Levine, A. J. (1994). Molecular abnormalities of 
mdm2 and p53 genes in adult soft tissue sarcomas. Cancer Res 54, 794-799. 
 
Cruz, M. C., Cavallo, L. M., Gorlach, J. M., Cox, G., Perfect, J. R., Cardenas, M. E., and 
Heitman, J. (1999). Rapamycin antifungal action is mediated via conserved complexes with 
FKBP12 and TOR kinase homologs in Cryptococcus neoformans. Molecular and cellular 
biology 19, 4101-4112. 
 
Davydov, I. V., Woods, D., Safiran, Y. J., Oberoi, P., Fearnhead, H. O., Fang, S., Jensen, J. P., 
Weissman, A. M., Kenten, J. H., and Vousden, K. H. (2004). Assay for ubiquitin ligase activity: 
high-throughput screen for inhibitors of HDM2. Journal of biomolecular screening 9, 695-703. 
 
Debelenko, L. V., Arthur, D. C., Pack, S. D., Helman, L. J., Schrump, D. S., and Tsokos, M. 
(2003). Identification of CARS-ALK fusion in primary and metastatic lesions of an 
inflammatory myofibroblastic tumor. Laboratory investigation; a journal of technical methods 
and pathology 83, 1255-1265. 
 
Degterev, A., Hitomi, J., Germscheid, M., Ch'en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, 
G. D., Yuan, C., Wagner, G., et al. (2008). Identification of RIP1 kinase as a specific cellular 






Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, 
T. J., Moskowitz, M. A., and Yuan, J. (2005). Chemical inhibitor of nonapoptotic cell death with 
therapeutic potential for ischemic brain injury. Nature chemical biology 1, 112-119. 
 
DeLeo, A. B., Jay, G., Appella, E., Dubois, G. C., Law, L. W., and Old, L. J. (1979). Detection 
of a transformation-related antigen in chemically induced sarcomas and other transformed cells 
of the mouse. Proc Natl Acad Sci U S A 76, 2420-2424. 
 
Demir, K., and Boutros, M. (2012). Cell perturbation screens for target identification by RNAi. 
Methods in molecular biology 910, 1-13. 
 
Deval, C., Talvas, J., Chaveroux, C., Maurin, A. C., Mordier, S., Cherasse, Y., Parry, L., Carraro, 
V., Jousse, C., Bruhat, A., and Fafournoux, P. (2008). Amino-acid limitation induces the GCN2 
signaling pathway in myoblasts but not in myotubes. Biochimie 90, 1716-1721. 
 
Dever, T., and Hinnebusch, A. (2005). GCN2 whets the appetite for amino acids. Molecular cell 
18, 141-142. 
 
Dickhout, J. G., Carlisle, R. E., Jerome, D. E., Mohammed-Ali, Z., Jiang, H., Yang, G., Mani, S., 
Garg, S. K., Banerjee, R., Kaufman, R. J., et al. (2012). Integrated stress response modulates 
cellular redox state via induction of cystathionine gamma-lyase: cross-talk between integrated 






Ding, K., Lu, Y., Nikolovska-Coleska, Z., Wang, G., Qiu, S., Shangary, S., Gao, W., Qin, D., 
Stuckey, J., Krajewski, K., et al. (2006). Structure-based design of spiro-oxindoles as potent, 
specific small-molecule inhibitors of the MDM2-p53 interaction. Journal of medicinal chemistry 
49, 3432-3435. 
 
Ding, L., Paszkowski-Rogacz, M., Nitzsche, A., Slabicki, M. M., Heninger, A. K., de Vries, I., 
Kittler, R., Junqueira, M., Shevchenko, A., Schulz, H., et al. (2009). A genome-scale RNAi 
screen for Oct4 modulators defines a role of the Paf1 complex for embryonic stem cell identity. 
Cell stem cell 4, 403-415. 
 
Dixon, S., Lemberg, K., Lamprecht, M., Skouta, R., Zaitsev, E., Gleason, C., Patel, D., Bauer, 
A., Cantley, A., Yang, W., et al. (2012). Ferroptosis: an iron-dependent form of nonapoptotic 
cell death. Cell 149, 1060-1072. 
 
Dixon, S. J., Patel, D. N., Welsch, M., Skouta, R., Lee, E. D., Hayano, M., Thomas, A. G., 
Gleason, C. E., Tatonetti, N. P., Slusher, B. S., and Stockwell, B. R. (2014). Pharmacological 
inhibition of cystine-glutamate exchange induces endoplasmic reticulum stress and ferroptosis. 
eLife 3, e02523. 
 
Dixon, S. J., and Stockwell, B. R. (2014). The role of iron and reactive oxygen species in cell 






Djuranovic, S., Nahvi, A., and Green, R. (2012). miRNA-mediated gene silencing by 
translational repression followed by mRNA deadenylation and decay. Science 336, 237-240. 
 
Dolma, S., Lessnick, S., Hahn, W., and Stockwell, B. (2003a). Identification of genotype-
selective antitumor agents using synthetic lethal chemical screening in engineered human tumor 
cells. Cancer cell 3, 285-296. 
 
Dolma, S., Lessnick, S. L., Hahn, W. C., and Stockwell, B. R. (2003b). Identification of 
genotype-selective antitumor agents using synthetic lethal chemical screening in engineered 
human tumor cells. Cancer Cell 3, 285-296. 
 
Dong, G., Chanudet, E., Zeng, N., Appert, A., Chen, Y. W., Au, W. Y., Hamoudi, R. A., 
Watkins, A. J., Ye, H., Liu, H., et al. (2011). A20, ABIN-1/2, and CARD11 mutations and their 
prognostic value in gastrointestinal diffuse large B-cell lymphoma. Clin Cancer Res 17, 1440-
1451. 
 
Dong, J., Qiu, H., Garcia-Barrio, M., Anderson, J., and Hinnebusch, A. (2000). Uncharged tRNA 
activates GCN2 by displacing the protein kinase moiety from a bipartite tRNA-binding domain. 
Molecular cell 6, 269-279. 
 
Dornan, D., Wertz, I., Shimizu, H., Arnott, D., Frantz, G. D., Dowd, P., O'Rourke, K., Koeppen, 
H., and Dixit, V. M. (2004). The ubiquitin ligase COP1 is a critical negative regulator of p53. 






Echeverri, C. J., Beachy, P. A., Baum, B., Boutros, M., Buchholz, F., Chanda, S. K., Downward, 
J., Ellenberg, J., Fraser, A. G., Hacohen, N., et al. (2006). Minimizing the risk of reporting false 
positives in large-scale RNAi screens. Nat Methods 3, 777-779. 
 
Echeverri, C. J., and Perrimon, N. (2006). High-throughput RNAi screening in cultured cells: a 
user's guide. Nature reviews Genetics 7, 373-384. 
 
Edinger, A. L., and Thompson, C. B. (2004). Death by design: apoptosis, necrosis and 
autophagy. Current opinion in cell biology 16, 663-669. 
 
Efeyan, A., Zoncu, R., Chang, S., Gumper, I., Snitkin, H., Wolfson, R. L., Kirak, O., Sabatini, D. 
D., and Sabatini, D. M. (2013). Regulation of mTORC1 by the Rag GTPases is necessary for 
neonatal autophagy and survival. Nature 493, 679-683. 
 
Efeyan, A., Zoncu, R., and Sabatini, D. M. (2012). Amino acids and mTORC1: from lysosomes 
to disease. Trends in molecular medicine 18, 524-533. 
 
Elbashir, S. M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., and Tuschl, T. (2001). 







Ellis, H. M., and Horvitz, H. R. (1986). Genetic control of programmed cell death in the 
nematode C. elegans. Cell 44, 817-829. 
 
Fawcett, T. W., Martindale, J. L., Guyton, K. Z., Hai, T., and Holbrook, N. J. (1999). Complexes 
containing activating transcription factor (ATF)/cAMP-responsive-element-binding protein 
(CREB) interact with the CCAAT/enhancer-binding protein (C/EBP)-ATF composite site to 
regulate Gadd153 expression during the stress response. The Biochemical journal 339 ( Pt 1), 
135-141. 
 
Feng, S., Yang, Y., Mei, Y., Ma, L., Zhu, D. E., Hoti, N., Castanares, M., and Wu, M. (2007). 
Cleavage of RIP3 inactivates its caspase-independent apoptosis pathway by removal of kinase 
domain. Cellular signalling 19, 2056-2067. 
 
Fernandes-Alnemri, T., Litwack, G., and Alnemri, E. S. (1994). CPP32, a novel human apoptotic 
protein with homology to Caenorhabditis elegans cell death protein Ced-3 and mammalian 
interleukin-1 beta-converting enzyme. The Journal of biological chemistry 269, 30761-30764. 
 
Fire, A., Xu, S., Montgomery, M. K., Kostas, S. A., Driver, S. E., and Mello, C. C. (1998). 
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. 






Friedmann Angeli, J. P., Schneider, M., Proneth, B., Tyurina, Y. Y., Tyurin, V. A., Hammond, 
V. J., Herbach, N., Aichler, M., Walch, A., Eggenhofer, E., et al. (2014). Inactivation of the 
ferroptosis regulator Gpx4 triggers acute renal failure in mice. Nature cell biology. 
 
Fu, W., Ma, Q., Chen, L., Li, P., Zhang, M., Ramamoorthy, S., Nawaz, Z., Shimojima, T., Wang, 
H., Yang, Y., et al. (2009). MDM2 acts downstream of p53 as an E3 ligase to promote FOXO 
ubiquitination and degradation. J Biol Chem 284, 13987-14000. 
 
Fujikawa, D. G. (2000). Confusion between neuronal apoptosis and activation of programmed 
cell death mechanisms in acute necrotic insults. Trends in neurosciences 23, 410-411. 
 
Fukui, H., Hanaoka, R., and Kawahara, A. (2009). Noncanonical activity of seryl-tRNA 
synthetase is involved in vascular development. Circulation research 104, 1253-1259. 
 
Fulda, S., and Debatin, K. M. (2006). Extrinsic versus intrinsic apoptosis pathways in anticancer 
chemotherapy. Oncogene 25, 4798-4811. 
 
Galluzzi, L., Bravo-San Pedro, J. M., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., 
Alnemri, E. S., Altucci, L., Andrews, D., Annicchiarico-Petruzzelli, M., et al. (2014). Essential 







Galluzzi, L., Maiuri, M. C., Vitale, I., Zischka, H., Castedo, M., Zitvogel, L., and Kroemer, G. 
(2007). Cell death modalities: classification and pathophysiological implications. Cell death and 
differentiation 14, 1237-1243. 
 
Ganguli, G., and Wasylyk, B. (2003). p53-independent functions of MDM2. Mol Cancer Res 1, 
1027-1035. 
 
Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. (1992). Identification of programmed cell 
death in situ via specific labeling of nuclear DNA fragmentation. The Journal of cell biology 
119, 493-501. 
 
Geng, Q. Q., Dong, D. F., Chen, N. Z., Wu, Y. Y., Li, E. X., Wang, J., and Wang, S. M. (2013). 
Induction of p53 expression and apoptosis by a recombinant dual-target MDM2/MDMX 
inhibitory protein in wild-type p53 breast cancer cells. International journal of oncology 43, 
1935-1942. 
 
Giaccia, A. J., and Kastan, M. B. (1998). The complexity of p53 modulation: emerging patterns 
from divergent signals. Genes Dev 12, 2973-2983. 
 
Giaever, G., Shoemaker, D. D., Jones, T. W., Liang, H., Winzeler, E. A., Astromoff, A., and 
Davis, R. W. (1999). Genomic profiling of drug sensitivities via induced haploinsufficiency. 





Gigant, B., Wang, C., Ravelli, R. B., Roussi, F., Steinmetz, M. O., Curmi, P. A., Sobel, A., and 
Knossow, M. (2005). Structural basis for the regulation of tubulin by vinblastine. Nature 435, 
519-522. 
 
Gjymishka, A., Palii, S. S., Shan, J., and Kilberg, M. S. (2008). Despite increased ATF4 binding 
at the C/EBP-ATF composite site following activation of the unfolded protein response, system 
A transporter 2 (SNAT2) transcription activity is repressed in HepG2 cells. The Journal of 
biological chemistry 283, 27736-27747. 
 
Gorman, A. M. (2008). Neuronal cell death in neurodegenerative diseases: recurring themes 
around protein handling. Journal of cellular and molecular medicine 12, 2263-2280. 
 
Green, D. R., and Levine, B. (2014). To be or not to be? How selective autophagy and cell death 
govern cell fate. Cell 157, 65-75. 
 
Grooten, J., Goossens, V., Vanhaesebroeck, B., and Fiers, W. (1993). Cell membrane 
permeabilization and cellular collapse, followed by loss of dehydrogenase activity: early events 
in tumour necrosis factor-induced cytotoxicity. Cytokine 5, 546-555. 
 
Gu, J., Kawai, H., Nie, L., Kitao, H., Wiederschain, D., Jochemsen, A. G., Parant, J., Lozano, G., 
and Yuan, Z. M. (2002). Mutual dependence of MDM2 and MDMX in their functional 





Gudkov, A. V., and Komarova, E. A. (2003). The role of p53 in determining sensitivity to 
radiotherapy. Nat Rev Cancer 3, 117-129. 
 
Guo, M., Chong, Y. E., Beebe, K., Shapiro, R., Yang, X. L., and Schimmel, P. (2009). The C-
Ala domain brings together editing and aminoacylation functions on one tRNA. Science 325, 
744-747. 
 
Guo, M., Schimmel, P., and Yang, X. L. (2010a). Functional expansion of human tRNA 
synthetases achieved by structural inventions. FEBS letters 584, 434-442. 
 
Guo, M., Yang, X. L., and Schimmel, P. (2010b). New functions of aminoacyl-tRNA synthetases 
beyond translation. Nature reviews Molecular cell biology 11, 668-674. 
 
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., and 
Weinberg, R. A. (1999). Creation of human tumour cells with defined genetic elements. Nature 
400, 464-468. 
 
Hahn, W. C., Dessain, S. K., Brooks, M. W., King, J. E., Elenbaas, B., Sabatini, D. M., 
DeCaprio, J. A., and Weinberg, R. A. (2002). Enumeration of the simian virus 40 early region 







Hanahan, D., and Weinberg, R. A. (2011). Hallmarks of cancer: the next generation. Cell 144, 
646-674. 
 
Hansen, B. S., Vaughan, M. H., and Wang, L. (1972). Reversible inhibition by histidinol of 
protein synthesis in human cells at the activation of histidine. The Journal of biological 
chemistry 247, 3854-3857. 
 
Harding, H., Novoa, I., Zhang, Y., Zeng, H., Wek, R., Schapira, M., and Ron, D. (2000). 
Regulated translation initiation controls stress-induced gene expression in mammalian cells. 
Molecular cell 6, 1099-1108. 
 
Harding, H. P., Zhang, Y., Zeng, H., Novoa, I., Lu, P. D., Calfon, M., Sadri, N., Yun, C., Popko, 
B., Paules, R., et al. (2003). An integrated stress response regulates amino acid metabolism and 
resistance to oxidative stress. Mol Cell 11, 619-633. 
 
Harris, S. L., and Levine, A. J. (2005). The p53 pathway: positive and negative feedback loops. 
Oncogene 24, 2899-2908. 
 
Hartwell, L. H., Culotti, J., Pringle, J. R., and Reid, B. J. (1974). Genetic control of the cell 
division cycle in yeast. Science 183, 46-51. 
 






He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., and Wang, X. (2009). Receptor 
interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 137, 1100-
1111. 
 
Heitman, J., Movva, N. R., and Hall, M. N. (1991). Targets for cell cycle arrest by the 
immunosuppressant rapamycin in yeast. Science 253, 905-909. 
 
Hengartner, M. O., Ellis, R. E., and Horvitz, H. R. (1992). Caenorhabditis elegans gene ced-9 
protects cells from programmed cell death. Nature 356, 494-499. 
 
Herman, A. G., Hayano, M., Poyurovsky, M. V., Shimada, K., Skouta, R., Prives, C., and 
Stockwell, B. R. (2011). Discovery of Mdm2-MdmX E3 ligase inhibitors using a cell-based 
ubiquitination assay. Cancer discovery 1, 312-325. 
 
Herzog, W., Muller, K., Huisken, J., and Stainier, D. Y. (2009). Genetic evidence for a 
noncanonical function of seryl-tRNA synthetase in vascular development. Circulation research 
104, 1260-1266. 
 
Hettmann, T., Barton, K., and Leiden, J. M. (2000). Microphthalmia due to p53-mediated 
apoptosis of anterior lens epithelial cells in mice lacking the CREB-2 transcription factor. 






Hinnebusch, A., and Natarajan, K. (2002). Gcn4p, a master regulator of gene expression, is 
controlled at multiple levels by diverse signals of starvation and stress. Eukaryotic cell 1, 22-32. 
 
Hitomi, J., Christofferson, D. E., Ng, A., Yao, J., Degterev, A., Xavier, R. J., and Yuan, J. 
(2008). Identification of a molecular signaling network that regulates a cellular necrotic cell 
death pathway. Cell 135, 1311-1323. 
 
Hjerpe, R., Aillet, F., Lopitz-Otsoa, F., Lang, V., England, P., and Rodriguez, M. S. (2009). 
Efficient protection and isolation of ubiquitylated proteins using tandem ubiquitin-binding 
entities. EMBO reports 10, 1250-1258. 
 
Holen, T. (2006). Efficient prediction of siRNAs with siRNArules 1.0: an open-source JAVA 
approach to siRNA algorithms. Rna 12, 1620-1625. 
 
Holler, N., Zaru, R., Micheau, O., Thome, M., Attinger, A., Valitutti, S., Bodmer, J. L., 
Schneider, P., Seed, B., and Tschopp, J. (2000). Fas triggers an alternative, caspase-8-
independent cell death pathway using the kinase RIP as effector molecule. Nature immunology 
1, 489-495. 
 
Honarpour, N., Du, C., Richardson, J. A., Hammer, R. E., Wang, X., and Herz, J. (2000). Adult 






Horvitz, H. R. (1999). Genetic control of programmed cell death in the nematode Caenorhabditis 
elegans. Cancer research 59, 1701s-1706s. 
 
Hosokawa, N., Hara, T., Kaizuka, T., Kishi, C., Takamura, A., Miura, Y., Iemura, S., Natsume, 
T., Takehana, K., Yamada, N., et al. (2009). Nutrient-dependent mTORC1 association with the 
ULK1-Atg13-FIP200 complex required for autophagy. Molecular biology of the cell 20, 1981-
1991. 
 
Huang, L., Yan, Z., Liao, X., Li, Y., Yang, J., Wang, Z. G., Zuo, Y., Kawai, H., Shadfan, M., 
Ganapathy, S., and Yuan, Z. M. (2011). The p53 inhibitors MDM2/MDMX complex is required 
for control of p53 activity in vivo. Proc Natl Acad Sci U S A 108, 12001-12006. 
 
Hurdle, J. G., O'Neill, A. J., and Chopra, I. (2005). Prospects for aminoacyl-tRNA synthetase 
inhibitors as new antimicrobial agents. Antimicrobial agents and chemotherapy 49, 4821-4833. 
 
Ishii, T., Bannai, S., and Sugita, Y. (1981). Mechanism of growth stimulation of L1210 cells by 
2-mercaptoethanol in vitro. Role of the mixed disulfide of 2-mercaptoethanol and cysteine. The 
Journal of biological chemistry 256, 12387-12392. 
 
Issaeva, N., Bozko, P., Enge, M., Protopopova, M., Verhoef, L. G., Masucci, M., Pramanik, A., 
and Selivanova, G. (2004). Small molecule RITA binds to p53, blocks p53-HDM-2 interaction 





Itahana, K., Mao, H., Jin, A., Itahana, Y., Clegg, H. V., Lindstrom, M. S., Bhat, K. P., Godfrey, 
V. L., Evan, G. I., and Zhang, Y. (2007). Targeted inactivation of Mdm2 RING finger E3 
ubiquitin ligase activity in the mouse reveals mechanistic insights into p53 regulation. Cancer 
Cell 12, 355-366. 
 
Izant, J. G., and Weintraub, H. (1984). Inhibition of thymidine kinase gene expression by anti-
sense RNA: a molecular approach to genetic analysis. Cell 36, 1007-1015. 
 
Jackson, A. L., Burchard, J., Leake, D., Reynolds, A., Schelter, J., Guo, J., Johnson, J. M., Lim, 
L., Karpilow, J., Nichols, K., et al. (2006). Position-specific chemical modification of siRNAs 
reduces "off-target" transcript silencing. Rna 12, 1197-1205. 
 
Jhee, K. H., McPhie, P., and Miles, E. W. (2000). Domain architecture of the heme-independent 
yeast cystathionine beta-synthase provides insights into mechanisms of catalysis and regulation. 
Biochemistry 39, 10548-10556. 
 
Jordanova, A., Irobi, J., Thomas, F. P., Van Dijck, P., Meerschaert, K., Dewil, M., Dierick, I., 
Jacobs, A., De Vriendt, E., Guergueltcheva, V., et al. (2006). Disrupted function and axonal 
distribution of mutant tyrosyl-tRNA synthetase in dominant intermediate Charcot-Marie-Tooth 






Kabeya, Y., Mizushima, N., Ueno, T., Yamamoto, A., Kirisako, T., Noda, T., Kominami, E., 
Ohsumi, Y., and Yoshimori, T. (2000). LC3, a mammalian homologue of yeast Apg8p, is 
localized in autophagosome membranes after processing. The EMBO journal 19, 5720-5728. 
 
Kawai, H., Lopez-Pajares, V., Kim, M. M., Wiederschain, D., and Yuan, Z. M. (2007). RING 
domain-mediated interaction is a requirement for MDM2's E3 ligase activity. Cancer Res 67, 
6026-6030. 
 
Keller, T. L., Zocco, D., Sundrud, M. S., Hendrick, M., Edenius, M., Yum, J., Kim, Y. J., Lee, H. 
K., Cortese, J. F., Wirth, D. F., et al. (2012). Halofuginone and other febrifugine derivatives 
inhibit prolyl-tRNA synthetase. Nature chemical biology 8, 311-317. 
 
Kerr, J. F., Wyllie, A. H., and Currie, A. R. (1972). Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. British journal of cancer 26, 239-257. 
 
Kery, V., Bukovska, G., and Kraus, J. P. (1994). Transsulfuration depends on heme in addition 
to pyridoxal 5'-phosphate. Cystathionine beta-synthase is a heme protein. The Journal of 
biological chemistry 269, 25283-25288. 
 
Khan, A. R., and James, M. N. (1998). Molecular mechanisms for the conversion of zymogens to 






Khvorova, A., Reynolds, A., and Jayasena, S. D. (2003). Functional siRNAs and miRNAs 
exhibit strand bias. Cell 115, 209-216. 
 
Kilberg, M., Shan, J., and Su, N. (2009). ATF4-dependent transcription mediates signaling of 
amino acid limitation. Trends in endocrinology and metabolism: TEM 20, 436-443. 
 
Kilby, N. J., Snaith, M. R., and Murray, J. A. (1993). Site-specific recombinases: tools for 
genome engineering. Trends in genetics : TIG 9, 413-421. 
 
Kim, S., You, S., and Hwang, D. (2011). Aminoacyl-tRNA synthetases and tumorigenesis: more 
than housekeeping. Nature reviews Cancer 11, 708-718. 
 
Kittler, R., and Buchholz, F. (2005). Functional genomic analysis of cell division by 
endoribonuclease-prepared siRNAs. Cell cycle 4, 564-567. 
 
Kittler, R., Putz, G., Pelletier, L., Poser, I., Heninger, A. K., Drechsel, D., Fischer, S., 
Konstantinova, I., Habermann, B., Grabner, H., et al. (2004). An endoribonuclease-prepared 
siRNA screen in human cells identifies genes essential for cell division. Nature 432, 1036-1040. 
 
Klionsky, D. J., Cregg, J. M., Dunn, W. A., Jr., Emr, S. D., Sakai, Y., Sandoval, I. V., Sibirny, 
A., Subramani, S., Thumm, M., Veenhuis, M., and Ohsumi, Y. (2003). A unified nomenclature 





Knudson, C. M., Tung, K. S., Tourtellotte, W. G., Brown, G. A., and Korsmeyer, S. J. (1995). 
Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science 270, 96-99. 
 
Koike, M., Shibata, M., Tadakoshi, M., Gotoh, K., Komatsu, M., Waguri, S., Kawahara, N., 
Kuida, K., Nagata, S., Kominami, E., et al. (2008). Inhibition of autophagy prevents 
hippocampal pyramidal neuron death after hypoxic-ischemic injury. The American journal of 
pathology 172, 454-469. 
 
Kolfschoten, I. G., van Leeuwen, B., Berns, K., Mullenders, J., Beijersbergen, R. L., Bernards, 
R., Voorhoeve, P. M., and Agami, R. (2005). A genetic screen identifies PITX1 as a suppressor 
of RAS activity and tumorigenicity. Cell 121, 849-858. 
 
Konig, R., Zhou, Y., Elleder, D., Diamond, T. L., Bonamy, G. M., Irelan, J. T., Chiang, C. Y., 
Tu, B. P., De Jesus, P. D., Lilley, C. E., et al. (2008). Global analysis of host-pathogen 
interactions that regulate early-stage HIV-1 replication. Cell 135, 49-60. 
 
Konovalova, S., and Tyynismaa, H. (2013). Mitochondrial aminoacyl-tRNA synthetases in 
human disease. Molecular genetics and metabolism 108, 206-211. 
 
Kopple, J. D., and Swendseid, M. E. (1975). Evidence that histidine is an essential amino acid in 





Kress, M., May, E., Cassingena, R., and May, P. (1979). Simian virus 40-transformed cells 
express new species of proteins precipitable by anti-simian virus 40 tumor serum. J Virol 31, 
472-483. 
 
Kroemer, G., and Levine, B. (2008). Autophagic cell death: the story of a misnomer. Nature 
reviews Molecular cell biology 9, 1004-1010. 
 
Krug, A. K., Gutbier, S., Zhao, L., Poltl, D., Kullmann, C., Ivanova, V., Forster, S., Jagtap, S., 
Meiser, J., Leparc, G., et al. (2014). Transcriptional and metabolic adaptation of human neurons 
to the mitochondrial toxicant MPP(+). Cell death & disease 5, e1222. 
 
Kuida, K., Zheng, T. S., Na, S., Kuan, C., Yang, D., Karasuyama, H., Rakic, P., and Flavell, R. 
A. (1996). Decreased apoptosis in the brain and premature lethality in CPP32-deficient mice. 
Nature 384, 368-372. 
 
Kushner, J. P., Boll, D., Quagliana, J., and Dickman, S. (1976). Elevated methionine-tRNA 
synthetase activity in human colon cancer. Proceedings of the Society for Experimental Biology 
and Medicine Society for Experimental Biology and Medicine 153, 273-276. 
 
Lahav, G., Rosenfeld, N., Sigal, A., Geva-Zatorsky, N., Levine, A. J., Elowitz, M. B., and Alon, 
U. (2004). Dynamics of the p53-Mdm2 feedback loop in individual cells. Nat Genet 36, 147-150. 





Lane, D. P., and Crawford, L. V. (1979). T antigen is bound to a host protein in SV40-
transformed cells. Nature 278, 261-263. 
 
Laster, S. M., Wood, J. G., and Gooding, L. R. (1988). Tumor necrosis factor can induce both 
apoptic and necrotic forms of cell lysis. Journal of immunology 141, 2629-2634. 
 
Lehner, B., Fraser, A. G., and Sanderson, C. M. (2004). Technique review: how to use RNA 
interference. Briefings in functional genomics & proteomics 3, 68-83. 
 
Lemasters, J. J. (1999). V. Necrapoptosis and the mitochondrial permeability transition: shared 
pathways to necrosis and apoptosis. The American journal of physiology 276, G1-6. 
 
Leng, R. P., Lin, Y., Ma, W., Wu, H., Lemmers, B., Chung, S., Parant, J. M., Lozano, G., 
Hakem, R., and Benchimol, S. (2003). Pirh2, a p53-induced ubiquitin-protein ligase, promotes 
p53 degradation. Cell 112, 779-791. 
 
Lev Bar-Or, R., Maya, R., Segel, L. A., Alon, U., Levine, A. J., and Oren, M. (2000). Generation 
of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl 
Acad Sci U S A 97, 11250-11255. 
 
Levine, A. J., Hu, W., and Feng, Z. (2006). The P53 pathway: what questions remain to be 






Levine, B., and Kroemer, G. (2008). Autophagy in the pathogenesis of disease. Cell 132, 27-42. 
Li, P., Nijhawan, D., Budihardjo, I., Srinivasula, S. M., Ahmad, M., Alnemri, E. S., and Wang, 
X. (1997). Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates 
an apoptotic protease cascade. Cell 91, 479-489. 
 
Licitra, E. J., and Liu, J. O. (1996). A three-hybrid system for detecting small ligand-protein 
receptor interactions. Proceedings of the National Academy of Sciences of the United States of 
America 93, 12817-12821. 
 
Linares, L. K., Hengstermann, A., Ciechanover, A., Muller, S., and Scheffner, M. (2003). HdmX 
stimulates Hdm2-mediated ubiquitination and degradation of p53. Proc Natl Acad Sci U S A 
100, 12009-12014. 
 
Lindsten, T., Ross, A. J., King, A., Zong, W. X., Rathmell, J. C., Shiels, H. A., Ulrich, E., 
Waymire, K. G., Mahar, P., Frauwirth, K., et al. (2000). The combined functions of proapoptotic 
Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol 
Cell 6, 1389-1399. 
 
Linke, K., Mace, P. D., Smith, C. A., Vaux, D. L., Silke, J., and Day, C. L. (2008). Structure of 
the MDM2/MDMX RING domain heterodimer reveals dimerization is required for their 






Linkermann, A., Skouta, R., Himmerkus, N., Mulay, S. R., Dewitz, C., De Zen, F., Prokai, A., 
Zuchtriegel, G., Krombach, F., Welz, P. S., et al. (2014). Synchronized renal tubular cell death 
involves ferroptosis. Proceedings of the National Academy of Sciences of the United States of 
America. 
 
Linzer, D. I., and Levine, A. J. (1979). Characterization of a 54K dalton cellular SV40 tumor 
antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 17, 
43-52. 
 
Lipinski, M. M., Hoffman, G., Ng, A., Zhou, W., Py, B. F., Hsu, E., Liu, X., Eisenberg, J., Liu, 
J., Blenis, J., et al. (2010). A genome-wide siRNA screen reveals multiple mTORC1 independent 
signaling pathways regulating autophagy under normal nutritional conditions. Developmental 
cell 18, 1041-1052. 
 
Liu, Y., and Huang, L. (2010). Designer lipids advance systemic siRNA delivery. Molecular 
therapy : the journal of the American Society of Gene Therapy 18, 669-670. 
 
Liu, Y., Shoji-Kawata, S., Sumpter, R. M., Jr., Wei, Y., Ginet, V., Zhang, L., Posner, B., Tran, 
K. A., Green, D. R., Xavier, R. J., et al. (2013). Autosis is a Na+,K+-ATPase-regulated form of 
cell death triggered by autophagy-inducing peptides, starvation, and hypoxia-ischemia. 






Lockshin, R. A., and Williams, C. M. (1964). Programmed cell death. II. Endocrine potentiation 
of the breakdown of the intersegmental muscles of silkmoths. J Insect Physiol 10, 643-649. 
 
Long, X., Spycher, C., Han, Z. S., Rose, A. M., Muller, F., and Avruch, J. (2002). TOR 
deficiency in C. elegans causes developmental arrest and intestinal atrophy by inhibition of 
mRNA translation. Current biology : CB 12, 1448-1461. 
 
Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J.-C., Mazière, J.-C., Chauffert, B., and 
Galmiche, A. (2013). Iron-dependent cell death of hepatocellular carcinoma cells exposed to 
sorafenib. International journal of cancer Journal international du cancer 133, 1732-1742. 
 
Maclean, K. N., Janosik, M., Oliveriusova, J., Kery, V., and Kraus, J. P. (2000). Transsulfuration 
in Saccharomyces cerevisiae is not dependent on heme: purification and characterization of 
recombinant yeast cystathionine beta-synthase. Journal of inorganic biochemistry 81, 161-171. 
 
Macnicol, P. K., Datko, A. H., Giovanelli, J., and Mudd, S. H. (1981). Homocysteine 
Biosynthesis in Green Plants: Physiological Importance of the Transsulfuration Pathway in 
Lemna paucicostata. Plant physiology 68, 619-625. 
 
Maiuri, M. C., Zalckvar, E., Kimchi, A., and Kroemer, G. (2007). Self-eating and self-killing: 
crosstalk between autophagy and apoptosis. Nature reviews Molecular cell biology 8, 741-752. 
Majno, G., and Joris, I. (1995). Apoptosis, oncosis, and necrosis. An overview of cell death. The 





Mali, P., Yang, L., Esvelt, K. M., Aach, J., Guell, M., DiCarlo, J. E., Norville, J. E., and Church, 
G. M. (2013). RNA-guided human genome engineering via Cas9. Science 339, 823-826. 
 
Mareninova, O. A., Sung, K. F., Hong, P., Lugea, A., Pandol, S. J., Gukovsky, I., and 
Gukovskaya, A. S. (2006). Cell death in pancreatitis: caspases protect from necrotizing 
pancreatitis. The Journal of biological chemistry 281, 3370-3381. 
 
Mason, R. P., Casu, M., Butler, N., Breda, C., Campesan, S., Clapp, J., Green, E. W., Dhulkhed, 
D., Kyriacou, C. P., and Giorgini, F. (2013). Glutathione peroxidase activity is neuroprotective in 
models of Huntington's disease. Nature genetics 45, 1249-1254. 
 
Mayhew, T. M., Myklebust, R., Whybrow, A., and Jenkins, R. (1999). Epithelial integrity, cell 
death and cell loss in mammalian small intestine. Histology and histopathology 14, 257-267. 
 
Menand, B., Desnos, T., Nussaume, L., Berger, F., Bouchez, D., Meyer, C., and Robaglia, C. 
(2002). Expression and disruption of the Arabidopsis TOR (target of rapamycin) gene. 
Proceedings of the National Academy of Sciences of the United States of America 99, 6422-
6427. 
 
Miller, J. C., Tan, S., Qiao, G., Barlow, K. A., Wang, J., Xia, D. F., Meng, X., Paschon, D. E., 
Leung, E., Hinkley, S. J., et al. (2011). A TALE nuclease architecture for efficient genome 





Mills, J. L., McPartlin, J. M., Kirke, P. N., Lee, Y. J., Conley, M. R., Weir, D. G., and Scott, J. 
M. (1995). Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 
345, 149-151. 
 
Mizushima, N. (2007). Autophagy: process and function. Genes & development 21, 2861-2873. 
 
Mizushima, N., and Klionsky, D. J. (2007). Protein turnover via autophagy: implications for 
metabolism. Annual review of nutrition 27, 19-40. 
 
Montes de Oca Luna, R., Wagner, D. S., and Lozano, G. (1995). Rescue of early embryonic 
lethality in mdm2-deficient mice by deletion of p53. Nature 378, 203-206. 
 
Moore, M. J., Wang, Q., Kennedy, C. J., and Silver, P. A. (2010). An alternative splicing 
network links cell-cycle control to apoptosis. Cell 142, 625-636. 
 
Mudd, S. H., Finkelstein, J. D., Irreverre, F., and Laster, L. (1965). Transsulfuration in 
mammals. Microassays and tissue distributions of three enzymes of the pathway. The Journal of 
biological chemistry 240, 4382-4392. 
 
Nakatogawa, H., Suzuki, K., Kamada, Y., and Ohsumi, Y. (2009). Dynamics and diversity in 






Nangle, L. A., Zhang, W., Xie, W., Yang, X. L., and Schimmel, P. (2007). Charcot-Marie-Tooth 
disease-associated mutant tRNA synthetases linked to altered dimer interface and neurite 
distribution defect. Proceedings of the National Academy of Sciences of the United States of 
America 104, 11239-11244. 
 
Ngo, V. N., Davis, R. E., Lamy, L., Yu, X., Zhao, H., Lenz, G., Lam, L. T., Dave, S., Yang, L., 
Powell, J., and Staudt, L. M. (2006). A loss-of-function RNA interference screen for molecular 
targets in cancer. Nature 441, 106-110. 
 
Noda, T., Matsunaga, K., Taguchi-Atarashi, N., and Yoshimori, T. (2010). Regulation of 
membrane biogenesis in autophagy via PI3P dynamics. Seminars in cell & developmental 
biology 21, 671-676. 
 
Novoa, I., Zeng, H., Harding, H. P., and Ron, D. (2001). Feedback inhibition of the unfolded 
protein response by GADD34-mediated dephosphorylation of eIF2alpha. The Journal of cell 
biology 153, 1011-1022. 
 
Novoa, I., Zhang, Y., Zeng, H., Jungreis, R., Harding, H. P., and Ron, D. (2003). Stress-induced 
gene expression requires programmed recovery from translational repression. The EMBO 
journal 22, 1180-1187. 
 
Nusslein-Volhard, C., and Wieschaus, E. (1980). Mutations affecting segment number and 





Oldham, S., Montagne, J., Radimerski, T., Thomas, G., and Hafen, E. (2000). Genetic and 
biochemical characterization of dTOR, the Drosophila homolog of the target of rapamycin. 
Genes & development 14, 2689-2694. 
 
Oppenheim, R. W., Flavell, R. A., Vinsant, S., Prevette, D., Kuan, C. Y., and Rakic, P. (2001). 
Programmed cell death of developing mammalian neurons after genetic deletion of caspases. The 
Journal of neuroscience : the official journal of the Society for Neuroscience 21, 4752-4760. 
 
Oren, M. (2003). Decision making by p53: life, death and cancer. Cell Death Differ 10, 431-442. 
Orth, K., Chinnaiyan, A. M., Garg, M., Froelich, C. J., and Dixit, V. M. (1996). The CED-3/ICE-
like protease Mch2 is activated during apoptosis and cleaves the death substrate lamin A. The 
Journal of biological chemistry 271, 16443-16446. 
 
Palii, S. S., Kays, C. E., Deval, C., Bruhat, A., Fafournoux, P., and Kilberg, M. S. (2009). 
Specificity of amino acid regulated gene expression: analysis of genes subjected to either 
complete or single amino acid deprivation. Amino acids 37, 79-88. 
 
Pant, V., Xiong, S., Iwakuma, T., Quintas-Cardama, A., and Lozano, G. (2011). 
Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during 






Parant, J., Chavez-Reyes, A., Little, N. A., Yan, W., Reinke, V., Jochemsen, A. G., and Lozano, 
G. (2001). Rescue of embryonic lethality in Mdm4-null mice by loss of Trp53 suggests a 
nonoverlapping pathway with MDM2 to regulate p53. Nat Genet 29, 92-95. 
 
Paul, B. D., Sbodio, J. I., Xu, R., Vandiver, M. S., Cha, J. Y., Snowman, A. M., and Snyder, S. 
H. (2014). Cystathionine gamma-lyase deficiency mediates neurodegeneration in Huntington's 
disease. Nature. 
 
Peng, T., Golub, T. R., and Sabatini, D. M. (2002). The immunosuppressant rapamycin mimics a 
starvation-like signal distinct from amino acid and glucose deprivation. Molecular and cellular 
biology 22, 5575-5584. 
 
Percudani, R., and Peracchi, A. (2003). A genomic overview of pyridoxal-phosphate-dependent 
enzymes. EMBO reports 4, 850-854. 
 
Pereira, C. M., and Oliveira, C. R. (1997). Glutamate toxicity on a PC12 cell line involves 
glutathione (GSH) depletion and oxidative stress. Free radical biology & medicine 23, 637-647. 
 
Phillips, A., Teunisse, A., Lam, S., Lodder, K., Darley, M., Emaduddin, M., Wolf, A., Richter, 
J., de Lange, J., Verlaan-de Vries, M., et al. (2010). HDMX-L is expressed from a functional 
p53-responsive promoter in the first intron of the HDMX gene and participates in an 





Popov, N., Wanzel, M., Madiredjo, M., Zhang, D., Beijersbergen, R., Bernards, R., Moll, R., 
Elledge, S. J., and Eilers, M. (2007). The ubiquitin-specific protease USP28 is required for MYC 
stability. Nature cell biology 9, 765-774. 
 
Poyurovsky, M. V., Jacq, X., Ma, C., Karni-Schmidt, O., Parker, P. J., Chalfie, M., Manley, J. L., 
and Prives, C. (2003). Nucleotide binding by the Mdm2 RING domain facilitates Arf-
independent Mdm2 nucleolar localization. Mol Cell 12, 875-887. 
 
Poyurovsky, M. V., Priest, C., Kentsis, A., Borden, K. L., Pan, Z. Q., Pavletich, N., and Prives, 
C. (2007). The Mdm2 RING domain C-terminus is required for supramolecular assembly and 
ubiquitin ligase activity. EMBO J 26, 90-101. 
 
Prelich, G. (2012). Gene overexpression: uses, mechanisms, and interpretation. Genetics 190, 
841-854. 
 
Proud, C. G. (1992). Protein phosphorylation in translational control. Current topics in cellular 
regulation 32, 243-369. 
 
Qiu, S., Adema, C. M., and Lane, T. (2005). A computational study of off-target effects of RNA 
interference. Nucleic acids research 33, 1834-1847. 
 
Refsum, H., Ueland, P. M., Nygard, O., and Vollset, S. E. (1998). Homocysteine and 





Rose, W. C. (1949). Amino acid requirements of man. Federation proceedings 8, 546-552. 
 
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., and Vousden, K. H. 
(2012). Small molecules that bind the Mdm2 RING stabilize and activate p53. Carcinogenesis 
33, 791-798. 
 
Sajish, M., Zhou, Q., Kishi, S., Valdez, D. M., Jr., Kapoor, M., Guo, M., Lee, S., Kim, S., Yang, 
X. L., and Schimmel, P. (2012). Trp-tRNA synthetase bridges DNA-PKcs to PARP-1 to link 
IFN-gamma and p53 signaling. Nature chemical biology 8, 547-554. 
 
Saldeen, J. (2000). Cytokines induce both necrosis and apoptosis via a common Bcl-2-inhibitable 
pathway in rat insulin-producing cells. Endocrinology 141, 2003-2010. 
 
Samara, C., Syntichaki, P., and Tavernarakis, N. (2008). Autophagy is required for necrotic cell 
death in Caenorhabditis elegans. Cell death and differentiation 15, 105-112. 
 
Sancak, Y., Peterson, T. R., Shaul, Y. D., Lindquist, R. A., Thoreen, C. C., Bar-Peled, L., and 
Sabatini, D. M. (2008). The Rag GTPases bind raptor and mediate amino acid signaling to 
mTORC1. Science 320, 1496-1501. 
 
Sang Won Lee, Y. S. K., Sunghoon Kim (2006). Multi-functional proteins in tumorigenesis: 





Santiago, Y., Chan, E., Liu, P. Q., Orlando, S., Zhang, L., Urnov, F. D., Holmes, M. C., Guschin, 
D., Waite, A., Miller, J. C., et al. (2008). Targeted gene knockout in mammalian cells by using 
engineered zinc-finger nucleases. Proceedings of the National Academy of Sciences of the 
United States of America 105, 5809-5814. 
 
Sato, H., Tamba, M., Ishii, T., and Bannai, S. (1999). Cloning and expression of a plasma 
membrane cystine/glutamate exchange transporter composed of two distinct proteins. The 
Journal of biological chemistry 274, 11455-11458. 
 
Schenone, M., Dancik, V., Wagner, B. K., and Clemons, P. A. (2013). Target identification and 
mechanism of action in chemical biology and drug discovery. Nature chemical biology 9, 232-
240. 
 
Schlabach, M. R., Luo, J., Solimini, N. L., Hu, G., Xu, Q., Li, M. Z., Zhao, Z., Smogorzewska, 
A., Sowa, M. E., Ang, X. L., et al. (2008). Cancer proliferation gene discovery through 
functional genomics. Science 319, 620-624. 
 
Scholl, C., Frohling, S., Dunn, I. F., Schinzel, A. C., Barbie, D. A., Kim, S. Y., Silver, S. J., 
Tamayo, P., Wadlow, R. C., Ramaswamy, S., et al. (2009). Synthetic lethal interaction between 
oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell 137, 821-834. 
 
Schreiber, S. L. (1998). Chemical genetics resulting from a passion for synthetic organic 





Schwanhausser, B., Busse, D., Li, N., Dittmar, G., Schuchhardt, J., Wolf, J., Chen, W., and 
Selbach, M. (2011). Global quantification of mammalian gene expression control. Nature 473, 
337-342. 
 
Schweichel, J. U., and Merker, H. J. (1973). The morphology of various types of cell death in 
prenatal tissues. Teratology 7, 253-266. 
 
Sehgal, S. N., Baker, H., and Vezina, C. (1975). Rapamycin (AY-22,989), a new antifungal 
antibiotic. II. Fermentation, isolation and characterization. The Journal of antibiotics 28, 727-
732. 
 
Semizarov, D., Frost, L., Sarthy, A., Kroeger, P., Halbert, D. N., and Fesik, S. W. (2003). 
Specificity of short interfering RNA determined through gene expression signatures. Proceedings 
of the National Academy of Sciences of the United States of America 100, 6347-6352. 
 
Sharma, S., and Rao, A. (2009). RNAi screening: tips and techniques. Nature immunology 10, 
799-804. 
 
Shastry, B. S. (1995). Overexpression of genes in health and sickness. A bird's eye view. 






Shimizu, S., Kanaseki, T., Mizushima, N., Mizuta, T., Arakawa-Kobayashi, S., Thompson, C. 
B., and Tsujimoto, Y. (2004). Role of Bcl-2 family proteins in a non-apoptotic programmed cell 
death dependent on autophagy genes. Nature cell biology 6, 1221-1228. 
 
Shoemaker, R. H., Wolpert-DeFilippes, M. K., Kern, D. H., Lieber, M. M., Makuch, R. W., 
Melnick, N. R., Miller, W. T., Salmon, S. E., Simon, R. M., Venditti, J. M., and et al. (1985). 
Application of a human tumor colony-forming assay to new drug screening. Cancer Res 45, 
2145-2153. 
 
Shukla, K., Thomas, A. G., Ferraris, D. V., Hin, N., Sattler, R., Alt, J., Rojas, C., Slusher, B. S., 
and Tsukamoto, T. (2011). Inhibition of xc(-) transporter-mediated cystine uptake by 
sulfasalazine analogs. Bioorg Med Chem Lett 21, 6184-6187. 
 
Sies, H. (1999). Glutathione and its role in cellular functions. Free radical biology & medicine 
27, 916-921. 
 
Silva, J. M., Marran, K., Parker, J. S., Silva, J., Golding, M., Schlabach, M. R., Elledge, S. J., 
Hannon, G. J., and Chang, K. (2008). Profiling essential genes in human mammary cells by 
multiplex RNAi screening. Science 319, 617-620. 
 
Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P., Lo, D., 
Weinberg, J., Linkermann, A., and Stockwell, B. R. (2014a). Ferrostatins inhibit oxidative lipid 





Skouta, R., Dixon, S. J., Wang, J., Dunn, D. E., Orman, M., Shimada, K., Rosenberg, P. A., Lo, 
D. C., Weinberg, J. M., Linkermann, A., and Stockwell, B. R. (2014b). Ferrostatins inhibit 
oxidative lipid damage and cell death in diverse disease models. Journal of the American 
Chemical Society 136, 4551-4556. 
 
Skovby, F., Kraus, J. P., and Rosenberg, L. E. (1984). Biosynthesis of human cystathionine beta-
synthase in cultured fibroblasts. The Journal of biological chemistry 259, 583-587. 
 
Soussi, T. (2005). The p53 pathway and human cancer. Br J Surg 92, 1331-1332. 
 
Sperandio, S., de Belle, I., and Bredesen, D. E. (2000). An alternative, nonapoptotic form of 
programmed cell death. Proceedings of the National Academy of Sciences of the United States 
of America 97, 14376-14381. 
 
St Johnston, D., and Nusslein-Volhard, C. (1992). The origin of pattern and polarity in the 
Drosophila embryo. Cell 68, 201-219. 
 
Steegers-Theunissen, R. P., Boers, G. H., Trijbels, F. J., Finkelstein, J. D., Blom, H. J., Thomas, 
C. M., Borm, G. F., Wouters, M. G., and Eskes, T. K. (1994). Maternal hyperhomocysteinemia: 
a risk factor for neural-tube defects? Metabolism: clinical and experimental 43, 1475-1480. 
 
Stockwell, B. R. (2000). Chemical genetics: ligand-based discovery of gene function. Nature 





Sulston, J. E., and Horvitz, H. R. (1977). Post-embryonic cell lineages of the nematode, 
Caenorhabditis elegans. Developmental biology 56, 110-156. 
 
Sulston, J. E., Schierenberg, E., White, J. G., and Thomson, J. N. (1983). The embryonic cell 
lineage of the nematode Caenorhabditis elegans. Developmental biology 100, 64-119. 
 
Sun, Y. (2003). Targeting E3 ubiquitin ligases for cancer therapy. Cancer biology & therapy 2, 
623-629. 
 
Sundrud, M. S., Koralov, S. B., Feuerer, M., Calado, D. P., Kozhaya, A. E., Rhule-Smith, A., 
Lefebvre, R. E., Unutmaz, D., Mazitschek, R., Waldner, H., et al. (2009). Halofuginone inhibits 
TH17 cell differentiation by activating the amino acid starvation response. Science 324, 1334-
1338. 
 
Szydlowska, K., and Tymianski, M. (2010). Calcium, ischemia and excitotoxicity. Cell calcium 
47, 122-129. 
 
Tan, S., Schubert, D., and Maher, P. (2001). Oxytosis: A Novel Form of Programmed Cell 
Death. Current Topics in Medicinal Chemistry 1, 497-506. 
 
Tanaka, Y., Guhde, G., Suter, A., Eskelinen, E. L., Hartmann, D., Lullmann-Rauch, R., Janssen, 
P. M., Blanz, J., von Figura, K., and Saftig, P. (2000). Accumulation of autophagic vacuoles and 





Tenopoulou, M., Kurz, T., Doulias, P. T., Galaris, D., and Brunk, U. T. (2007). Does the calcein-
AM method assay the total cellular 'labile iron pool' or only a fraction of it? The Biochemical 
journal 403, 261-266. 
 
Tewari, M., Quan, L. T., O'Rourke, K., Desnoyers, S., Zeng, Z., Beidler, D. R., Poirier, G. G., 
Salvesen, G. S., and Dixit, V. M. (1995). Yama/CPP32 beta, a mammalian homolog of CED-3, 
is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. 
Cell 81, 801-809. 
 
Thornberry, N. A., Bull, H. G., Calaycay, J. R., Chapman, K. T., Howard, A. D., Kostura, M. J., 
Miller, D. K., Molineaux, S. M., Weidner, J. R., Aunins, J., and et al. (1992). A novel 
heterodimeric cysteine protease is required for interleukin-1 beta processing in monocytes. 
Nature 356, 768-774. 
 
Toledo, F., and Wahl, G. M. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo 
veritas. Nat Rev Cancer 6, 909-923. 
 
Toledo, F., and Wahl, G. M. (2007). MDM2 and MDM4: p53 regulators as targets in anticancer 
therapy. Int J Biochem Cell Biol 39, 1476-1482. 
 
Tsui, F. W., Andrulis, I. L., Murialdo, H., and Siminovitch, L. (1985). Amplification of the gene 
for histidyl-tRNA synthetase in histidinol-resistant Chinese hamster ovary cells. Molecular and 





Tsukada, M., and Ohsumi, Y. (1993). Isolation and characterization of autophagy-defective 
mutants of Saccharomyces cerevisiae. FEBS letters 333, 169-174. 
 
Uldrijan, S., Pannekoek, W. J., and Vousden, K. H. (2007). An essential function of the extreme 
C-terminus of MDM2 can be provided by MDMX. EMBO J 26, 102-112. 
 
Valentine, J. M., Kumar, S., and Moumen, A. (2011). A p53-independent role for the MDM2 
antagonist Nutlin-3 in DNA damage response initiation. BMC cancer 11, 79. 
 
Vassilev, L. T., Vu, B. T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., 
Kammlott, U., Lukacs, C., Klein, C., et al. (2004). In vivo activation of the p53 pathway by 
small-molecule antagonists of MDM2. Science 303, 844-848. 
 
Vattem, K. M., and Wek, R. C. (2004). Reinitiation involving upstream ORFs regulates ATF4 
mRNA translation in mammalian cells. Proceedings of the National Academy of Sciences of the 
United States of America 101, 11269-11274. 
 
Vitvitsky, V., Thomas, M., Ghorpade, A., Gendelman, H. E., and Banerjee, R. (2006). A 
functional transsulfuration pathway in the brain links to glutathione homeostasis. The Journal of 
biological chemistry 281, 35785-35793. 
 






von Ahsen, O., and Bomer, U. (2005). High-throughput screening for kinase inhibitors. 
Chembiochem : a European journal of chemical biology 6, 481-490. 
 
Wade, M., Li, Y. C., and Wahl, G. M. (2013). MDM2, MDMX and p53 in oncogenesis and 
cancer therapy. Nature reviews Cancer 13, 83-96. 
 
Walsh, D. P., and Chang, Y. T. (2006). Chemical genetics. Chemical reviews 106, 2476-2530. 
 
Wang, L., Jhee, K. H., Hua, X., DiBello, P. M., Jacobsen, D. W., and Kruger, W. D. (2004). 
Modulation of cystathionine beta-synthase level regulates total serum homocysteine in mice. 
Circulation research 94, 1318-1324. 
 
Wei, M. C., Zong, W. X., Cheng, E. H., Lindsten, T., Panoutsakopoulou, V., Ross, A. J., Roth, 
K. A., MacGregor, G. R., Thompson, C. B., and Korsmeyer, S. J. (2001). Proapoptotic BAX and 
BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292, 727-730. 
 
Welsch, M. E., Snyder, S. A., and Stockwell, B. R. (2010). Privileged scaffolds for library design 
and drug discovery. Current opinion in chemical biology 14, 347-361. 
 
West, T., Atzeva, M., and Holtzman, D. M. (2006). Caspase-3 deficiency during development 
increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. 





Westbrook, T. F., Martin, E. S., Schlabach, M. R., Leng, Y., Liang, A. C., Feng, B., Zhao, J. J., 
Roberts, T. M., Mandel, G., Hannon, G. J., et al. (2005). A genetic screen for candidate tumor 
suppressors identifies REST. Cell 121, 837-848. 
 
Willems, P., Wanschers, B. F., Esseling, J., Szklarczyk, R., Kudla, U., Duarte, I., Forkink, M., 
Nooteboom, M., Swarts, H., Gloerich, J., et al. (2013). BOLA1 is an aerobic protein that 
prevents mitochondrial morphology changes induced by glutathione depletion. Antioxidants & 
redox signaling 18, 129-138. 
 
Wolpaw, A. J., Shimada, K., Skouta, R., Welsch, M. E., Akavia, U. D., Pe'er, D., Shaik, F., 
Bulinski, J. C., and Stockwell, B. R. (2011). Modulatory profiling identifies mechanisms of 
small molecule-induced cell death. Proceedings of the National Academy of Sciences of the 
United States of America 108, E771-780. 
 
Wu, D., and Cederbaum, A. I. (2001). Removal of glutathione produces apoptosis and necrosis 
in HepG2 cells overexpressing CYP2E1. Alcoholism, clinical and experimental research 25, 
619-628. 
 
Wu-Baer, F., Ludwig, T., and Baer, R. (2010). The UBXN1 protein associates with 
autoubiquitinated forms of the BRCA1 tumor suppressor and inhibits its enzymatic function. 





Wuite, J., Davies, B. I., Go, M. J., Lambers, J. C., Jackson, D., Mellows, G., and Tasker, T. C. 
(1985). Pseudomonic acid, a new antibiotic for topical therapy. Journal of the American 
Academy of Dermatology 12, 1026-1031. 
 
Xirodimas, D. P., Saville, M. K., Bourdon, J. C., Hay, R. T., and Lane, D. P. (2004). Mdm2-
mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118, 83-97. 
 
Xu, Y. (2003). Regulation of p53 responses by post-translational modifications. Cell Death 
Differ 10, 400-403. 
 
Yagoda, N., von Rechenberg, M., Zaganjor, E., Bauer, A., Yang, W., Fridman, D., Wolpaw, A., 
Smukste, I., Peltier, J., Boniface, J., et al. (2007). RAS-RAF-MEK-dependent oxidative cell 
death involving voltage-dependent anion channels. Nature 447, 864-868. 
 
Yang, D., Buchholz, F., Huang, Z., Goga, A., Chen, C. Y., Brodsky, F. M., and Bishop, J. M. 
(2002). Short RNA duplexes produced by hydrolysis with Escherichia coli RNase III mediate 
effective RNA interference in mammalian cells. Proceedings of the National Academy of 
Sciences of the United States of America 99, 9942-9947. 
 
Yang, J. Y., Zong, C. S., Xia, W., Wei, Y., Ali-Seyed, M., Li, Z., Broglio, K., Berry, D. A., and 
Hung, M. C. (2006). MDM2 promotes cell motility and invasiveness by regulating E-cadherin 





Yang, J. Y., Zong, C. S., Xia, W., Yamaguchi, H., Ding, Q., Xie, X., Lang, J. Y., Lai, C. C., 
Chang, C. J., Huang, W. C., et al. (2008). ERK promotes tumorigenesis by inhibiting FOXO3a 
via MDM2-mediated degradation. Nat Cell Biol 10, 138-148. 
 
Yang, W., and Stockwell, B. (2008a). Synthetic lethal screening identifies compounds activating 
iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chemistry & 
biology 15, 234-245. 
 
Yang, W. S., Sriramaratnam, R., Welsch, M. E., Shimada, K., Skouta, R., Viswanathan, V. S., 
Cheah, J. H., Clemons, P. A., Shamji, A. F., Clish, C. B., et al. (2014). Regulation of Ferroptotic 
Cancer Cell Death by GPX4. Cell 156, 317-331. 
 
Yang, W. S., and Stockwell, B. R. (2008b). Synthetic lethal screening identifies compounds 
activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. 
Chemistry & biology 15, 234-245. 
 
Yang, Y., Ludwig, R. L., Jensen, J. P., Pierre, S. A., Medaglia, M. V., Davydov, I. V., Safiran, 
Y. J., Oberoi, P., Kenten, J. H., Phillips, A. C., et al. (2005). Small molecule inhibitors of HDM2 
ubiquitin ligase activity stabilize and activate p53 in cells. Cancer Cell 7, 547-559. 
 
Yao, P., and Fox, P. (2013). Aminoacyl-tRNA synthetases in medicine and disease. EMBO 






Youle, R. J., and Strasser, A. (2008). The BCL-2 protein family: opposing activities that mediate 
cell death. Nature reviews Molecular cell biology 9, 47-59. 
 
Yuan, J., and Kroemer, G. (2010). Alternative cell death mechanisms in development and 
beyond. Genes & development 24, 2592-2602. 
 
Yuan, J., Shaham, S., Ledoux, S., Ellis, H. M., and Horvitz, H. R. (1993). The C. elegans cell 
death gene ced-3 encodes a protein similar to mammalian interleukin-1 beta-converting enzyme. 
Cell 75, 641-652. 
 
Zhang, D. W., Shao, J., Lin, J., Zhang, N., Lu, B. J., Lin, S. C., Dong, M. Q., and Han, J. (2009). 
RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to 
necrosis. Science 325, 332-336. 
 
Zhang, H., Stallock, J. P., Ng, J. C., Reinhard, C., and Neufeld, T. P. (2000). Regulation of 
cellular growth by the Drosophila target of rapamycin dTOR. Genes & development 14, 2712-
2724. 
 
Zhang, W., He, H., Wang, H., Wang, S., Li, X., Liu, Y., Jiang, H., Jiang, H., Yan, Y., Wang, Y., 
and Liu, X. (2013). Activation of transsulfuration pathway by salvianolic acid a treatment: a 
homocysteine-lowering approach with beneficial effects on redox homeostasis in high-fat diet-





Zhou, D., and White, R. H. (1991). Transsulfuration in archaebacteria. Journal of bacteriology 
173, 3250-3251. 
 
Zhou, H., Xu, M., Huang, Q., Gates, A. T., Zhang, X. D., Castle, J. C., Stec, E., Ferrer, M., 
Strulovici, B., Hazuda, D. J., and Espeseth, A. S. (2008). Genome-scale RNAi screen for host 
factors required for HIV replication. Cell host & microbe 4, 495-504. 
 
Ziauddin, J., and Sabatini, D. M. (2001). Microarrays of cells expressing defined cDNAs. Nature 
411, 107-110. 
 
Zong, W. X., Lindsten, T., Ross, A. J., MacGregor, G. R., and Thompson, C. B. (2001). BH3-
only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence 
of Bax and Bak. Genes & development 15, 1481-1486. 
 
Zong, W. X., and Thompson, C. B. (2006). Necrotic death as a cell fate. Genes & development 
20, 1-15. 
 
Zuris, J. A., Thompson, D. B., Shu, Y., Guilinger, J. P., Bessen, J. L., Hu, J. H., Maeder, M. L., 
Joung, J. K., Chen, Z. Y., and Liu, D. R. (2014). Cationic lipid-mediated delivery of proteins 








Appendix I – Metabolomics data. Data are fold change over indicated treatment in 
normalized metabolite amount. Listed here are metabolites that showed a 1.5 fold increase or 
greater between siCARS vs siNT in vehicle treatment. Color-coding shows statistical 
significance according to Welch’s two-sample t-test.  
 
 
Fold Change, Welch's Two-sample t-test     
 













1.02 0.85 0.21 0.43 3.72 




1.44 0.80 0.64 0.80 2.34 
adenylosuccinate 2.29 1.76 0.96 1.21 2.23 
glucose 1.43 0.73 1.97 1.38 2.19 
3-methyl-2-oxovalerate 1.43 0.80 1.34 0.80 2.13 




1.41 1.21 1.50 0.99 1.92 
1-
oleoylglycerophosphoserine 





cystathionine 1.38 0.96 1.56 0.89 1.75 




1.47 1.00 1.37 0.97 1.73 
asparagine 1.64 1.11 1.61 0.89 1.71 




1.34 1.08 1.17 0.93 1.67 
2-methylbutyrylcarnitine 
(C5) 
1.37 1.31 0.77 1.11 1.65 
UDP-glucuronate 1.07 1.37 0.89 1.33 1.65 




1,4 or 1,3-diphosphate 




0.98 0.65 1.04 0.64 1.60 
N-acetylcysteine 0.42 0.76 0.26 0.89 1.59 
2-aminoadipate 0.61 0.88 0.74 0.80 1.54 
creatine phosphate 1.15 1.22 1.33 1.06 1.54 
leucylalanine 1.42 1.25 0.94 0.91 1.52 
adenosine 5'-triphosphate 
(ATP) 
2.08 1.37 1.93 1.27 1.51 
adenosine 5'-diphosphate 
(ADP) 






Appendix II – RNAseq data.	  	  siCARS/siNT	  is	  fold	  change	  in	  FPKM	  value	  from	  averages	  of	  
biological	  triplicates	  of	  each	  treatment.	  Listed	  here	  are	  genes	  that	  had	  greater	  than	  2.5	  fold	  increase	  









LOC284561 23.54 10.34 1.24 
ASNS 11.22 6.53 1.54 
SNORA14B 9.74 0.00 0.22 
LOC730755 8.90 1.17 0.68 
SLC7A11 8.57 4.49 1.29 
SLC1A4 8.54 5.73 1.52 
JDP2 8.10 6.39 1.28 
PCK2 8.10 4.58 2.05 
SNORA2B 6.77 1.11 0.83 
NUPR1 6.59 9.26 2.67 
SLC6A9 6.34 5.51 1.52 
ESM1 6.23 1.39 1.26 
PSAT1 5.96 3.77 1.14 
CBS 5.78 3.32 1.64 
PHGDH 5.45 2.98 1.10 
GPT2 5.08 3.81 1.27 












LOC100271831 4.54 4.25 0.57 
SLC7A5 4.39 3.69 1.29 
TXNIP 4.34 2.24 5.15 
SIGLEC15 4.34 1.34 0.93 
LOC100506670 4.34 3.28 1.34 
IL13RA2 4.19 1.36 1.54 
OSCAR 4.17 2.18 2.11 
VLDLR 4.12 2.75 1.13 
HMOX1 4.04 4.39 4.54 
SLC3A2 3.84 2.54 1.68 
BCL2A1 3.61 1.40 2.55 
SESN2 3.53 3.57 3.33 
FGF1 3.40 1.12 1.01 
C14orf34 3.36 1.17 0.71 
SLC7A5P2 3.33 2.66 1.36 
LOC100652989 3.32 2.74 1.45 
TRIB3 3.31 2.83 2.48 
DDR2 3.26 2.83 1.69 
S1PR1 3.22 1.30 0.73 
LOC100506267 3.21 1.43 1.11 












SNORA28 3.12 2.13 0.00 
SLC4A5 3.11 2.53 1.38 
UPP1 3.09 1.39 2.94 
MMP3 3.07 0.98 2.22 
PCNA-AS1 3.00 1.83 0.33 
MTHFD2 2.98 2.49 1.51 
GARS 2.92 2.19 1.42 
SNORA33 2.90 1.70 0.89 
MAOA 2.88 1.20 1.63 
ATF4 2.87 2.35 0.74 
SLC1A5 2.83 2.18 1.19 
SNORD3D 2.82 0.79 0.46 
ATF3 2.80 3.14 2.69 
APOL6 2.77 2.10 0.90 
AOX1 2.76 1.15 1.15 
SNORD3B-1 2.76 1.20 0.47 
SNORD3B-2 2.76 1.20 0.47 
SERPINE1 2.74 1.17 1.08 
ANK2 2.74 1.49 1.49 
FGF5 2.72 0.77 0.79 












KIF21B 2.65 2.26 1.14 
PTPRR 2.61 1.16 1.32 
PSPH 2.60 2.37 1.35 
IL1B 2.60 1.95 4.11 
MGLL 2.59 0.99 1.51 
PYCR1 2.57 1.83 1.34 
ZNF643 2.55 1.95 1.37 
TSC22D3 2.54 3.60 3.75 
HECW2 2.51 1.37 4.46 
 
 
 
	  
